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ABSTRACT 
The emergence of human immunodeficiency virus-1 (HIV) exacerbated the already enormous 
number of cases of tuberculosis (TB) worldwide because HIV dramatically increases the 
susceptibility of humans to TB. The cause of this increased susceptibility to TB in HIV-infected 
individuals is not fully understood. In this thesis, I developed an SIV/TB cynomolgus macaque 
model and multiple in vitro and ex vivo assays to examine how HIV induces reactivation of latent 
TB and how HIV reduces various M. tuberculosis-specific immunological responses.  In the 
animal model, I provide evidence that initial T cell depletion after SIV inoculation in monkeys 
with latent TB perturbs the control of the infection, and directly corresponds to the reactivation 
of TB. There was also a quantifiable decrease in the total number of T cells within 
granulomatous lung tissue in co-infected reactivated animals compared to animals with active 
TB without SIV. A significant decrease in IFN-g releasing T cells in lung draining lymph nodes 
of co-infected monkeys compared to monkeys with active disease also was observed. In in vitro 
and ex vivo experiments we determined that the addition of exogenous SIVmac251 to cells from 
monkeys infected with M. tuberculosis (without SIV) leads to a specific decrease in TNF and 
 V 
IFN-g production in M. tuberculosis-specific T cells between 12 and 24hrs after incubation.  This 
decrease in T cell cytokine production was caused by SIV-induced disruption in antigen 
presenting cells. Specifically, the decrease in TNF production by M. tuberculosis-specific T cells 
was caused, at least in part, by SIV-induced IL-5 production by monocytes, which demonstrates 
a novel role for IL-5. The wide range of experiments implemented in this thesis provides novel 
evidence for the increased susceptibility of TB in HIV-infected individuals.  
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2.0  TUBERCULOSIS INTRODUCTOIN 
2.1 THE HISTORY OF TUBERCULOSIS 
Some of the earliest cases of presumed human TB date back thousands of years. Greek physician 
Hippocrates (460-370 BC) describes kyphosis, most likely caused by Pott’s disease (M. 
tuberculosis infecting the spine) as the result of a disease that can occur above or below the 
diaphragm and is associated with solid tubercles in the lungs and abscesses in the lumbar region 
[1]. Hippocrates also gave patients poor prognoses if the spinal curvature was above the 
diaphragm in a child or young adult. Hippocrates was not the first to describe symptoms of TB. 
Multiple descriptions in ancient and historical texts appear to mention TB calling it phthisis, 
scrofula, King’s Evil, lupus vulgaris, consumption, etc [2, 3]. As paleopathology and 
paleohistology, the study of ancient diseases, became more prevalent, the natural history of M. 
tuberculosis was revealed.  
Mycobacterial tuberculosis complex (MtbC) amplified DNA was discovered in an extinct 
fossilized long-horned bison that died more than 17,000 years ago [4] and the first known case of 
human TB caused by MtbC occurred in ancient Egypt between 2050-1650 BC [5]. TB has also 
been identified in calcified and non-calcified tissues within mummified remains that include 
granulomas in lung and other organs [6]. These studies have confirmed that TB has evolved with 
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humans over thousands of years.  This co-evolution with humans has allowed M. tuberculosis to 
become a resilient pathogen.   
The 19th
7
 century was a remarkable time for scientists struggling to identify the cause of 
tuberculosis. Louis Pasteur and Robert Koch were fascinating infectious disease researchers in a 
bitter rivalry to identify the causative agent of TB. In 1882 Robert Koch identified the bacillus 
using his own scientific method called Koch’s postulates [ ]. Koch’s work on M. tuberculosis 
continued as he identified ‘giant cells’ that contain and frequently ‘degrade’ the bacillus [8]. In 
1901, Koch was one of the first to ask whether 1) people were susceptible to bovine tuberculosis 
and 2) bovine tuberculosis could be a potential vaccine for TB [9].  
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In 1908 Albert Calmette and Camille Guérin began passaging virulent M. bovis in an 
alkaline glycerin-ox bile-potato media until they developed an attenuated strain that could be 
used as a vaccine for TB. This attenuated form of M. bovis became known as Bacillus Calmette-
Guerin (BCG) and was first given to children orally 48hrs after birth in the 1920s [10]. Despite 
the centuries of TB research, and the widespread use of the BCG vaccine in children in most 
countries for nearly 100 years, TB still remains a global pandemic (Figure 1).  
 
Figure 1. TB incidence rate per country in 2010 
2.2 TB EPIDEMIOLOGY  
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Roughly one third of the world’s population is infected with M. tuberculosis [11], although only 
a fraction of those present with active disease. In 2010, there were 8.8 million incident cases of 
active TB and 1.1 million deaths from TB among HIV-uninfected people and 350,000 deaths in 
HIV-infected individuals [11] (Figure 2). Although the total number of TB cases has been 
gradually decreasing since 2006 and TB incidence rates have been falling globally since 2002, it 
remains a major cause of death worldwide. The highest incident rates of TB are in sub-Saharan 
Africa, which is due in part to the high prevalence of HIV.  
 
Figure 2. 2010 TB rates and death estimates 
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2.3 TB PATHOLOGY 
M. tuberculosis is transmitted via aerosolized droplets from an individual with active TB. The 
bacillus infects via the respiratory tract, encountering alveolar macrophages in the airways, and 
transiting to the lung parenchyma, where innate and adaptive immune responses cooperate to 
signal that a bacterial infection is taking place. This leads to macrophage production of 
chemokines and proinflammatory cytokines that attract other leukocytes such as dendritic cells to 
the site of infection [12]. Dendritic cells phagocytose M. tuberculosis (either in the airways or in 
the parenchyma) and migrate to lung-draining lymph nodes to prime T cells.  Primed T cells 
migrate to the infection site to form the granuloma in an attempt to wall off the infected 
macrophages.  An asymptomatic individual with contained M. tuberculosis is considered to have 
latent TB. In contrast, active disease, in which bacterial replication and dissemination is not 
controlled by the granuloma, leads to the symptomatic and clinical presentation of TB and 
without effective treatment can be fatal [13]. The death rate of untreated TB is approximately 
70% (range: 55-75%) in smear positive and 20% (10-30%) in smear negative HIV-uninfected 
patients (reviewed in [14]). The death rate in HIV-infected individuals with untreated TB is 
approximately 81% (70-99%) in patients with positive smears and 76% (63-90%) in individuals 
with smear negative sputum (reviewed in [14]).  
The granuloma is an organized cellular structure composed of macrophages, 
lymphocytes, dendritic cells, neutrophils, and sometimes fibroblasts, often with a necrotic center. 
This structure serves to contain the bacilli, and acts as an immune microenvironment for cellular 
interactions that limit M. tuberculosis replication. However, simple formation of a granuloma is 
not sufficient for control of infection, as persons with active TB have multiple granulomas in the 
lungs and thoracic lymph nodes, and possibly extrapulmonary tissues. Instead, the granuloma 
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must have optimal immunologic function to contain or eliminate the bacilli. As a highly evolved 
pathogen, M. tuberculosis has devised strategies for persisting within the granuloma, and 
avoiding elimination by the host response. In latent infection, the host and bacillus co-exist, with 
the granuloma serving as the site of bacterial persistence and host resistance. Disruption of the 
structure or function of the granuloma is likely to lead to reactivation of latent M. tuberculosis 
infection, dissemination, and active disease.  
2.4 TB INFECTION OUTCOME 
The risk of becoming infected with M. tuberculosis upon exposure is about 25% [15], which 
suggests that the innate response to the bacillus is sufficient to prevent infection in the majority 
of immune-competent individuals. About 90-95% of the infected individuals develop 
asymptomatic latent TB, while the remaining develop active TB [11]. Latently infected 
individuals are estimated to have a 10% lifetime risk of reactivation. Co-infection with HIV 
dramatically increases the risk of reactivation to 10% per year [16], which will be discussed in 
chapter 3. 
 M. tuberculosis can be detected with a tuberculin skin test (TST), in which purified 
protein derivative (PPD) from M. tuberculosis is injected into the top layer of skin [17], or the 
newer blood tests (e.g. Interferon gamma release assays, IGRA). An individual infected with M. 
tuberculosis or vaccinated with BCG has a delayed type hypersensitivity reaction to PPD that is 
detected 48 to 72 hours after injection. A positive response to PPD is defined as >10 mm 
induration (hard swelling) at the site of injection in an immune competent individual. Individuals 
that are immunocompromised are considered positive with an induration of 5mm. The induration 
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at the injection site is caused by the recruitment of adaptive immune cells specific for 
mycobacteria. Epidemiologic data supports that a tuberculin test is positive in BCG-vaccinated 
persons for only ~5 years post-vaccine [18, 19], as the responses wane to BCG. To differentiate 
BCG vaccination from M. tuberculosis infection, the IGRA can be used, which relies on IFN-g 
release to M. tuberculosis-specific proteins, ESAT-6 and CFP-10.  
An asymptomatic individual with a positive skin test is considered to have latent TB. In 
contrast, active disease, in which bacterial replication and dissemination is not controlled by the 
granuloma; leads to the symptomatic and clinical presentation of TB and without effective 
treatment may be fatal [13]. Although granulomas within individuals with latent TB can 
sometimes be visualized on X-rays, it is difficult for radiologists to differentiate active and latent 
lesions. Active TB presents with a variety of symptoms, including cough, night sweats, loss of 
appetite, and weight loss. In many parts of the world, TB is diagnosed based on symptoms and 
the observation of acid-fast bacilli in sputum smears upon microscopy. Chest radiograph findings 
of granulomas or infiltrates can also be useful in the diagnosis [11]. M. tuberculosis can be 
cultured from sputum, gastric aspirates and bronchial alveolar fluid in individuals with active 
TB, and culture remains the “gold standard” for diagnosis of active TB. However, culture is not 
possible in all parts of the world, and a substantial fraction of those with active TB are smear or 
culture negative. Thus diagnosis of TB can be very challenging, especially in children, and 
sometimes only improvement of symptoms upon initiation of anti-tuberculous chemotherapy 
confirms the diagnosis of TB.  
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2.5 TB TREATMENT-VACCINES 
In an ideal world there would be an effective vaccine for preventing TB. BCG is the most widely 
used vaccine ever--it has been administered to more than 4 billion individuals worldwide over 
the last 90+ years (reviewed in [20]). In clinical trials, the effectiveness of BCG in preventing TB 
ranges significantly from 0% to 85% (reviewed in [18, 20]). There are several hypotheses for the 
widely disparate results of these trials, including different strains and preparations of BCG 
vaccine used, the influence of environmental mycobacteria or helminthes, and nutritional and 
genetic variations among populations. It does appear that BCG can prevent the incidence of 
disseminated TB in children (reviewed in [18, 20]), however it fails to prevent infection or 
disease in most adult populations. In addition, individuals that receive a BCG vaccination as an 
infant without a boost in adolescence lose their ability to respond to TST [19], which suggests 
that the vaccine does a poor job at inducing adaptive immunity. However, boosting with later 
BCG administration does not improve protection [19]. Even more telling, the vast majority of TB 
cases and deaths occur in countries where most newborns are vaccinated with BCG, supporting 
that this vaccine is ineffective. There is an urgent need for a better vaccine to prevent infection 
and the need for improved drugs to rapidly cure TB.  
Currently there are 3 objectives for development of new vaccines: 1) delay disease 
progression, 2) completely eradicate the infection from the host and 3) prevent infection [11]. 
There are 12 potential TB vaccines in clinical trials consisting of recombinant BCG vaccines, 
viral-vectored booster vaccines and fusion protein in adjuvant as booster vaccines (reviewed in 
[21]). The current vaccines are only in Phase I or II clinical trials, so any information about 
efficacy is years off. To make matters worse, HIV has been shown to decrease vaccine 
effectiveness, which is a problem because areas with the highest HIV rates have the highest TB 
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rates [11, 22]. The ineffectiveness of BCG and the uncertainty of TB vaccines in the pipeline 
necessitate the need for more effective drug treatments. 
2.6 TB TREATMENT-DRUGS 
The current treatment for TB is based on drugs that have been around for more than 50 years. 
Individuals that have newly detected drug-susceptible TB are put on a 6-month 4-drug regimen 
that include rifampin (targets DNA-primed RNA polymerase), isoniazid (targets enoyl-ACP 
reductase and mycolic acid elongation), pyrazinamide (targets fatty acid biosynthesis/membrane, 
depolarization/ribosomal protein S1 (RpsA), protein translation and the ribosome-sparing 
process of trans-translation) and ethambutol (targets cell wall arabinan deposition) given for 2 
months, followed by rifampin and isoniazid for 4 months [23, 24]. Treatment for latent infection 
(to prevent reactivation) includes isoniazid monotherapy for 6-9 months, or a rifampin regimen 
for 4 months [23, 25].  New data suggests that 3 months of rifapentine and isoniazid is also 
effective against latent infection [26]. HIV complicates drug treatment because protease 
inhibitors interact with rifampin and reduce their effectiveness and compliance [23]. The 
emergence of multidrug resistance (MDR) M. tuberculosis strains has required the use of second 
line, less effective drugs such as kanamycin, streptomycin and fluoroquinolones [23, 24]. The 
long duration of treatment, the need for directly observed therapy to improve compliance high 
prevalence of side effects with TB drugs, HIV-infection and the development of MDR TB add to 
the challenges of treating TB.  
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2.7 TB  IMMUNOLOGY 
M. tuberculosis becomes phagocytosed by alveolar macrophages when it enters the airways. If 
the macrophages are able to kill M. tuberculosis immediately, then an infection will not occur. 
However, if the macrophages cannot prevent infection, the bacilli are transported to the lymph 
nodes, where a cell mediated adaptive immune response is primed. Lymphocytes and monocytes 
migrate to the site of infection, usually within 2 to 6 weeks post-infection. This influx leads to 
the formation of a granuloma. The bacilli within the granuloma may remain there for the lifetime 
of the host, they may disseminate within the lungs or into other tissues to form new granulomas 
or they may be released into the airways following granuloma cavitation, which results in the 
possibility of infecting other individuals.  
Granulomas play an essential role in containing the mycobacteria. The architecture and 
composition of a granuloma is incredibly diverse (reviewed in [27, 28]). Granulomas can consist 
of any combination of macrophages, dendritic cells, neutrophils, B cells, T cells and fibroblasts. 
Human granulomas can be necrotic, solid cellular, fibrotic, suppurative and mineralized or a 
combination of each with well-defined or unusual characteristics. Granuloma diversity does not 
just occur among people, it also occurs within the same host! It is likely that each cell type has a 
role to play in containing M. tuberculosis infection.   
2.7.1 Macrophages 
The phagocytosis of M. tuberculosis by alveolar macrophages is probably the first event that 
takes place when M. tuberculosis enters the airways. M. tuberculosis binds to complement 
receptors, mannose receptors (MR), toll like receptors (TLRs) and Fcg-receptors to gain access to 
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macrophages [29]. Depending on the route of entry and the cytokine milieu, the infection can 
induce either pro-inflammatory or anti-inflammatory responses. Th1 cytokines (IFN-g and TNF) 
can induce classically activated macrophages (CAM) while Th2 cytokines (IL-4, IL-13 and IL-
10) can induce alternatively activated macrophages (AAM) [30].  
CAMs up-regulate MHC Class I and Class II molecules and produce proinflammatory 
cytokines such as IL-1, IL-6, TNF and IL-12 and are capable of killing phagocytosed 
mycobacteria [28, 30]. CAMs are associated with inducible nitric oxide synthase production. 
AAMs up-regulate MHC Class II molecules along with various receptors such as mannose 
receptor and are primarily involved in humoral immunity and allergic or anti-parasitic responses 
[30]. Since the airway is considered by some to be an anti-inflammatory environment, due to the 
constant exposure to pathogens and the need to prevent excessive inflammation, it is possible 
that alveolar macrophages are inherently alternatively activated [31], which may decrease their 
ability to kill M. tuberculosis upon infection. Although AAMs may provide a foothold for a new 
infection of M. tuberculosis, they are probably necessary to prevent excessive pathology 
associated with TB. This means there must be a balance between pro- and anti-inflammatory 
responses within a granuloma for it to function properly.  
 
2.7.1.1 Killing M. tuberculosis 
When M. tuberculosis enters an activated macrophage it becomes subject to replication 
inhibition and killing by intra-lysosomal acidic hydrolases, reactive oxygen intermediates (ROI), 
reactive nitrogen intermediates (RNI) upon phago-lysosomal fusion and enzyme-mediated 
degradation (reviewed in [32]). TNF and IFN-g are needed to activate macrophages [33, 34], at 
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least in murine models, and are likely important in activation of human macrophages.  M. 
tuberculosis has developed multiple strategies to thrive in this environment. M. tuberculosis has 
the ability to prevent phagolysosomal fusion [35] and maturation [36], neutralize reactive ROIs 
and RNIs [37], and prevent vacuole acidification [38].  
2.7.1.2 Signaling T cells 
Not only can M. tuberculosis prevent its degradation within an infected macrophage it can also 
reduce the ability of macrophages to signal T cells. M. tuberculosis can prevent MHC-II and 
MHC-I antigen processing (reviewed in [39]). Mycobacterial 19-kDa lipoprotein can reduce 
MHC-II expression on infected macrophages through a TLR-2 dependent mechanism [40]. M. 
tuberculosis can also reduce cathepsin S activity which is essential in processing MHC class-II-
associated variant chain, a necessary step in peptide loading [41].  The decreased degradation 
along with the reduction in antigen processing and MHC-II expression allow M. tuberculosis 
bacilli to evade CD4 T cell surveillance.  
Peptides presented by MHC-I molecules on macrophages and dendritic cells are targets 
for CD8 T cell recognition, and subsequent degradation of the cell. Since MHC-I molecules 
generally load peptides in the cytosol and M. tuberculosis typically remains within phagosomes 
non-traditional loading of MHC-I molecules with M. tuberculosis-peptides needs to occur. 
Secreted membrane proteins ESAT-6 and CFP-10 may cause the phagosomal membrane to 
become leaky [42], which would allow bacterial peptides to enter the cytosol and be processed 
by the proteasome for MHC-I processing. It is also possible that the bacteria are transported to 
the cytosol from the phagolysosome through a dislocon [43]. Other possible mechanisms for 
cross presentation by MHC-I molecules are the vacuolar cross presentation model [44] and the 
“detour pathway” [45]. The vacuolar cross presentation model suggests that peptides derived 
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from bacterial proteins that are generated within the phagolysosomal lumen, load directly on 
MHC-I molecules when they are recycled through the endocytic system and the detour pathway 
suggests that uninfected antigen presenting cells take up apoptotic bodies containing M. 
tuberculosis or its peptides from an infected phagocyte.  
2.7.2 Dendritic Cells 
Dendritic cells are professional antigen-presenting cells that have the ability to prime naïve T 
cells [46]. Dendritic cells are capable of expressing high levels of co-stimulatory molecules 
while releasing IL-12 to induce priming [47]. After the initial infection, M. tuberculosis is 
engulfed by resident dendritic cells and migrate to the draining lymph node to prime 
lymphocytes [48-51]. Priming initiates when specific naïve CD4 or CD8 T cells bind to either 
MHC-II or to MHC-I molecules, respectively, presenting a specific epitope, Dendritic cells can 
also induce T cells to produce IL-2 along with expressing costimulatory molecules that help T 
cells grow and differentiate [46, 50]. Dendritic cells are necessary in developing an adaptive 
immune response to M. tuberculosis; depleting them in mice during acute TB results in higher 
bacterial burden and delays CD4 T cell priming [52]. 
Since infected dendritic cells have the ability to migrate, they may also play a role in the 
dissemination of M. tuberculosis [51]. Dendritic cells also support M. tuberculosis growth [47]. 
While macrophages have the ability to reduce mycobacterial burden, dendritic cells do not, 
which indicates they may also serve as a reservoir for M. tuberculosis [50]. Dendritic cells are 
necessary for priming T cells to M. tuberculosis, however they can be exploited by M. 
tuberculosis to increase both dissemination and growth.   
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2.7.3 T Lymphocytes  
Host defense against M. tuberculosis is dependent on both innate and adaptive cellular responses. 
CD4 and CD8 T cells act as the adaptive arm of the immune system and are essential in 
controlling TB [53-57]. T cells are primary produces of cytokines needed to activate 
macrophages and also directly kill M. tuberculosis within infected macrophage through cytolytic 
activity. T cells are also a major component of granulomas and are essential in preventing the 
dissemination of M. tuberculosis [28, 58, 59].  
2.7.3.1 CD4 T cells  
The primary role of CD4 T cells is to orchestrate the immune system by producing cytokines and 
chemokines. CD4 T cells are essential for containment of M. tuberculosis and long-term survival 
of mice during TB, which was demonstrated by a significant decrease in survival time and an 
increase in bacterial burden in M. tuberculosis infected MHC-II-/- and CD4-/- mice [56] and 
CD4 T cell depleted mice [60].  In humans, the importance of CD4 T cells was “confirmed” by 
HIV-infected individual’s increased susceptibility to TB [16, 61], albeit this is an 
oversimplification of the incredibly complex interaction between HIV and M. tuberculosis, 
which is discussed below. 
CD4 T Cells- Th1 Responses 
The orchestration of the immune system by CD4 T cells during TB revolves around the 
production of Th1 cytokines, which include TNF and IFN-g which activate macrophages [33, 
34], and the production of IL-2 that is needed for T cell proliferation [62]. IL-12 is produced by 
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dendritic cells and plays a central role in inducing Th1 immunity during TB [63]. Humans with 
IL-12Rb1 deficiency cannot respond to IL-12 and are more susceptible to TB [64]. 
IFN-g is a pro-inflammatory cytokine that is produced by both CD4 and CD8 T cells 
(reviewed in [65]). As mentioned above, IFN-g activates macrophages, which facilitates killing 
of intracellular pathogens through the induction of reactive oxygen species, nitrogen 
intermediates and increased phagosome-lysosome fusion [66]. During the acute phase of 
infection, CD4 T cells are the main producers of IFN-g [56]. IFN-g production is delayed in the 
absence of CD4 T cells during acute TB in mice but recovers after 3 weeks [56]. In the absence 
of IFN-Ȗ mice infected with M. tuberculosis have dramatically reduced survival and an increase 
in bacterial burden [67]. These mice also have a reduced ability to produce reactive nitrogen 
intermediates [67]. These studies suggest that IFN-g and CD4 T cell production of IFN-g are 
important in controlling M. tuberculosis. 
Tumor necrosis factor (TNF) is a pro-inflammatory cytokine that is not only produced by 
CD4 T cells but also macrophages, dendritic cells, natural killer cells and CD8 T cells (reviewed 
in [65]). TNF has both transmembrane and soluble cytokine forms that are involved in 
lymphocyte activation, production of cytokines and chemokines, angiogenesis, and upregulation 
of cell adhesion molecule expression [68, 69]. CD4 T cells can also produce TNF which can act 
synergistically with IFN-g to activate infected macrophages [70].  The neutralization of TNF 
exacerbates TB in mice [71], macaques with acute and latent TB [72] and humans [73].   
Cytokine production by CD4 T cells is a dynamic process that occurs along a spectrum. 
CD4 T cells can produce only one cytokine or they can be multifunctional, producing more than 
four cytokines at a time [74, 75]. Multifunctional CD4 T cell responses wax and wane 
throughout TB [76], but there is some evidence that multifunctional activity (IFN-g, TNF, IL-2) 
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increased post-TB treatment in infected individuals [74]. However, it is difficult to differentiate 
between cause and effect when it comes to an increase in these cells because it is possible that 
the temporary increase in antigen load associated with treatment may result in more priming of T 
cells.  There is also evidence that multifunctional T cells are seen in the setting of increased 
disease [77, 78], likely reflecting increased antigen availability from replicating bacilli. 
  
CD4 T Cells- Th2 Responses 
Th2 responses are essential mediators of asthma and are an effective response against 
extracellular pathogens [79]. Th2 CD4 T cells can produce IL-10, IL-4, IL-5 and IL-13.  As 
mentioned above, Th2 cytokines are capable of inducing AAMs [30], which fail to kill M. 
tuberculosis [80]. Increases in Th2 responses have been associated with increased pathology in 
individuals with TB [77, 81-83]. For example, a positive correlation was made between IL-4 
production and humans with increased cavitary pulmonary lesions [83]. IL-10 produced by CD4 
T cells can directly antagonize CD4 T cell responses by inhibiting macrophage function of cells 
infected with mycobacteria [84] and decreasing IL-12 production [85].  
Th2-mediated dampening of immune responses is not necessarily a detrimental 
occurrence within TB. If pro-inflammatory responses remained unchecked, granulomas would 
induce more tissue damage, which could lead to a functional disruption [28].  Th2 responses may 
function to balance the proinflammatory response with an anti-inflammatory response within the 
granuloma.  
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2.7.3.2 CD8 T Cells 
M. tuberculosis-specific CD8 T cells are very similar to their M. tuberculosis-specific CD4 T cell 
counterparts. CD8 T cells can also produce Th1 cytokines [86, 87] and can be cytolytic to M. 
tuberculosis infected macrophages [57]. CD8 T cells contain specific cytolytic activity that 
involves the degranulation of a cytolytic granule that release perforin, granzyme B and 
granulysin into an infected cell presenting a specific antigen on MHC-I [88].  Perforin inserts 
into the membrane of the target cell, and upon dimerization, it creates a pore that allows 
granzyme B and granulysin to enter. Granzyme B plays a role in apoptosis and granulysin has 
anti-microbial activity.  
 CD8 T cells have not been as well researched in TB immunology as CD4 T cells.  They 
appear to not be as essential for the containment of TB in mice. CD8-/- mice have increased 
bacterial burden during the chronic infection, with small differences in survival compared to wild 
type animals [89]. The depletion of CD8 T cells in a murine TB model did not lead to increased 
pathology [90]. However, the depletion of CD8 T cells at the beginning of infection in 
nonhuman primates infected with M. tuberculosis prevents containment of the infection, leading 
to higher bacterial burden and pathology ([91], Flynn and Lin unpublished data). It has been 
suggested that CD8 T cells preferentially recognize heavily infected cells, which is not the case 
with CD4 T cells [92]. CD8 T cells are also important to study because MHC-I molecules are on 
all cells and M. tuberculosis DNA can be detected on MHC-class-II negative cells [93], which 
would allow these cells to be susceptible to only CD8 T cells.  
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2.7.4 Animal Models 
Animal models are essential for better understanding various human diseases. The TB field has 
gained an incredible amount of information from the multiple animals used to study M. 
tuberculosis including zebrafish, mice, guinea pigs, rabbits, cows, and non-human primates.  
Although each model has its own limitations, these models allow researchers to explore 
microbial and immunological changes that cannot be performed in humans.   
2.7.4.1 Zebrafish (Danio rerio) 
Zebrafish are used in multiple areas of biomedical research that range from disease modeling to 
drug screening (reviewed in [94]).  Mycobacterium marinum, a close relative to the MtbC [95] is 
a natural pathogen to fish and amphibians [96], which makes in an ideal TB model (reviewed in 
[97]). Some advantages to M. marinum are that it grows more quickly than M. tuberculosis and 
is less virulent so it requires less stringent biosafety protocols. However, there are differences 
between M. marinum and M. tuberculosis, including temperature of growth, and the ability of M. 
marinum to quickly escape the phagosome and live in the cytosol of cells, which M. tuberculosis 
does not, in general, do. Zebrafish have transparent larvae, which are ideal for live imagining and 
examining host-pathogen interactions in real-time [98, 99]. This animal model has verified many 
‘firsts’ in the TB world. Using fluorescent M. marinum this animal model has provided us with 
details about bacilli transfer from one granuloma to another, that “mycobacterial expansion of 
early granulomas is driven by the continual cycle of death of infected macrophages and their 
phagocytosis by multiple newly recruited macrophages” and that innate immunity was sufficient 
to initiate granuloma formation without adaptive immunity, which were never observed before 
[98, 99].  
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2.7.4.2 Guinea Pigs (Cavia porcellus) 
Guinea pigs were first used by Robert Koch to develop vaccines against TB [8]. Guinea pigs are 
very susceptible to the disease and display a wide range of granuloma types and pathology, with 
some similarities to humans [100, 101]. Guinea pigs have been used to assess dissemination of 
M. tuberculosis from the site of inoculation [102, 103] and to determine virulence of human TB 
strains [104]. The mouse model of TB has overshadowed the guinea pig model because there are 
more reagents developed for mice compared to guinea pigs, which makes immunological 
analysis of mice easier. However, the guinea pig model is still used today to assess vaccine 
efficacy [105], drug efficacy [106] and pathogenesis [107]. 
2.7.4.3 Rabbits (Oryctolagus cuniculus) 
Unlike most other mammals, rabbits are naturally resistant to M. tuberculosis and extremely 
susceptible to M. bovis [108]. Although rabbits are resistant to M. tuberculosis, they still develop 
granulomas that eventually resolve [108]. M. bovis infection of rabbits leads to the development 
of granulomas that do not contain infection, and often develop into cavities that resemble the 
ones found in humans [109]. Rabbits may develop a spectrum of TB, but the lack of available 
reagents for studying their immunology and the high cost of their housing in a BSL3 facility 
make this animal model less than ideal for TB.  
2.7.4.4 Mice (Mus musculus) 
Mice are by far the most studied research animal in the world [110]. Mice are ideal animals to 
study because of the plethora of available reagents, and the availability of genetically identical 
mice and hundreds of knockout and transgenic strains. They are relatively cheap and easy to 
breed and house, and their short life spans allow researchers to follow the entire course of 
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disease in a fraction of the time it would take in a human. In light of these benefits, mice are the 
most widely used animals in TB research.   
The immunologic and bacterial response to M. tuberculosis in mice differs from humans. 
When C57/BL6 mice are exposed to ~100 CFU of aerosolized M. tuberculosis they develop an 
adaptive immune response in 2 weeks with bacterial load stabilizing in the lungs around 105-6
53
 
CFU/lung from about 4 weeks to up to 1 year [ , 54, 71, 111]. This high bacterial load results in 
the recruitment of CD4 and CD8 T cells that are maintained there throughout the infection [53]. 
These T cells and macrophages make up granulomas that form in the mice, however these 
granulomas differ significantly than the ones that form in humans [28, 33, 37, 53, 72, 112, 113].  
Murine granulomas appear to be more of a cluster of infected and uninfected macrophages, T 
cells and other immune cells with less organization than those found in humans and macaques. 
There is no caseous necrosis in standard mice, and the granulomas are not as variable as humans.  
Despite the differences in immunologic response to M. tuberculosis by humans and mice 
they are great starting point for examining a specific immunologic function that has not been 
examined in humans. For example, studies determining that TNF neutralization in TB mice 
caused increased pathology [114] lead to the examination of TNF neutralization for patients with 
rheumatoid arthritis and other chronic inflammatory diseases (reviewed in [68]), and now the 
risk of TB in patients receiving anti-TNF agents is well known, with protective measures in place 
for these patients. However, additional research demonstrated that the mechanism by which TNF 
controls murine TB may be different than in human TB; in mice, TNF neutralization leads to the 
inability to form or maintain granulomas. In humans and non-human primates, neutralization of 
TNF leads to exacerbation of disease, but the overall structure of the granuloma is similar to non-
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neutralized subjects [72]. Although mouse research has its drawbacks, it still has been a good 
predictor of TB in humans (reviewed in [115]).  
2.7.4.5 Non-Human Primates (Macaca mulatta & Macaca fascicularis) 
Rhesus and cynomolgus macaques are both currently being used as TB animal models [72, 91, 
112, 113]. Cynomolgus macaques bronchoscopically inoculated with a low dose (~ 25CFU) of 
Erdman strain M. tuberculosis become TST positive by 4-6 weeks post-infection. Half of the 
animals will develop active TB and the other half will develop latent infection [113]. Monkeys 
with active TB present the same signs of disease as humans, which include weight loss, 
coughing, radiological evidence of disease, high sedimentation rates and culturable M. 
tuberculosis from either gastric aspirates or bronchial alveolar fluid [72, 112, 113, 116]. Latent 
TB is defined as being TST positive without any signs of disease.  
These infection outcomes (active or latent) are clinically defined, using methodology 
similar, although more rigorous, to that used in diagnosing human TB. The clinical 
classifications were validated at necropsy. Monkeys classified clinically as having active TB had 
significantly higher gross pathology scores, overall bacterial burden, and increased dissemination 
of infection compared to those classified as having latent infection [113]. Natural reactivation 
occurs in <5% of latently infected macaques. In our lab, we have demonstrated induction of 
reactivation of latent infection with anti-TNF antibody and with CD4 depletion via antibody.  
In addition to having similar outcomes of disease as humans, the pathology of TB in 
monkeys and humans is similar [116]. Macaques form well defined granulomas that represent 
the spectrum of granulomas seen in humans. Granulomas can be necrotic, solid cellular, 
mineralized, suppurative, fibrotic and cavitary, and include coalescing and satellite granulomas 
[72, 112, 113, 116]. These granulomas may be located in the lungs or be disseminated to the 
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draining lymph nodes, spine, liver, spleen, kidneys, colon and other organs. Granulomas within 
individual monkeys vary dramatically, which is similar to humans. Because non-human primates 
are more similar to humans than the other animal models, they have the opportunity to provide 
us with a better understanding of the disease that we cannot ethically explore in humans.  
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3.0  HIV INTRODUCTION 
 
Figure 3. Prevalence of HIV in 2009 per country. 
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3.1 HIV EPIDEMIOLOGY  
More than 33.3 million people are infected with HIV worldwide (Figure 3) and 2.6 million were 
newly infected with HIV in 2009 [22] (Figure 4). There is an income disparity in HIV incidence 
rates because 97% of new HIV infections in 2009 occurred in low and middle-income countries 
[22]. There were approximately 1.8 million deaths associated with AIDS in 2009 (Figure 4). 
Sub-Saharan Africa has the highest prevalence of HIV-1 infection with an estimated 22.5 million 
people infected [22]. 
 
Figure 4. HIV infection and AIDS-related rates in 2009 
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3.2 HIV DIVERSITY 
Based on full-length viral genome sequencing there are three HIV-1 groups known as M (main; 
99% of total infections), O (outlier; <0%) and N (non M or O; 0.22%) and 8 groups of HIV-2 
(Groups A-H, 0.17%) [117, 118]. Each group of HIV is divided into various clades. Group M, 
for example has 9 clades that are designated A to D, F to H, J, K. Each clade differs from the 
others in amino acid composition by at least 20% in the envelope region [119, 120]. Within each 
clade there are multiple subtypes of HIV that add to its diversity. 
3.3 HIV HISTORY 
The HIV pandemic has developed over decades. The first indication of acquired immune 
deficiency syndrome (AIDS) was observed in 1981 when seemingly healthy men became 
severely ill and developed Pneumocystis carinii pneumonia, mucosal candidiasis and multiple 
viral infections [121, 122]. These individuals were mostly homosexuals and drug users that 
developed these diseases in specific communities [122]. Patterns of these opportunistic infections 
began to dramatically rise in these cohorts and possible causes were examined.  HIV was 
eventually isolated from an enlarged lymph node of a man with persistent generalized 
lymphadenopathy in 1983 [123]. From here it was determined that HIV actually infected blood 
lymphocytes and could be horizontally transmitted [123, 124].  
HIV did not just randomly emerge in the 1980’s de novo. Simian immunodeficiency virus 
(SIV) that infects non-human primates probably gave rise to HIV [125]. It is estimated that the 
most recent common ancestor for HIV-1 group M is 1908 [126], which suggests that HIV-1 has 
 26 
been adapting to humans long before the first viral sequence of HIV was identified in an 
individual from a 1959 human sample [127].  
3.4 THE HIV VIRION 
HIV is a lentivirus with a cone shaped core composed of p24 Gag capsid (CA) protein. The 
virion is 100 to 120 nm in diameter. HIV has 3 structural Gag proteins: matrix, capsid and 
nucleocapsid. The envelope contains viral proteins (gp120 and gp41) [118]. Below the envelope, 
the matrix forms the inner shell, the capsid forms the conical core encapsulating the viral 
genomic RNA and the nucleocapsid interacts with the viral RNA inside the capsid.  There are 
two identical RNA strands that are associated with viral RNA-dependent DNA polymerase (Pol), 
which is a reverse transcriptase (RT) along with protease (PR) and integrase (IN) in complex 
with the nucleocapsid proteins [118]. HIV contains three major enzymes that function at 
different times during replication. These enzymatic activities include the RNA-dependent DNA 
polymerase with its RNase H function that acts in the early steps of viral replication to form 
double stranded DNA of viral RNA [118]. IN functions inside the nucleus to incorporate viral 
cDNA into the host chromosome and the protease processes Gag and Gag-Pol polyproteins 
within the budding virion and induces maturation of the viral particle into an infectious virus 
[128]. 
The genomic size of HIV is 10kb. The primary transcript of HIV is a full length viral 
mRNA, which is translated into Pol and Gag proteins, which get cleaved by PR into RT, PR, IN 
and other accessory proteins such as MA, CA and NC [118].  HIV also contains env, vpr, vif, 
vpu, tat, rev and nef genes that are transcribed into proteins of the same names. Splicing is an 
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important event that is needed for the transcription of multiple subgenomic precursors. The 
relative amounts of spliced mRNA are determined by the rev gene, which is a product of 
multiply spliced mRNA [129]. Tat is a regulatory protein that interacts with an RNA loop 
structure formed in the 3’ portion of the viral long terminal repeat (LTR), which increases viral 
replication. Rev also binds an RNA stem-loop structure called Rev-responsive element located in 
the viral envelope mRNA [130]. This interaction involves cellular and viral proteins, which 
permit unspliced mRNA to enter the cytoplasm from the nucleus to give rise to full-length viral 
proteins.   
A variety of other viral proteins are associated with the core, such as Nef and Vif. Nef 
has multiple functions but is primarily involved in cellular activation and enhanced infectivity 
[131]. Vif is involved in increasing infectivity. Other proteins associated with the virion are Tat, 
Rev and Vpr. Envelope (Env) protein, precursor gp160 is cleaved by furin, an endoprotease into 
gp41 and gp120 [132], which make up the receptor responsible for binding host cells.  
3.5 HIV REPLICATION  
HIV usually infects cells through an interaction between a gp120 viral envelope protein and cell 
surface expressed CD4 and either CCR5 or CXCR4 [118]. Using CD4 and the various co-
receptors, HIV can infect CD4 T cells, macrophages and to a lesser extent, dendritic cells. Since 
HIV is a retrovirus that must integrate into the DNA of the host cell, it must adapt to that 
particular cell.  
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3.5.1 Viral Replication in CD4 T cells 
Viral replication is efficient and occurs rapidly in activated CD4 T cells. Viral long terminal 
repeats (LTR) contain binding sites for cellular factors that regulate HIV transcription and are 
abundant in activated T cells and macrophages [133-135]. Since host factors are not efficient 
enough to induce the appropriate amount of replication, viral proteins such as Tat [136], Rev 
[137] and Vpr [138] increase gene expression. Activated cells produce more virus than quiescent 
cells within plasma of HIV-infected individuals [139, 140]. This increased replication within 
activated lymphocytes also leads to a rapid turnover of these cells [140].  
Cell activation is not required for HIV infection [141]. However, quiescent cells, in G0 
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phase of replication are refractory to infection because they have the ability to block reverse 
transcription of HIV [ ]. In order for the establishment of provirus, the cell needs to go beyond 
G0 cell cycle phase. CD4 T cells may receive a subtle stimulatory signal that helps push it into 
an early stage of cell cycle (G1
143
) that may be sufficient to begin viral replication from integrated 
viral DNA [ ]. Most cells that express viral RNA do not express cellular activation markers 
[144] and these cells persist after antiretroviral therapy [143]. This means that the virus may 
temporarily push a cell from G0 to G1
145
, which will allow replication to commence while reducing 
cytotoxicity.  HIV Nef may create conditions that allow the virus to enter nonactivated cells 
[ ]. Nef and Tat genes may be transcribed before the provirus is established [146], which 
means that they may help prepare a cell for infection. 
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3.5.2 Viral Replication in Macrophages 
HIV infects and replicates in macrophages both in vitro [147, 148] and in vivo [149]. Despite 
macrophages being a non-dividing cell they have been shown to contain proviral DNA [150]. 
HIV may establish infection in macrophages through a ‘reverse transcription complex’ (RTC, 
reviewed in [151]). When HIV enters a cell the viral core undergoes a rearrangement that 
becomes the RTC. The RTC contains nuclear targeting signals that guide it through the nuclear 
pore and help establish an active infection within the cell.  
Rhesus macaques infected with highly pathogenic SIV/HIV chimeric virus 
SHIV(DH12R) that completely depletes CD4 T cells maintain plasma viremia though tissue 
macrophages [152]. The infection of macrophages by HIV is important because they may act as 
reservoirs in tissues (reviewed in [153]). These reservoirs prevent the eradication of virus during 
antiretroviral therapy ([154], reviewed in [155]) and also may help disseminate the virus to 
autologous CD4 T cells [156], which can lead to the preferential infection and depletion of HIV-
specific CD4 T cells.  
3.5.3 HIV Pathology  
A person infected with HIV usually sustains a significant loss of CD4 T cells during chronic 
infection. Decreases in CD4 T cell counts are used as a clinical benchmark for the course of 
disease. Patients with <200 CD4 T cells/ml of blood are considered to have acquired immune 
deficiency syndrome (AIDS) [157]. CD4 T cell reduction leads to compromised cellular and 
humoral immune responses, which renders the patient more susceptible to opportunistic 
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pathogens.  These opportunistic infections can eventually lead to the death of an infected 
individual. 
HIV infection can be characterized by three specific phases: 1) Primary infection (acute) 
phase is associated with a massive increase in viral load that is accompanied by a decrease in 
peripheral and gut CD4 T cells that eventually leads to a viral set-point; 2) chronic phase which 
is associated with a gradual increase in viral load and an irreversible decrease in CD4 T cell 
counts and 3) the final phase (AIDS) which is associated with the terminal failure of the immune 
system  (reviewed in [158, 159]) (Figure 5).  
 
Figure 5. Changes in viral load and T cells in an HIV-infected individual 
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3.5.3.1 Primary Infection Phase 
Viral load observed in blood directly correlates to the risk of HIV transmission [160]. HIV is 
usually transmitted during sexual intercourse, through blood or vertically from mother to fetus 
[161]. During this early stage, the infected individual may become symptomatic presenting with 
clinical symptoms such as fever, skin rash, oral ulcers and lymphadenopathy that is associated 
with seroconversion [162, 163]. 
After HIV is transmitted through the mucosal barrier, the virus will be well established in 
a lymphatic tissue reservoir within the first few weeks of infection [164]. This HIV reservoir acts 
a principal site for viral production and persistence that leads to CD4 T cell depletion and 
destruction of follicles and the lymphatic tissue architecture [165]. During this period there is a 
profound depletion in gut-associated lymphoid tissue (GALT) that results in a reduction of CD4 
T cells that remain depleted throughout the course of disease [166]. The depletion is 
predominately limited to CCR5+ (CD45RA-CD45RO+) memory CD4 T cells [166, 167]. This 
depletion does not only occur within the GALT but also in most lymph nodes and peripheral 
blood [166-169]. This depletion of CD4 T cells occurs independent of route of transmission. 
Once this infection is established, an adaptive cellular response to HIV is primed that generates a 
partial control of viral replication [170]. 
During this early stage millions of resting CD4 T cells and macrophages become infected 
[171] and billions of virions in immune complexes bind to follicular dendritic cells (fDC) within 
lymph nodes [162, 165, 172]. The resting CD4 T cells remain infected throughout the course of 
disease, which provide an opportunity for the virus to evade immune surveillance until 
replication becomes activated. Infected fDCs provide an opportunity for HIV to preferentially 
infect HIV-specific CD4 T cells when they begin priming [173].  These reservoirs are 
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maintained throughout the disease course and become a major issue during anti-retroviral 
therapy because drugs target integrated viral DNA. The acute phase of HIV ends when viral 
titers decrease and hit their target set point and there is a significant increase in peripheral HIV-
specific T cells [174].  
3.5.3.2 Chronic Phase 
The massive depletion of CD4 T cells within GALT persists in the chronic phase [166], with an 
initial increase in peripheral CD4 T cell levels [169, 174]. This phase can last between 1 to 15+ 
years in individuals that are not being treated. During this phase there is a constant balance 
between CD4 T cell killing and viral production. Since 10-100 million infected activated CD4 T 
cells are killed each day [175], there is a constant turnover of CD4 T cells. The massive amount 
of CD4 T cell death along with the constant turnover of T cells can place a lot of stress on the 
proliferative ability of naïve T cells and disrupt lymph node architecture [176].  
HIV also preferentially infects HIV-specific CD4 T cell [173]. HIV does not just kill 
CD4 T cells during the chronic phase of infection, but also impairs CD8 and CD4 T cell function 
[177-179]. The constant stimulation of HIV-specific CD8 and CD4 T cells eventually causes 
them to become exhausted, which means they are less responsive to antigenic stimulation and/or 
cellular proliferation[180-183].  This decrease in responsiveness of T cells to HIV and the 
extensive amounts of cell death eventually lead to a loss of viral control and the final stage of 
disease.  
3.5.3.3 The Final Phase (AIDS) 
AIDS occurs when HIV-infected individuals have <200 CD4 T cells/ml of blood. This results in 
a significant loss of the immune system’s ability to prevent infections. As peripheral CD4 T cell 
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levels decrease, there is a direct correlation to the number of opportunistic pathogens that can 
infect the host [157]. Individuals with AIDS typically live between 1-3+ years in the United 
States.   
3.6 HIV TREATMENT 
When HIV was identified in 1983 scientists set out to develop both drugs and vaccines to cure 
and prevent disease, respectively. Although we cannot cure or prevent HIV, chemotherapy has 
dramatically decreased morbidity and mortality associated with HIV [184].   
3.6.1 Drugs 
The first antiretroviral therapy that was approved by the FDA was 3’-azido-3’-deoxythymidine 
(AZT) in 1987 [185]. AZT dramatically decreased viral load by inhibiting viral RT and HIV 
replication [186]. Its mechanism of action involves both the termination of viral DNA production 
and a competition for nucleosides used by viral polymerase. Because HIV has such a high 
mutation rate, AZT did not prove to be an effective mono-therapy long term [185]. This 
eventually led to the development of multiple drugs that work by inhibiting multiple viral 
proteins.  
There are over 20 anti-retrovirals approved by the FDA to treat HIV [187]. These drugs 
include nucleoside RT inhibitors (NRTIs), non-nucleoside RT inhibitors (NNRTIs), protease 
inhibitors (PI), integrase inhibitors (II) and fusion inhibitors (FI). Each of these drugs targets a 
specific viral protein that is required for viral replication or fusion. The error-prone HIV RT 
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causes a approximately 10-5 to 10-6 188 mutations per base pair/cycle [ ], which leads to mutations 
that allow HIV to bypass these inhibitors. To decrease the probability that a mutation will cause 
drug resistance, individuals are given a combination of anti-retrovirals (highly active anti-
retroviral therapy; HAART) that include different families of drugs to prevent multiple steps in 
the viral replication pathway. HAART has dramatically increased the life expectancy of HIV-
infected individuals. 
3.6.2 Vaccines 
Although HAART has dramatically increased life expectancy in HIV-infected individuals, there 
are severe side effects associated with the drug cocktail [184]. These side effects and the need to 
prevent disease have led to the search for an effective vaccine. With any vaccine, the overall aim 
is to reduce infection in the population. A few of the vaccine approaches have involved whole 
killed virus, live attenuated variants, subunits of viral proteins, viral proteins in live vectors, 
sequence-derived peptides, anti-HIV neutralizing antibodies, DNA gene transfer and viral like 
particles [118, 181, 188-191]. 
Some challenges face the development of an HIV vaccine: HIV integrates into cellular 
genome resulting in latent reservoirs; HIV can be transmitted from infected cells; cell-to-cell 
transfer of infection takes place; there are multiple HIV variants; the virus infects cells that are 
immune sanctuaries such as the brain and testes; the virus compromises immune function; and 
HIV has a high mutation rate [118, 181, 188-191]. These challenges have prevented the 
development of a successful vaccine but increasing our basic understanding of HIV biology will 
increase the odds of overcoming this obstacle.   
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3.7 IMMUNOLOGIC RESPONSE TO HIV 
The immune response to HIV is dynamic and involves both adaptive and innate cellular 
responses. Dendritic cells and macrophages provide a bridge between the two responses by 
presenting viral epitopes that either prime T and B cells or activate them, respectively. HIV has 
developed multiple mechanisms that evade immune surveillance and leads to the destruction of 
both the innate and adaptive immune responses [118]. 
3.7.1 Dendritic Cells 
Dendritic cells play an important role in HIV immunology (reviewed in [192]). Dendritic cells 
prime HIV-specific lymphocytes. HIV has exploited these cells by using them to infect HIV-
specific CD4 T cells upon priming [173]. Dendritic cells are also exploited by HIV to traverse 
the epithelial barrier in the genital tract to initial a productive infection [193]. 
3.7.2 Monocytes and Macrophages 
As discussed above, macrophages can be infected with HIV. HIV can infect both tissue 
macrophages and peripheral blood monocytes.  Although HIV infects a small fraction of 
macrophages and monocytes, they contribute significantly to viral replication [152]. Infected 
monocytes traffic to various tissues and cause a significant amount of dissemination of HIV 
[194] and they act as a reservoir of HIV during antiretroviral therapy [195]. HIV not only uses 
macrophages and monocytes as reservoirs for viral transcription it also has the ability to disrupt 
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macrophage phagocytosis [196-198], intracellular killing [196] and cytokine production [199, 
200].  
Macrophages respond to pathogens through pathogen-associated molecular patters using 
pattern-recognition receptors (PRR), that include Toll-like receptors (TLR) and they can respond 
by releasing appropriate cytokines [88]. TLR signaling is directed through two pathways that 
either increase the expression of proinflammatory cytokine or type 1 IFN genes, which can be 
affected by HIV-1 (reviewed in [201]). HIV and SIV have been shown to decrease TLR4 and 
CD14 on PBMC [202, 203]. HIV also reduces downstream signaling from TLR pathways [204]. 
HIV can modulate NF-kB [205], IRAK-4 phosphorylation [206], MyD88 activation [207] and 
various kinases JNK, ERK1/2 and MAPK phosphorylation [208]. These changes in signal 
transduction manipulate the ability of macrophages to respond to other pathogens. For example, 
Tat has the ability to inhibit LPS-activation of ERK1/2 in monocyte-derived macrophages [209], 
which can decrease macrophage ability to recognize microorganisms.  
HIV has the ability to modulate macrophage-induced cytokine production (reviewed in 
[30, 199]). Monocytes from healthy donors that are infected with HIV and differentiated into 
macrophages initially release more TNF, IL-1b, IL-6 and IL-8 in response to LPS compared to 
HIV uninfected macrophages [210]. This increase in cytokine production eventually decreases in 
both monocyte-derived macrophages and alveolar macrophages [204, 211]. HIV-infected 
individuals also have higher levels of anti-inflammatory cytokines such as IL-10 in their 
bronchial alveolar fluid than HIV-uninfected individuals [212]. However, the decrease in pro-
inflammatory cytokines in HIV-infected macrophages does not always occur because LPS-
induced TNF and IL-1b has also been observed in asymptomatic HIV-infected individuals [213]. 
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The decrease in macrophage-induced killing may result from a reduction in phagocytosis 
because Tat and Nef have the ability to down-regulate mannose receptors [214, 215]. HIV-
infected individuals have a reduced ability to activate alveolar macrophages upon exposure to 
Pneumocycstis jirovecii [216]. The decrease in macrophage activation may result from the ability 
of HIV to switch the activation status of macrophages from M1 to M2 (reviewed in [30]), which 
could impair the ability of macrophages to kill microbes. HIV may induce the M2 activation 
status of macrophages by inducing IL-4 and IL-13 production within infected humans.  
HIV decreases the ability of macrophages to signal lymphocytes [217-220]. HIV reduces 
T cell proliferation by down-regulating B7 and CD40L co-stimulatory molecules [220, 221] 
along with CD3 and MHC [222, 223] on infected macrophages. The reduction in these molecules 
may lead too less responsive lymphocytes.    
3.7.3 T Lymphocytes 
T cells are important for both HIV proliferation and killing [88, 118]. CD4 T cells can be 
infected with HIV. At the same time CD4 T cells can release cytokines that activate infected 
cells and they can kill infected cells through death receptors. CD8 T cells can release cytokines 
and become cytolytic.  
3.7.3.1 CD4 T cells 
As mentioned above, HIV can infect CD4 T cells. CD4 T cells can release either Th1 cytokines 
(IFN-g, TNF and IL-2) or Th2 cytokines (IL-4, IL-5, IL-10 and IL-13) [88, 118]. Th1 responses 
predominantly activate other cells and are proinflammatory while Th2 responses are generally 
anti-inflammatory and induce a humoral response. Th1 responses help activate fellow T cells and 
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macrophages. This is a double-edged sword because it increases HIV killing but it can also 
increase viral replication since HIV preferentially infects and replicates in activated CD4 T cells 
[143].   
The loss of CD4 T cells in HIV-infected individuals may be a result of direct infection 
that leads to cellular death [167, 224], cell death induced by viral proteins [225] and a decrease 
in the proliferation of naïve T cells [226]. Not only does HIV kill CD4 T cells it can also 
decrease their responsiveness to stimulation [183, 227]. The decrease in responses to recall 
antigens is correlated to an increase in disease progression [228]. The increase in CD4 T cell 
death and decrease in their ability to respond to HIV lead to increased viral replication, and 
increased pathology.  
3.7.3.2 CD8 T cells  
Cytotoxic CD8 T cells are a major component to the immune response to HIV (reviewed in 
[229]). Cytolytic T cells can both release cytolytic granules that lyse infected cells and also 
release activating cytokines [77]. Cytolytic T cell production precedes production of neutralizing 
antibodies, indicating that this activity is responsible for the initial decrease in viral load [230]. 
Since these cells cannot become infected with HIV and all cells express MHC-I molecules, CD8 
T cells can potentially kill any cell that HIV infects. HIV may reduce the ability of cytolytic T 
cells to respond to infected cells by causing a defect in T cell receptor signaling [231], altering 
cellular maturation [232], impairing effector functions [233], and reducing their survival [234]. 
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3.7.4 Humoral Response to HIV 
Antibody responses to HIV generally appear within the first 2 weeks [235]. Neutralizing 
antibodies are responsible for the removal of the majority of viral particles in the blood [236]. 
The neutralization of viral particles by antibodies leads to viral escape [236], which means the 
virus rapidly escapes neutralization by generating new emerging variants. Although, the virus 
continually escapes neutralization, the antibody response to HIV is essential at maintaining viral 
titers [237]. Anti-HIV antibodies are usually detected within the first 3 weeks of infection [118].  
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4.0  INTRODUCTION TO THE CO-INFECTION 
This chapter is adapted from the original publication with permission: 
Diedrich, CR & Flynn, J. HIV/Mycobacterium tuberculosis co-infection immunology: How 
does HIV exacerbate TB? Infection and Immunity. April 2011, p1407-1417, Vol. 79, No. 4. 
Citation: [238] 
 
 
The emergence of human immunodeficiency virus-1 (HIV) has exacerbated an already enormous 
number of cases of tuberculosis (TB) worldwide (Figure 6). TB affects HIV+ individuals 
throughout all phases of HIV infection and is the leading killer of HIV+ people [239]. Of the 9.4 
million new cases of active TB each year, 1.4 million of those individuals are HIV+ [240]. It is 
widely accepted that HIV causes a depletion of CD4 T cells, which is likely to contribute to the 
susceptibility of co-infected persons to TB, as this T cell subset is important in control of TB. 
However, HIV has effects on other cells, including macrophages, and influences cytokine 
production, which may also prevent a host from containing an initial or latent Mycobacterium 
tuberculosis infection. In this review, we highlight gaps in the human co-infection literature that 
must be addressed to gain a more complete understanding of the interaction between the 
pathogens M. tuberculosis and HIV. 
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Figure 6. HIV prevalence in new TB cases globally in 2010 
The current human HIV/TB literature provides a solid foundation for our current 
understanding of how these pathogens interact in vitro and in vivo. Several hypotheses have been 
generated to identify how HIV increases the risk of TB, and how M. tuberculosis infection may 
exacerbate HIV infection. Here, we summarize the data that underlies these hypotheses. 
However, it must be noted that these hypotheses are based on indirect evidence, extrapolating 
from the experimentally tractable peripheral sampling to events in M. tuberculosis-infected 
tissues. Although many of these hypotheses are likely valid, confirming the events occurring in 
the granulomas is a necessary next step. Focusing on confirming these hypotheses at the tissue 
level in future HIV/TB co-infection studies may identify new mechanisms that drugs and 
vaccines can target to prevent or cure TB within co-infected people.  
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4.1 HIV/TB PATHOLOGY 
It is well established that HIV impairs the ability to control M. tuberculosis infection [16, 241-
244]. Clinical studies provide compelling evidence that HIV leads to an increased risk of 
developing TB shortly after HIV infection. Among miners in South Africa, HIV+ individuals 
were two to three times more likely to develop TB than HIV- miners within two years of HIV-
seroconversion [241, 242] and after 11 years, half of the HIV+ miners developed TB [241].  
Although HIV+ individuals in these studies are more prone to developing TB, half of the cases 
of TB were attributed to time and not HIV due to the high incidence rate of TB among South 
African miners. It was not determined whether TB was the result of reactivation of latent 
infection or newly acquired M. tuberculosis infection. It is important to differentiate between 
reactivation and newly acquired TB because the mechanisms by which the human host controls 
primary and latent infection, and the effects of HIV on these mechanisms, may differ. Evidence 
from DNA fingerprinting (typing for IS6110 RFLP) studies indicate that HIV+ people in 
endemic regions, such as South Africa and Malawi, are primarily developing TB from new 
infection, rather than by reactivation of latent infection [243, 245]. In this type of study, the 
pattern of IS6110 sequences among M. tuberculosis isolates from patients within the cohort 
indicate whether the TB case is newly acquired as opposed to relapse of latent TB. HIV+ 
individuals are between 2.2 [245] and 5.5 [243] times more likely to develop TB from a new 
source compared to HIV-negative individuals. HIV+ individuals are also more likely to become 
infected with M. tuberculosis and die from TB than their HIV- counterparts (Figure 7, [14]). 
Not only are HIV+ individuals at greater risk of acquiring M. tuberculosis and developing 
active TB, they have an increased risk of mortality from TB [244, 246]. Although it has been 
well known over the past 25 years that HIV/M. tuberculosis co-infection is remarkably 
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detrimental [16, 247, 248], the mechanisms by which HIV disrupts the function in both 
established and newly forming granulomas, leading to the increased morbidity and mortality of 
co-infected people compared to people with TB alone remains to be determined [249].    
 
Figure 7. Flow chart of TB susceptibility and TB death rates in HIV-infected and HIV-uninfected 
individuals 
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4.2 THE EFFECTS OF HIV ON THE M. TUBERCULOSIS GRANULOMA  
It has been proposed that the increase in pathology associated with HIV/M. tuberculosis co-
infection is caused by a functional disruption of the local immune response within the granuloma 
[249-253]. These disruptions presumably decrease the ability of the granuloma to contain M. 
tuberculosis, leading to increased bacterial growth with more mycobacterial dissemination and 
severe pathology.  The cause for the disruption can be divided into general and overlapping 
processes: 1) an increase in viral load within involved tissue leading to 2) a decrease in total 
number of CD4 T cells along with 3) a disruption of macrophage function and 4) a perturbation 
of M. tuberculosis-specific T cell function and that lead to functional and detrimental changes 
within granulomas.  Here we review the available data for these HIV-induced changes. 
 
4.3 HIV REPLICATION AT SITES OF M. TUBERCULOSIS INFECTION 
Hypothesis:  
HIV replication increases at sites of M. tuberculosis infection, which leads to a reduction in 
containment of M. tuberculosis. 
 
HIV preferentially replicates within activated CD4 T cells and macrophages. Because CD4 T 
cells and macrophages are major components of the granuloma, and some proportion of these T 
cells are likely to be activated (an ideal situation for HIV uptake and replication), sites of M. 
tuberculosis infection are considered ideal for HIV replication. Increased viral load within 
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involved tissue would likely cause a disruption in equilibrium between granuloma function and 
mycobacterial growth. The available literature supports that M. tuberculosis leads to increased 
viral replication in vitro, ex vivo and in vivo.  
4.3.1 M. tuberculosis increases HIV replication in stimulated co-infected macrophages in 
vitro 
Multiple studies have been performed to determine whether M. tuberculosis influences HIV 
replication.  The data on replication of HIV within M. tuberculosis co-infected macrophages is 
controversial supporting both increases [254-258] and decreases [254] in viral replication.  In 
vitro studies have demonstrated the importance of macrophage activation state and the presence 
of pro-inflammatory cytokines in inducing HIV replication. THP-1 macrophage cell lines in 
contact with lymphocytes or neutrophils induce viral replication [256, 257].  These co-infected 
macrophages increase HIV replication when CCAAT enhancer binding protein beta (C/EBPb) 
transcription factor is inhibited and an increase in NF-kB production is induced, which binds to 
HIV long terminal repeat and initiates viral transcription. HIV replication decreased in the 
presence of neutralizing antibodies against TNF and IL-6, and increased in the presence of 
antibodies against IL-10 and TGF-b [255], which further supports that co-infected activated 
macrophages increase HIV replication.  However, the increase in viral replication may be M. 
tuberculosis strain-specific, since clinical strains of M. tuberculosis can manipulate replication of 
HIV to different degrees. For example, the strain CDC1551, which is a clinical strain, but 
considered less virulent [259], induces more HIV replication than the more virulent clinical 
HN878 strain in co-infected peripheral blood mononuclear cells (PBMC) [258].  M. tuberculosis 
has also been shown to decrease HIV replication in co-infected macrophages. Monocyte-derived 
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macrophages incubated with heat-inactivated M. tuberculosis prior to HIV infection prevented 
viral replication despite an increase in CCR5, a coreceptor used by HIV to infect cells [254]. 
However the majority of data supports the increase in HIV replication and this may be 
deleterious to the co-infected individual because the increase in HIV replication enhances 
transmission of HIV to autologous T cells in vitro [260] and M. tuberculosis specific CD4 T cells 
in vivo [261]. The increase in HIV transmission may be caused by an increase in T cell 
proliferation and viral release occurring when T cells are incubated with HIV/M tuberculosis co-
infected macrophages compared to macrophages infected with HIV alone [260].   
4.3.2 M. tuberculosis microenvironments increase HIV replication ex vivo and in vivo  
The immune environment created by M. tuberculosis also promotes viral replication ex vivo. M. 
tuberculosis causes an increase in inflammatory cytokines in vivo, which can lead to activation 
of T cells and macrophages, which induces replication of HIV. Garrait et al, determined that 
pleural fluid from individuals with TB incubated with HIV-infected PBMC induces more 
replication then when incubated with pleural fluid from individuals without TB [262]. This 
increase in replication was dependent on IL-6 and TNF, which supports the notion that activated 
cells induced by proinflammatory environments may increase HIV replication. This supports 
work that confirmed that HIV replication increases in activated CD4 T cells [263] and CD14+ 
macrophages [264], which are prevalent at sites of M. tuberculosis infection. 
High viral titers are inversely proportional to peripheral CD4 T cell counts and correlated 
with susceptibility to various opportunistic infections [265-267] and advancement to AIDS. One 
study concluded that there was a 5 to 160-fold increase in plasma viral titers during acute 
infection with M. tuberculosis [268] while another determined that viral titer was 2.5 times 
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higher in HIV+ individuals upon TB diagnosis [269]. A transient increase in viral titer may occur 
in co-infected people during acute TB due to an increase in activated CD4 T cells. However, the 
majority of clinical research has demonstrated that plasma viral titer does not correlate with 
susceptibility to active TB in co-infected people [270] or monkeys infected with SIV and M. 
tuberculosis [253, 271].  Likewise, treatment of TB does not necessarily lead to a reduction in 
plasma viral load [272]; further supporting that peripheral viral load does not by itself represent 
susceptibility to TB.  
Although little correlation between plasma viral titer and reactivation of TB has been 
observed in co-infected individuals, high viral loads within involved tissues have been suggested 
as a cause of the functional disruption within the granuloma [249, 268, 273]. Nakata et al, 
determined that HIV replicates within the lungs by measuring viral load and p24 in 
bronchoalveolar lavage (BAL) cells from co-infected individuals [274]. BAL represents the 
airway environment, which may be an initial site of M. tuberculosis replication, and is also a site 
of M. tuberculosis replication during active TB, but may not accurately represent events within 
the granulomas in the lung parenchyma. BAL cells from individuals co-infected with HIV and 
M. tuberculosis sampled from the airways of involved lungs (radiographic evidence of TB 
infiltrate) had higher viral titers and p24 than cells from the airways of uninvolved lungs in the 
same persons [274].  In this same study, viral load within BAL cells was higher than in plasma. 
This study was one of the first to demonstrate that HIV may replicate more at sites of disease. 
Other studies have confirmed that sites of M. tuberculosis infection have increased viral 
replication in co-infected patients [273, 275, 276]. Pleural fluid from co-infected subjects have 
higher viral titers [276] and increased HIV heterogeneity [273] compared to plasma from the 
same patients. Increases in viral titer and heterogeneity within M. tuberculosis-involved tissue 
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may increase viral fitness [275] and decrease the ability to contain both infections. On the 
contrary, granulomas from cynomolgus macaques co-infected with SIVmac251 and M. 
tuberculosis displayed similar SIV viral loads compared to uninvolved tissues, albeit with 
substantial variability [271]. Since these monkeys had very low plasma and PBMC viral loads, 
they may not represent exactly what is occurring within co-infected humans.  
These studies provide a basic framework for our understanding of how M. tuberculosis 
manipulates HIV replication. However, no clinical studies have demonstrated that granulomas 
provide this ideal environment for HIV replication, which emphasizes the need for clinical 
researchers to determine whether the granuloma environment is influencing virus replication 
directly, and the need for animal models of co-infection.  
4.4 CHANGES IN T CELL NUMBER WITHIN GRANULOMA 
Hypothesis:  
HIV induces active or reactivated TB by reducing CD4 T cells within granulomas. 
 
  CD4 T cells are essential for containment of M. tuberculosis and long-term survival of infected 
mice, which was demonstrated by a significant decrease in survival time and increase in bacterial 
burden in MHC-II-/- and CD4-/- mice [56]. HIV and SIV cause substantial reductions in 
peripheral, mucosal and gut CD4 T cells shortly after infection by preferentially infecting 
activated CD4 T cells [158, 167, 277, 278] and resting memory CD4 T cells [166, 279]. Studies 
have determined that SIV, and presumably HIV, kill up to 60% gut CD4 T cells within the first 
10 days of infection, with an 80% reduction of these cells by 2 weeks post infection [158, 277]
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The affected cells are mostly effector memory T cells [167, 279], which are abundant in these 
sites. Because HIV depletes these cells within the periphery, gut and mucosal tissue [278, 280], it 
has been hypothesized that HIV-induced depletion of CD4 T cells within granulomas leads to a 
direct disruption of the containment of M. tuberculosis infection [249, 281].   
4.4.1 HIV-induced decreases in peripheral CD4 T cells correlates with susceptibility to 
TB  
Peripheral CD4 T cell count is a standard measure of disease progression in HIV infected 
individuals, and this has been reported for many HIV/M. tuberculosis co-infection studies [270, 
271, 282-284].  HIV+ individuals are more susceptible than HIV- people to TB regardless of 
peripheral CD4 T cell counts [16, 285], although susceptibility increases with decreasing 
peripheral CD4 T cells. HIV+ individuals with <200 CD4 T cells/ml blood are more susceptible 
to TB than HIV+ individuals with >500 CD4 T cells/ml blood regardless of anti-retroviral 
therapy [270]. Similarly, an acute and transient decrease in peripheral CD4 T cells post-
SIVmac251 inoculation in monkeys with latent TB significantly correlated with time to 
development of reactivation TB [271]. The reduction in CD4 T cells was not confined to the 
periphery, as co-infected monkeys that reactivated latent TB within 17 weeks of SIVmac251 
inoculation had a trend of fewer BAL CD4 T cells compared to monkeys that reactivated after 26 
weeks. A decreased frequency of BAL CD4 T cells has also been noted in HIV+ individuals with 
TB compared to HIV- individuals with TB [281, 284, 286] and also in HIV+ individuals without 
TB that live in areas with high TB incidence rates compared to HIV- individuals in the same 
community [286].    
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4.4.2 Depletion of T cells in TB granulomas of AIDS patients and SIV co-infected 
monkeys 
Histological analysis was used to provide the first data on CD4 counts in granulomas in AIDS 
patients with TB [252]. Lymph node biopsies from patients with AIDS and tuberculous adenitis 
had fewer CD4 T cells than individuals without AIDS and tuberculous adenitis. In the absence of 
CD4 T cells within the granulomas, CD8 T cells were distributed throughout the granuloma 
without being confined to the periphery, as is normally observed.  This suggests that CD4 T cells 
help maintain the architecture and integrity of the granuloma during co-infection. The reduction 
in CD4 T cells within granulomas of AIDS patients is not surprising because one characteristic 
of AIDS patients is <200 CD4 T cells/ml blood and likely reflects a long duration of CD4 T cell 
depletion. Another study demonstrated that similar numbers of granulomas were observed in 
HIV+ and HIV- patients with pleural TB [287]. No difference in the number of bacilli assessed 
by staining or culture positive tissues were observed between the two groups. However, 
individuals with <100 CD4 T cells/ml blood were more likely to have acid-fast bacilli within 
biopsied granulomas than individuals with >100 CD4 T cells/ml. CD4 T cell count threshold may 
be needed in preventing bacterial growth in co-infected individuals. Taken together, these studies 
demonstrate that the peripheral decrease in T cells correlates to a decrease within the granuloma 
during AIDS. If this correlation also occurs throughout the entire HIV infection course, this may 
also explain why co-infected individuals with fewer CD4 T cells are more prone to developing 
active TB [270].  Many co-infected people present with TB well before the development of 
AIDS so these granulomas may not represent what is occurring in the majority of co-infected 
people. We observed significantly fewer CD4 and CD8 T cells within lung granulomas of co-
 51 
infected monkeys compared to granulomas from those with active TB alone [271]. The decrease 
in lung T cell numbers was independent of peripheral CD4 T cell counts, which means that HIV 
may selectively kill T cells directly involved in maintaining granulomas (i.e. activated T cells at 
the site) prior to loss of peripheral T cells and signs of AIDS.    
 Taken together these studies demonstrate that CD4 (and possibly CD8) T cells play a 
very important role in preventing development of TB in co-infected individuals. However, more 
studies are needed to confirm that T cell depletion is occurring within granulomas.  Future 
studies may also provide a correlation between peripheral, airway and granuloma T cell counts, 
which may be used as a biomarker for disease progression.  
4.5 CHANGES IN MACROPHAGE FUNCTION 
Hypothesis:  
The ability of HIV to manipulate macrophage function inhibits killing of intracellular M. 
tuberculosis. 
 
Alveolar macrophages are presumably the first group of cells infected with M. tuberculosis and 
are the primary immune cells within the airways. They can act as a reservoir for both HIV and 
M. tuberculosis. Following entry of M. tuberculosis into the parenchyma, monocytes migrate to 
the lungs and differentiate into different macrophage types within the granuloma. All of these 
macrophage types may be susceptible to HIV infection, as well as M. tuberculosis infection. HIV 
envelope phenotyping has suggested that HIV infects activated (HLA-DR+) alveolar 
macrophages (CD14+, CD36+) as well as lymphocytes (CD26+) in pleural fluid [264] or 
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airways [288] in co-infected individuals.  Since HIV has been shown to infect macrophages in 
vivo, HIV is likely to disrupt the function of M. tuberculosis-infected macrophages [212, 257, 
288-290], leading to granuloma dysfunction and increased bacterial growth and dissemination.  
4.5.1 HIV decreases responsiveness to M. tuberculosis ex vivo 
Macrophage apoptosis appears to be a critical immune response to M. tuberculosis during co-
infection [212, 289, 291, 292]. Although it is not fully understood, HIV infection of alveolar 
macrophages from healthy adults [289] or HIV+ adults [212] is associated with reduced M. 
tuberculosis-induced apoptosis compared to macrophages infected with M. tuberculosis alone. 
Exogenous HIV Nef protein added to M. tuberculosis-infected macrophages inhibits ASK1/p38 
MAPK signaling, which leads to a decrease in TNF release and TNF-dependent apoptosis [293], 
suggesting that infectious virus is not necessary for inducing this functional change within a 
macrophage. This is important because HIV is a retrovirus, with an error prone reverse 
transcriptase that causes numerous site mutations that render most viral buds noninfectious 
[294]. Since phagolysosome fusion is inhibited in M. tuberculosis infected alveolar macrophages 
from HIV+ individuals [290], apoptosis may be used as a last resort of infected macrophages. 
This allows other activated macrophages to engulf the nearby apoptotic bodies, which may lead 
to the killing of the mycobacteria, and enhanced induction of T cell responses [295]. M. 
tuberculosis induced apoptosis in macrophages is complex and may not always be beneficial to 
the host. Some evidence suggests that an increase in apoptosis occurs in alveolar macrophages 
from AIDS patients with pulmonary TB compared to individuals with only pulmonary TB [296]. 
An increase in apoptosis may be beneficial to the pathogens because it would allow them to exit 
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macrophages capable of killing. This may also lead to increased dissemination of M. tuberculosis 
and HIV.  
HIV appears to manipulate both apoptosis [212, 289] and the ability of macrophages to 
acidify M tuberculosis-infected phagosomes [290, 297]. These changes in macrophage function 
may increase the risk of developing active or reactivated TB in co-infected patients. One 
limitation to many of the studies addressing how HIV and M. tuberculosis change macrophage 
function is the use of cell lines or monocyte-derived macrophages [256, 268, 298] rather than 
alveolar macrophages [212, 257, 289, 290, 299] or macrophages from granulomatous tissue. 
Having said that, it is possible that alveolar macrophages may respond differently than 
macrophages recruited to granulomas, as these environments are very different and represent 
different stages of the infectious process.  
4.6 CHANGES IN M. TUBERCULOSIS-SPECIFIC T CELL RESPONSES 
Hypothesis: 
HIV impairs the function of M. tuberculosis-specific T cells within involved tissue. 
 
T cell mediated responses are essential to protection against disease due to both M. tuberculosis 
and HIV.  T cells release cytokines, including IFNg, TNF, IL-2, as well as a variety of cytolytic 
molecules that are important in controlling both M. tuberculosis and HIV. HIV can exhaust HIV-
specific and nonspecific T cells [300, 301], which has led to the hypothesis that HIV reduces the 
number and functionality of M. tuberculosis (M. tuberculosis)-specific T cells in co-infected 
individuals [282, 283, 286, 302, 303].    
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4.6.1 HIV decreases peripheral M. tuberculosis-specific T cell responses 
Numerous studies have examined M. tuberculosis-specific T cell responses in individuals 
infected with M. tuberculosis by stimulating PBMC, BAL or pleural fluid cells with purified 
protein derivative (PPD) or culture filtrate protein (CFP) (both are mixtures of mycobacterial 
proteins and lipids), killed M. tuberculosis, or peptide pools from immunogenic M. tuberculosis-
specific proteins, ESAT-6, CFP10 and Ag85 [261, 282, 283, 302-305]. Zhang and colleagues 
demonstrated that PBMC stimulated with heat killed M. tuberculosis from co-infected 
individuals proliferated significantly less, released less IFNg and expressed less IL-2 and IL-12 
mRNA than TB-only patients [302]. PBMC from HIV/PPD+ (latently infected) individuals that 
were stimulated with whole M. tuberculosis lysate, ESAT6 or Ag85B proliferated less and 
released less IFNg than PBMC from HIV- PPD+ individuals [303]. Likewise, PBMC stimulated 
with killed M. tuberculosis released less TNF without a decrease in IFNg release in co-infected 
individuals with active TB compared to people with TB alone [282]. These decreases were not 
observed in mitogen- or Candida albicans antigen-stimulated cells, which supports that HIV is 
specifically manipulating M. tuberculosis-specific T cells. It should be noted that a few studies 
have demonstrated that co-infected individuals can have a high number of peripheral IFNg-
releasing M. tuberculosis-specific T cells even with a low number of CD4 T cells [306-308]. 
However, the majority of these data support, at least peripherally, that HIV impairs the ability of 
T cells to respond to M. tuberculosis. The reduction in the observable number of peripheral M. 
tuberculosis-specific CD4 T cells may result from their direct infection by HIV in co-infected 
individuals [261].  
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One inherent limitation of HIV/TB co-infection clinical research is that it is difficult to 
assess changes in an immunologic response before and after HIV infection. One excellent study 
addressed this limitation by examining changes in the number of M. tuberculosis-specific 
peripheral CD4 T cells in individuals with latent M. tuberculosis infection before and after HIV 
seroconversion [283].  They determined that within 3 months post HIV seroconversion a 
dramatic decrease of peripheral M. tuberculosis-specific memory (CD27+CD45RO+) CD4 T 
cells releasing IFNg occurred in 4 out of 5 individuals. Although only 5 individuals with latent 
TB became HIV seropositive during this study, it is the first to demonstrate that HIV specifically 
reduces M. tuberculosis-specific T cells over time.  Changes in the peripheral responses have 
provided evidence to support the hypothesis that HIV depletes and/or functionally disrupts M. 
tuberculosis-specific T cells. However, since TB is rarely a systemic disease it remains to be 
seen whether these peripheral changes are replicated within involved tissue. An alternative 
hypothesis is that HIV causes increased M. tuberculosis replication in the tissues, and the 
peripheral cells migrate to the lungs in response to increased antigen, which would present as a 
reduction in peripheral responses but may not indicate a true loss of specific responses.  
4.6.2 HIV reduces M. tuberculosis-specific T cell responses in the airways 
BAL cells from HIV+ individuals (previously vaccinated with BCG, an avirulent vaccine strain 
of M. bovis) incubated with BCG resulted in significantly fewer IFNg and TNF releasing BCG-
specific CD4 T cells than HIV- individuals [286]. This depletion also occurred in 
IFNg+TNF+IL-2+ polyfunctional CD4 T cells within the HIV group. Although these individuals 
did not have any signs of TB at the time of collection or in the past, this study demonstrates that 
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HIV specifically impairs the function of both single and polyfunctional mycobacteria (BCG)-
specific T cells even without active TB.   
The reduction in BAL T cell responses to mycobacteria also occurs in individuals co-
infected with HIV and M. tuberculosis. AIDS patients with pulmonary TB have a reduced ability 
to produce IFNg mRNA in isolated BAL cells compared to individuals with pulmonary TB alone 
[305]. The functional changes in the context of HIV are not limited to cytokine release. A 
reduction in proliferation of pulmonary lymphocytes from BAL stimulated with either PPD or an 
avirulent M. tuberculosis strain was observed in individuals with AIDS and TB compared to 
individuals with TB alone [304]. T cell responses in AIDS patients may not recapitulate what is 
occurring within HIV+ individuals prior to the significant depletion of CD4 T cells associated 
with AIDS.  However, the BAL studies suggest that HIV disrupts multiple pulmonary T cell 
functions that may be required to prevent reactivation of latent M. tuberculosis infection.   
4.6.3 HIV changes cytokine profile within granulomas 
In situ hybridization and immunohistochemistry have been used to identify changes in cytokine 
expression within co-infected granulomas [250, 251]. Although these techniques cannot 
determine changes in function of M. tuberculosis-specific T cells, they provide an overall 
summary of how cells are responding within the context of granulomas. Bezuidenhout et al., 
determined that the same number of granulomas within HIV+ and HIV- individuals with pleural 
TB express Th1 (IFNg, IL-12, TNF) or Th2 (IL-4, IL-10) mRNA [251].  However, it was 
determined that granulomas within HIV+ patients expressed more IFNg, TNF, IL-12 and IL-4 
mRNA than granulomas from HIV- individuals. The increase in TNF mRNA expression 
correlated with an increase in necrotic granulomas within the co-infected patients. This does not 
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necessarily mean that the M. tuberculosis-specific T cells are producing more cytokines in co-
infected granulomas. It is possible that the increase in HIV antigens within the granulomas 
causes an increase in HIV-specific T cell activity too, which cannot be determined without 
antigen specific functional assays. The increase in cytokine mRNA expression may also be the 
result of more cells within the granulomas of co-infected individuals compared to HIV- 
individuals.  If the increase in cytokine mRNA leads to increased inflammation, excessive 
pathology or changes in granuloma function and architecture may occur that inhibit the control 
of M. tuberculosis infection. Contrary to the previous result, another immunohistochemistry 
study determined that granulomas from HIV+ individuals with TB expressed less TNF and had 
more extensive necrosis than granulomas from individuals with TB alone [250]. The decrease in 
TNF expression may be due to a functional disruption or a decrease in the number of T cells and 
infected macrophages within the granulomas. Due to the highly invasive nature of granuloma-
based studies, and the difficulties in obtaining autopsy tissues (and selection bias to these 
samples), the one solution is the use of a realistic animal model. These studies may elucidate the 
mechanistic changes that occur within the granuloma as a result of HIV infection, and identify 
targets for preventive or intervention therapies. 
A significant amount of evidence supports the hypothesis that HIV reduces M. 
tuberculosis-specific T cell functions. However, most of these studies have confirmed these 
changes within the periphery or BAL cells, which may interact differently within the structured 
environment of a granuloma. No clinical studies have examined functional T cell changes within 
granulomatous tissue, which could be addressed with an animal model.  
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4.6.4 Anti-retroviral treatment increases M. tuberculosis-specific T cell responses 
Anti-retroviral treatment has been used to treat individuals that are co-infected with both HIV 
and M. tuberculosis. Wilkinson et al determined that anti-retroviral treatment in co-infected 
individuals led to an increase in the percentage of naive (CD27+CD45RA+) CD4 T cells after 36 
weeks post anti-retroviral therapy and a sustained increase in central memory (CD27+CD45RA-) 
by 12 weeks post treatment [309]. The increase in central and naïve CD4 T cells correlate with 
an increase in ESAT-6/CFP10-specific T cells 48 weeks post anti-retroviral treatment. 
Surprisingly, a decrease in IFNg release was observed when PPD was used as a stimulator in this 
study. Another study followed co-infected patients for 12 months and found an increase in 
polyfunctional effector memory (CD27-CD45RO+) and terminal memory (CD27-CD45RO-) 
CD4 T cell responses to PPD [310].  Although anti-retroviral therapy increases T cell responses 
in co-infected patients, these responses are significantly lower than individuals with TB alone 
[311]. Although anti-retroviral therapy increases M. tuberculosis-specific T cell responses in co-
infected individuals this increase in M. tuberculosis-specific T cell responses may not always 
ameliorate TB pathology and may actually exacerbate TB (see section on IRIS below) [312, 
313].   
4.7 IRIS FURTHER COMPLICATES THE CO-INFECTION 
Highly active anti-retroviral treatment (HAART) ameliorates the symptoms of HIV-induced 
disease through a dramatic reduction in plasma viremia and restoration of CD4 T cell levels 
[314]. Individuals on HAART are still more susceptible to TB than HIV- individuals [270]. This 
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susceptibility to TB is inversely proportional to peripheral CD4 T cell count [270]. Individuals 
co-infected with HIV and TB on HAART have a delayed increase in M. tuberculosis-specific T 
cell responses and may not reach levels observed in HIV- adults [311].  
Co-infected individuals on HAART may have excessive inflammation during immune 
reconstitution, and they may suffer from TB-associated immune reconstitution inflammatory 
syndrome (IRIS), which occurs in two forms. Paradoxical TB-IRIS occurs in patients on TB 
treatment before HAART. Unmasking TB-IRIS occurs in patients who are not on TB treatment 
when they start HAART, and may represent either reactivation of latent infection or enhanced 
symptoms from TB that was not previously diagnosed as active disease or was subclinical [315]. 
This is believed to be the result of increased inflammation in the tissues, which can enhance the 
symptoms of TB, or possibly even trigger reactivation. The available data on IRIS in M. 
tuberculosis-infected persons strongly suggest that excessive inflammation in the setting of 
subclinical or latent M. tuberculosis infection is detrimental to control of the infection [312, 313, 
316, 317]. The excessive inflammation may be caused by an increase in antigenic burden, 
perhaps by reconstituting CD4 T cell effector function in the granuloma which can kill M. 
tuberculosis and release antigen [318], dysregulation of cytokine responses [316] and/or an 
increase in T cell migration and activation at the site of infection  [312, 313, 317]. Higher 
concentrations of TNF, IL-6 and IFNg were observed in patients with TB-IRIS compared to 
individuals with TB alone [316]. The increases in cytokine release may be due to the increase in 
Th1 responses such as IFNg releasing T cells [313, 317] and T cell activation (HLA-DR+) [312] 
observed in individuals that develop IRIS shortly after HAART initiation. One possibility for the 
increase in Th1 function may be caused by a defect in regulatory T cell function [319], however 
recent studies have reported no difference in the number of regulatory T cells between co-
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infected individuals with and without IRIS [320, 321]. It should be noted that it is not known 
whether these mechanistic changes are the cause or the result of IRIS, so no predictive clinical 
biomarker has been identified.  
Although the mechanisms that lead to IRIS-associated TB are not fully understood, and 
have been reviewed more fully elsewhere [315, 322, 323] this unfortunate side-effect of HAART 
demonstrates that preventing TB is not as straightforward as simply replacing CD4 T cells in the 
periphery or even in the granuloma [315]. Instead, a balance of pro- and anti-inflammatory 
responses is necessary for optimal control of M. tuberculosis at the granuloma level. The 
resurgence of immune responses following HAART is likely deficient in reconstituting that 
balance in some individuals. Again, data are lacking on granulomas and tissues in TB-IRIS 
patients, and currently, we have no animal model where this phenomenon can be studied.  
4.8 ANIMAL MODELS: THEIR POTENTIAL TO ADDRESS GAPS IN HUMAN 
HIV/TB CO-INFECTION LITERATURE 
The available human data has shaped our current understanding of how HIV manipulates M. 
tuberculosis infection and disease. Building on the solid base of knowledge these studies have 
provided will substantially increase our understanding of the co-infection. A priority should be to 
increase the number of studies that focus on tissue events, especially at the granuloma level in 
HIV/M tuberculosis co-infected people. The difficulties in obtaining such samples are obvious. 
Appropriate and relevant animal models may be the next best choice for determining the events 
that occur in the tissue and granulomas of co-infected individuals. The TB field has several 
experimental animal models. The advantages of an animal model include the ability to control 
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the timing, dose, and strain of infection, to sample or necropsy at pre-determined time points, 
and to obtain tissue at necropsy. Currently there are only a few animal models available for 
studying interactions between HIV and TB. These models may be able to address some of the 
gaps in the human HIV/TB literature.  
4.8.1 Mouse models 
Mouse models have been invaluable for addressing immunological and pathogenesis questions in 
TB. Genetic similarities and the availability of genetically manipulated strains, reagents, low cost 
and relatively easy maintenance makes them ideal for most TB research facilities. A 
disadvantage of the mouse model is that TB in mice is a chronic infection that differs from both 
active and latent TB in humans. Murine models have demonstrated the importance of IFNg, 
TNF, activated macrophages and CD4 T cells, among other factors, in controlling TB [56, 71, 
111]. However, mice are not susceptible to HIV and there is not a suitable homologous murine 
virus so wild type mice are not ideal candidates for co-infection research.  
 The most basic HIV/M. tuberculosis mouse model is one in which mice are rendered 
CD4 T cell deficient, either through antibody-mediated depletion or genetic manipulation [56, 
111]. Because CD4 T cells are depleted during HIV infection it is logical to study CD4 deficient 
mice as a model for HIV/TB co-infection.  CD4 T cell deficient mice are more susceptible to 
advanced TB than wild type mice, supporting the importance of CD4 T cells in containing 
primary and chronic TB.  However, the disease associated with HIV is not entirely caused by 
depletion of CD4 T cells. Viral particles can induce non-specific apoptosis [324], disruption of 
lymph node architecture [325], T cell anergy [300], and affect macrophages, all of which have 
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been associated with HIV pathology.  These aspects of HIV infection cannot be recapitulated in 
CD4 T cell depleted mice.  
To address how viral proteins, specifically HIV Nef, manipulate immunological 
responses Nef transgenic mice have been developed [326-328].  These mice express Nef in CD4 
T cells, macrophage and dendritic cells and subsequently develop AIDS-like disease 
characterized by CD4 T cell depletion as well as lung, heart and kidney diseases [327, 328]. This 
transgenic mouse model demonstrates that Nef expression within CD4 T cells is a major 
determinant of pathogenicity of HIV infection [326]. Nef expression within CD4 T cells causes 
increased activation and apoptosis, which eventually leads to their depletion. Future TB studies 
may be able to use this transgenic mouse to determine how Nef expression changes immunologic 
responses to TB.  
Another mouse model that may increase our understanding of how HIV manipulates TB 
pathology are humanized bone marrow–liver–thymus (BLT) mice reconstituted with human 
hematopoietic stem cells, which produces human lymphoid tissues [224].  Human CD4 T cells 
reconstitute the gastrointestinal and female reproductive tract, causing these mice to be 
susceptible to rectal [224] and vaginal [329] HIV inoculation. HIV infection results in systemic 
viral loads, a depletion of systemic CD4 T cells and T cell activation similar to what is observed 
in humans with HIV [224, 329]. Infecting these mice with HIV and M. tuberculosis may identify 
how HIV behaves within granulomas. Prophylaxis has been shown to reduce infection rates 
within these mice [329], which indicates that anti-retroviral effectiveness in the context of a 
HIV/M. tuberculosis co-infection may be studied in these mice. The use of HAART in co-
infected mice may be able to address how HIV induces functional changes in M. tuberculosis-
specific T cells within granulomas, but also how the virus changes granuloma formation and 
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architecture. BLT mice may be used to identify immunologic targets that can be examined within 
more expensive primate models or clinical studies. 
4.8.2 Nonhuman primate models 
Nonhuman primates (NHP) have helped elucidate our understanding of HIV [330-332] and M. 
tuberculosis [72, 91, 112, 113] infections. Serial blood, BAL and LN biopsy samples can be 
obtained from NHP during the course of infection and all tissues are available at necropsy, 
addressing an inherent limitation of clinical studies. This model may be ideal for approaching 
questions that cannot be answered in clinical studies.   
 Several NHP models of HIV/TB co-infection have been developed [253, 271, 333-336].  
SIV-infected rhesus macaques have been inoculated with BCG [333, 334, 336, 337] or M. 
tuberculosis [253]. These models have recapitulated the decrease in peripheral mycobacterial-
specific T cell responses observed HIV/TB co-infected humans. The similarities between these 
results and human co-infection studies demonstrate the validity of the NHP as an animal model 
for co-infection. We recently reported a cynomolgus macaque model of SIV-induced reactivation 
of latent TB, which should be very useful in understanding how HIV manipulates TB 
immunology and pathology [271]. This model examined aspects of the co-infection that haven’t 
been addressed in human studies. For example, the severity of the initial but transient reduction 
in peripheral T cell numbers during acute SIV was correlated with time to reactivation and 
reductions in T cell numbers also occurred within lung granulomas of co-infected monkeys 
compared to monkeys with active TB without SIV [271]. Data extrapolated from this model and 
clinical studies helped elucidate a potential mechanism for the reactivation of latent TB 
granuloma (see chapter 8). These models have the potential to be used for immunomodulation, 
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vaccine and antiretroviral-based studies to study efficacy of therapies against TB in the context 
of the co-infection.  
Animal models will allow us to assess HIV-induced changes in M. tuberculosis-specific 
immune responses that may lead to reactivation of TB and increased susceptibility to TB in 
HIV+ individuals. Although every animal model has its limitations we hope that these new 
mouse and NHP models will provide evidence supporting or refuting the various hypotheses 
about how HIV manipulates TB pathology. Increasing our basic understanding of how these 
pathogens interact in vivo will help us uncover possible treatments for co-infected people.  
4.9 HOW CAN TISSUE-BASED STUDIES IMPROVE TREATMENT?  
Future studies may demonstrate that a high level of HIV replication within the granuloma 
correlates to granuloma dysfunction and mycobacterial growth. This is important because it is 
unknown whether anti-retrovirals reduce viral load within granulomas or even if they penetrate 
granulomas in the appropriate concentrations in co-infected patients.  Drug concentration in 
granulomas can be quantified by direct measurement in animal models, and this may be 
necessary to determine the best treatment for co-infected persons, taking into account penetration 
of granuloma, viral load, and type of granuloma. A further important factor is that understanding 
the correlation between viral titer within BAL and plasma with viral titers in granulomatous 
tissue will provide a better opportunity to assess the efficacy of HAART in co-infected 
individuals, and possibly identify biomarkers for drug efficacy. These studies will be essential 
for development of tractable biomarkers in the blood that translate to granuloma dysfunction and 
predict outcome in co-infected individuals.  
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However, if clinical and animal-based studies demonstrate that HIV does not replicate 
specifically within granulomas, the functional change to the immune response may occur in the 
lymph nodes, where priming of the initial and perhaps ongoing T cell responses occurs. The 
thoracic lymph nodes are a common site of M. tuberculosis infection, and may actually be a site 
for reactivation of latent infection [72]. This may be validated by correlating changes in M. 
tuberculosis-specific T cell function with viral load within these lymph nodes. If a positive 
correlation is present, drug effectiveness may be determined by examining changes in viral load 
within these tissues during drug treatment.  
4.10 CONCLUSION  
The mechanisms by which HIV disrupts TB granuloma function and lead to increased morbidity 
and mortality have been extrapolated from clinical and animal studies, but remain poorly 
understood. Changes in T cell and macrophage function within granulomas need to be examined 
in future clinical and animal studies to elucidate possible mechanisms by which HIV disrupts TB 
immune pathology. These studies may provide insight into potential drug and/or vaccine 
therapies. In addition, it is important to understand the parallels between easily obtained samples 
(like blood) and the tissue responses, so that one can correctly interpret the blood-based data. 
Only through studies that correlate blood and tissue responses can we begin to search for 
biomarkers for disease status that can be used in vaccine and drug studies.  
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5.0  STATEMENT OF THE PROBLEM 
TB is the leading killer of individuals infected with human immunodeficiency virus-1 (HIV). 
Immunocompromised individuals have a significantly greater risk of developing active TB than 
individuals that are HIV-uninfected. Although clinical reports have elucidated a significant 
amount of information about how the co-infection manipulates our immune system, there are 
some drawbacks to only studying humans. These reports have been limited because of the 
paucity of available time points, limited availability of leukocyte samples, the undefined status of 
the immune system prior to infection, the dose of the inoculum, the ethical obligation to 
commence treatment, and the extent to which post mortem tissue samples are available.  
 Because our current understanding about HIV/M. tuberculosis co-infection has 
predominantly been derived from clinical and in vitro reports, there exists a need for an animal 
model recapitulating the co-infection to fill in gaps in knowledge. Cynomolgus macaques 
(Macaca fasicularis) have been used as animal models of human infection with M. tuberculosis 
and simian immunodeficiency virus (SIV) infection. In this study, we developed a non-human 
primate model of co-infection by infecting cynomolgus macaques with latent TB with 
SIVmac251. We also developed an in vitro and ex vivo SIV/M. tuberculosis co-infection method 
to determine how SIV manipulates both macrophage and M. tuberculosis-specific T cell 
function.   
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The co-infection animal model allowed us to examine multiple immunologic and 
microbiologic aspects over the entire course of disease that would not have been possible in 
humans. We focused on examining changes in peripheral T cells over time, changes in cytokine 
concentrations within plasma, how SIV manipulates granuloma composition and architecture, 
viral concentrations in the periphery over time and within tissue at necropsy and how SIV 
changes T cell effector functions within granulomas and thoracic lymph nodes. For the first time 
we demonstrated that SIV can induce the reactivation of latent TB. In this model we provide 
evidence that initial T cell depletion after SIV inoculation in monkeys with latent TB perturbs 
the control of the infection, and directly corresponds to the reactivation of TB, even though 
peripheral T cell numbers quickly return to pre-SIV levels. This model addressed my first 
specific aim and part of my second aim.  
We also developed in vitro and ex vivo experiments to examine how HIV manipulates 
both macrophage and M. tuberculosis-specific T cell function. We used peripheral T cells and 
monocytes, monocyte-derived macrophages and thoracic lymph node homogenates from M. 
tuberculosis-infected macaques (without SIV) along with exogenous SIV to determine how the 
virus changes immunologic responses to M. tuberculosis.  Here we determined that SIV reduces 
M. tuberculosis-specific T cell responses through the manipulation of antigen presenting cells. 
This manipulation of M. tuberculosis-specific T cell function results from SIV inducing M. 
tuberculosis-infected macrophages to produce IL-5, which specifically caused a reduction in M. 
tuberculosis-specific CD4 T cells releasing TNF. These studies suggest a novel role for IL-5 and 
address specific aims 2 and 3.  
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5.1 SPECIFIC AIM 1: ESTABLISH A CYNOMOLGUS MACAQUE MODEL OF M. 
TUBERCULOSIS/SIV CO-INFECTION 
Hypothesis: 
 SIVmac251 will reactivate latent TB in cynomolgus macaques. 
 
A clinically relevant M. tuberculosis/SIV co-infection model will enable a detailed investigation 
throughout the course of disease and provide information about how HIV reactivates latent TB.  
5.2 SPECIFIC AIM 2:  EXAMINE CHANGES IN M. TUBERCULOSIS-SPECIFIC T 
CELL EFFECTOR FUNCTIONS THAT RESULT FROM M. TUBERCULOSIS/SIV CO-
INFECTION 
Hypothesis: 
 SIV will reduce the responsiveness of M. tuberculosis-specific T cells. 
 
T cell effector functions are crucial in controlling M. tuberculosis.  HIV has the ability to kill and 
reduce the responsiveness of both CD4 and CD8 T cells. HIV-induced manipulation of M. 
tuberculosis-specific T cell responses may decrease containment of M. tuberculosis.  
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5.3 SPECIFIC AIM 3: DETERMINE HOW SIV MANIPULATES MACROPHAGE 
FUNCTION THAT RESULTS FROM M. TUBERCULOSIS/SIV CO-INFECTION 
Hypothesis: 
 Co-infected macrophages will have a reduced ability to stimulate M. tuberculosis-specific T 
cells. 
Macrophages are a major component of granulomas and their function is essential in containing 
M. tuberculosis. Macrophages both kill intracellular pathogens and can activate T cells. HIV and 
M. tuberculosis can both reduce normal macrophage function. This dysfunction is exacerbated 
during the co-infection.  
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6.0  REACTIVATION OF LATENT TUBERCULOSIS IN CYNOMOLGUS 
MACAQUES INFECTED WITH SIV IS ASSOCIATED WITH EARLY PERIPHERAL T 
CELL DEPLETION AND NOT VIRUS LOAD 
 
This chapter is adapted from the original publication: 
 
Diedrich CR, Mattila JT, Klein E, Janssen C, Phuah J, et al. (2010) Reactivation of 
Latent Tuberculosis in Cynomolgus Macaques Infected with SIV Is Associated with Early 
Peripheral T Cell Depletion and Not Virus Load. PLoS ONE 5(3): e9611. 
doi:10.1371/journal.pone.0009611. Citation: [271]. 
 
This is an open-access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any 
medium, provided the original author and source are credited. 
 
6.1 ABSTRACT 
 
HIV-infected individuals with latent Mycobacterium tuberculosis (M. tuberculosis) infection are 
at significantly greater risk of reactivation tuberculosis (TB) than HIV-negative individuals with 
latent TB, even while CD4 T cell numbers are well preserved. Factors underlying high rates of 
reactivation are poorly understood and investigative tools are limited. We used cynomolgus 
macaques with latent TB co-infected with SIVmac251 to develop the first animal model of 
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reactivated TB in HIV-infected humans to better explore these factors. All latent animals 
developed reactivated TB following SIV infection, with a variable time to reactivation (up to 11 
months post-SIV). Reactivation was independent of virus load but correlated with depletion of 
peripheral T cells during acute SIV infection. Animals experiencing reactivation early after SIV 
infection (<17 weeks) had fewer CD4 T cells in the periphery and airways than animals 
reactivating in later phases of SIV infection. Co-infected animals had fewer T cells in involved 
lungs than SIV-negative animals with active TB despite similar T cell numbers in thoracic lymph 
nodes. Co-infected animals had fewer IFN-g producing T cells within the thoracic lymph nodes 
than monkeys with active TB. Granulomas from these animals demonstrated histopathologic 
characteristics consistent with a chronically active disease process. These results suggest initial T 
cell depletion may strongly influence outcomes of HIV-M. tuberculosis co-infection.  
  
6.2 INTRODUCTION 
Approximately 90% of human Mycobacterium tuberculosis (M. tuberculosis) infections are 
clinically latent and likely represent an immune response that successfully limits bacterial 
growth, resulting in persistence within multi-cellular structures called granulomas [338]. While 
granulomas are composed of many different cell types, macrophages and T cells are important 
components that collaborate to limit bacterial replication and prevent dissemination. The immune 
response of immunocompetent individuals can prevent active tuberculosis for years or decades, 
and latently infected individuals have only a 5-10% lifetime risk of developing reactivated 
tuberculosis (TB) [339]. Immunosuppressed individuals have a significantly greater chance of 
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developing active disease, and TB is the leading killer of individuals infected with human 
immunodeficiency virus (HIV) [14]. In contrast to most opportunistic infections, which present 
in the later stages of HIV infection, TB afflicts HIV-positive individuals throughout the course of 
infection, even while CD4 numbers are well preserved [340-342]. While factors explaining the 
high rates of reactivated TB in co-infected humans remain unclear, depletion of CD4 T cells 
[281] and increased virus loads [343] within granulomatous tissue may be contributors. 
Co-infections in humans, and the accompanying immune responses, are inherently 
difficult to investigate and studies are frequently confounded by uncontrolled variables. Our 
current understanding of immune responses to HIV-M. tuberculosis co-infection comes 
predominantly from human clinical studies [249, 343]. As with all clinical studies involving 
human subjects, there are limitations to studies that can be performed with HIV-M. tuberculosis 
co-infected individuals. Some challenges include difficulty determining which infection occurred 
first and when, limited availability of pre- and post-infection samples, restrictions on 
unnecessary invasive procedures to obtain tissue samples, and limited availability of post 
mortem tissue samples for immunologic analysis. Additionally, most HIV-TB clinical studies are 
in individuals with active tuberculosis, and cannot fully explore the events that precede or occur 
during reactivation. Human studies also have numerous uncontrolled variables including the 
undefined status of the immune system prior to infection and the presence of other undiagnosed 
co-infecting pathogens that may have an effect on the host immune response. Consequently, a 
biologically relevant animal model of HIV-M. tuberculosis co-infection where the amount and 
sites of sampling could be increased and the confounding variables minimized would be an 
extremely valuable asset.  
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Good animal models for HIV and TB exist, but there is not a model which recapitulates 
HIV-infection in an individual with latent TB. Macaques are frequently used to model HIV by 
infection with simian immunodeficiency virus (SIV) or SHIV, a HIV-SIV chimera. Depending 
on the macaque species and the virus type used, these animals can be excellent models for 
human infection and disease [174, 344-350]. Macaques are also valuable in studying tuberculosis 
[113, 116, 336, 351-353]. Cynomolgus macaques infected with a low number of M. tuberculosis 
bacilli develop clinical signs and pathology similar to humans with active TB or develop 
subclinical latent infections, with equal proportions of each infection outcome observed [113, 
116]. Moreover, latency can be maintained for significant time periods.  In our experience 
working with cynomolgus macaques over the past decade, only two of approximately 85 latently 
infected monkeys spontaneously reactivated [13,19, Flynn and Lin unpublished data]. Thus, 
cynomolgus macaques with latent TB have a <5% chance of spontaneously reactivating TB 
within a few years of infection and can maintain this latent state for years [113, 354].  
Nonhuman primates have been used to examine interactions between SIV and 
mycobacteria. Macaques co-infected with SIV and M. tuberculosis (strain H37Rv) [253] or SIV 
and M. bovis BCG [334, 336] have been used to examine how mycobacteria induce AIDS-like 
symptoms. Rhesus (M. mulatta) or pigtail (M. nemestrina) macaques were inoculated with 
mycobacteria after SIV infection or simultaneously co-infected with BCG and SIV [334, 336]. 
These studies indicated that SIV could be immunosuppressive and sometimes exacerbate 
mycobacterial disease. Despite the range of model systems available, similar studies into disease 
processes underlying reactivated TB in HIV-infected humans with latent TB have yet to be done. 
In the current study we use cynomolgus macaques infected with SIVmac251, a virulent 
HIV-like virus, to develop a novel model of HIV-induced reactivated TB. We used this model to 
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examine immunologic, microbiologic and virologic changes in the peripheral blood and tissues 
that have not been extensively investigated in human or nonhuman primate HIV/SIV-M. 
tuberculosis co-infection studies. Co-infected animals showed a spectrum of disease severity, 
with the animals that reactivated <17 weeks post-SIV infection experiencing more severe 
pathology than animals that reactivated >26 weeks post-SIV infection. We found that time to 
reactivation correlated with significant peripheral CD4 T cell depletion but not virus load during 
the acute phase of SIV infection. The co-infected animals had fewer T cells in lung tissue than 
SIV-negative macaques with active TB, and a trend towards fewer T cells in the pulmonary 
lymph nodes than SIV-only macaques. Co-infected animals also had fewer IFN-g releasing T 
cells within thoracic lymph nodes compared to monkeys with active TB. We also present 
evidence of rapid impaired local control of latent M. tuberculosis infection, following SIV 
infection. These studies pave the way for detailed investigations of factors underlying reactivated 
TB in HIV-M. tuberculosis co-infected humans that were not previously possible. 
6.3 MATERIALS AND METHODS 
6.3.1 Ethics Statement 
All experimental manipulations and protocols were approved by the University of Pittsburgh 
School of Medicine Institutional Animal Care and Use Committee. The animals were housed and 
maintained in accordance with standards established in the Animal Welfare Act and the Guide 
for the Care and Use of Laboratory Animals. 
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6.3.2 Experimental Animals 
Fifteen adult (>4 years of age) cynomolgus macaques (Macaca fascicularis) of Chinese origin 
were used for these studies (Covance, Alice, TX; USA Valley Biosystems, West Sacramento, 
CA). Prior to the study, animals were tested to ensure they were free of M. tuberculosis, SIV, 
SHIV or simian retrovirus D infection. Animals were also given physical and clinical 
examinations including differential blood cell counts, erythrocyte sedimentation rate (ESR), 
serum chemistry profile and thoracic radiography to ensure they were free of underlying disease 
processes. All animals were given 14-day prophylactic Bactrim (sulfamethoxazole and 
trimethoprim) treatments to eliminate potential Pneumocystis colonization infection. SIV-
infected animals were housed under BSL-2 conditions while M. tuberculosis-infected animals 
were housed under BSL-3 conditions. Bronchoalveolar lavage (BAL), gastric aspirate and other 
procedures were performed as previously described [113, 116]. We used historical controls from 
previous studies [18,21, Flynn and Lynn unpublished data] on animals with active and latent TB 
to minimize the number of animals used in this study.  
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6.3.3 M. tuberculosis and SIV infection 
 
Figure 8. Schematic representation of experimental design 
The experimental design of these studies is described in (Figure 8). Ten animals were infected 
with ~25 CFU Erdman strain M. tuberculosis via intra-bronchial instillation as previously 
described [116]. M. tuberculosis infection was confirmed in all ten animals by conversion of 
negative to positive tuberculin skin test and peripheral blood mononuclear cells (PBMC) 
responses elevated from baseline in lymphocyte proliferation (LPA) and PBMC enzyme-linked 
immunosorbent spot (ELISPOT) assays. Animals were classified as latent or active 8-10 months 
post infection with the criteria for latency defined as TST positive but with no signs of clinical 
disease as previously described [113, 116]. Of the original ten animals infected with M. 
tuberculosis, six were classified as latent and selected for SIV infection. A seventh latent 
monkey (10405) and infected with the same dose and strain of M. tuberculosis from another 
study, was added to this group to increase the number of animals.  
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For SIV infection, concentrated SIVmac251 stock (kindly provided by Dr. Keith 
Reimann, Beth Israel Deaconess Medical Center, Harvard University) was diluted in RPMI 
medium, and 106-107
113
 TCID50 units of virus injected intravenously. Seven animals with latent 
TB and four M. tuberculosis-negative animals were infected with SIV, with the four M. 
tuberculosis-negative animals designated as the SIV-only control group. Historical data from 
latent and active control monkeys were used for comparison to minimize the number of animals 
needed for this study. Some data from these monkeys, as well as full characterization of 
pathology and disease outcome, has been published previously [ ]. Criteria for assessing 
reactivation included prolonged weight or appetite loss, elevated erythrocyte sedimentation rate 
(ESR), M. tuberculosis-positive gastric aspirate or BAL cultures, or radiographic evidence of 
lung involvement, as shown in (Table 1).  
6.3.4 Necropsy procedures 
Animals were humanely euthanized and necropsied as previously described [116] when 
indicators of active TB were present (in co-infected monkeys) or at the end of the study (11 
months post-SIV). Necropsies were conducted by veterinarians with substantial experience 
examining M. tuberculosis-infected cynomolgus macaques (E.K., C.J.). Lung lobes, liver, spleen, 
and kidney were examined for evidence of tuberculous disease. Similarly, thoracic, axillary and 
inguinal lymph nodes were examined for the presence of granulomas. All gross pathology 
associated with tuberculous disease was recorded and quantified using a previously established 
scoring system validated to differentiate latent from active tuberculosis in this model [113]. 
Tissue (granulomas, lymph nodes, uninvolved lung from each lobe, extrapulmonary organs) was 
divided into pieces for histology and RNA isolation, and the remainder was mechanically 
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homogenized into single-cell suspension for immunologic and microbiologic analysis and virus 
load determination. 30-40 samples per monkey were examined histologically and used for 
bacterial, virologic and immunologic assays. In several monkeys, gut tissue was obtained for 
analysis of T cell frequencies. Bacterial numbers in tissues were quantified by plating dilutions 
of tissue homogenate onto 7H10 agar plates and the number of colony forming units (CFU) in 
the original sample calculated after 4-6 weeks of incubation at 37°C/5% CO2
 
. 
6.3.5 Immunologic analysis  
Blood was drawn from SIV-only and co-infected animals every week prior to and for the first 
eight weeks post infection. Thereafter, blood was drawn from M. tuberculosis-SIV co-infected 
animals every other week and SIV-only animals monthly. PBMC were isolated via percoll 
gradient centrifugation as previously described [331]. Axillary or inguinal lymph nodes were 
biopsied at pre-infection, 4, 8 and 16 weeks post SIV infection. PBMC and lymph node cells 
were subjected to flow cytometry and IFN  Axillary or inguinal lymph nodes were biopsied at 
pre-infencluded autologous monocyte-derived dendritic cells, as antigen-presenting cells, as 
previously described [116, 331].  
 
6.3.6 ELISPOT assays for M. tuberculosis- and SIV-induced IFNg responses 
ELISPOT assays were performed as previously described [116, 331] with 150,000 PBMC or 
lymph node cells per well using ELISPOT reagents with known cross reactivity against macaque 
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IFNg (MabTech, Mariemont, OH) [18]. M. tuberculosis antigens used in ELISPOT were peptide 
pools (overlapping 20-mers; 10 ug/mL) from CFP-10 (Rv3872) and ESAT-6 (Rv3875) 
synthesized by Sigma-Genosys (Woodlands, TX). Peptide pools for viral antigens gag, pol, env, 
tat, nef and rev (overlapping 20-mers) all used at 10 ug/mL, based on SIVmac239) were obtained 
from the AIDS Research and Reference Reagent Program (National Institutes of Health, 
Germantown, MD). Phorbol 12,13-dibutyrate (PDBu) and ionomycin (50 nM and 10 uM final 
concentration respectively; Sigma) were used as positive controls. Media-only wells were used 
as negative controls. Cells in ELISPOT assays were incubated with antigens for two days at 
37°C/5% CO2 331 prior to being developed as previously described [ ] and read using an 
ELISPOT plate reader (Cellular Technology LTD, Cleveland, OH). All conditions were 
performed in duplicate wells. ELISPOT data were normalized and expressed as SFU per 106
  
 
cells. 
6.3.7 Flow cytometry 
All antibodies used for flow cytometry were direct conjugates against human proteins and 
obtained from BD Biosciences (San Jose, CA) unless otherwise noted. Approximately 1x106 
PBMC or tissue cells were stained using combinations of the following antibodies: CD3 (clone 
SP34-2), CD4 (clone L200), CD8 (clone DK25 [Dako; Carpinteria, CA], clone SK-1, clone 
OKT8 [eBioscience; San Diego, CA]) CD29 (clone HUTS-29) and CD69 (clone FN50) (clone 
2H7 [eBioscience]). Cell phenotypes were read with a LSR II flow cytometer (BD Biosciences) 
and positively-stained populations gated using fluorochrome-matched isotype antibodies as 
negative controls using the FlowJo software package (Tree Star Inc., Ashland, OR). 
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6.3.8 Plasma cytokine determination during acute SIV 
Frozen plasma was saved every week for the first 8 weeks post SIV inoculation in the co-
infected and SIV-only infected animals. Plasma was thawed and sterile filtered filtered (0.22mm).  
Bio-plex nonhuman primate beads were used according to manufacturer’s instructions. 
Cytokines analyzed were: IFN-g, TNF, IL-10, IL-15 and IL-18. Samples were read on a Luminex 
100 IS Bio-Plex System machine (Luminex Corporation, Austin, TX). 
 
6.3.9 Virus load determination 
Quantitative real time reverse transcriptase (qRT-PCR) for the SIV  gag gene was used to 
measure virus loads as previously described [331, 355]. RNA was isolated from 1x106 percoll 
gradient-isolated PBMC or lymph node cells, and from 2x105
 
 BAL or tissue cells using the 
Qiagen RNeasy kit (Valencia, CA). Plasma virus load was determined by isolating RNA from 
200 uL of plasma using the Purelink Viral RNA/DNA mini kit (Invitrogen, Carlsbad, CA) as per 
manufacturer’s instructions. 
6.3.10 Statistical analysis 
Data were analyzed using Prism (Graphpad Software, San Diego, CA). Pair-wise comparisons 
between groups (e.g. latent and co-infected animals) was performed using the Mann-Whitney 
test with p<0.05 considered statistically significant.  
  81 
6.4 RESULTS 
6.4.1 CD4 T cells were transiently depleted in the periphery of SIV-infected animals 
coincident with peak virus load in PBMC. 
We measured viral titers in SIV-infected animals to determine how SIV infection correlated with 
reactivation or whether M. tuberculosis infection influenced SIV loads. SIV titers in plasma, 
PBMC, and lymph node cells were similar between co-infected monkeys and SIV-only monkeys 
(Figure 9). Peak virus loads in PBMC and plasma occurred at 2-3 weeks post SIV infection and 
then declined to low levels for the duration of the study. The greatest virus burden in BAL cells 
from co-infected monkeys occurred two weeks after peak virus load in the peripheral blood. 
Virus loads in cells from peripheral lymph nodes were not significantly different between time 
points, but these sites maintained moderate virus loads (104-106 copies/106 cells). 
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Figure 9. SIV loads in plasma, PBMC and lymph nodes of Mtb-SIV co-infected and SIV-only monkeys 
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6.4.2 SIV causes reactivation of latent tuberculosis 
We previously described the clinical, microbiologic, radiologic and immunologic parameters 
used to define latent infection and active disease in macaques and demonstrated that these are 
validated by quantitative measurements of bacterial burden and gross pathology at necropsy 
[113, 116]. Briefly, latent monkeys are asymptomatic and lack radiographic or microbiologic 
evidence of M. tuberculosis infection beyond three months post infection [113, 116]. 
Reactivation is defined as evidence of active TB either by microbiologic, radiographic or clinical 
parameters after a period of stable latent infection [113]. Based on these criteria, three of the 
seven co-infected monkeys with latent TB had findings consistent with reactivated TB 12-17 
weeks post-SIV infection while the remaining four monkeys reactivated between 26-48 weeks 
post-SIV (Table 1). Monkey 1807 was necropsied after positive BALs and had relatively low 
necropsy and bacterial number scores, suggesting that positive cultures from BALs do not 
necessarily correlate with significant disease burden, but may signify the first sign of reactivation 
[113]. Considering this, Monkey 1907 was necropsied approximately 28 weeks after the first 
positive BAL and with additional positive clinical results to confirm reactivation was underway. 
While a spectrum of disease was observed, we loosely categorized the monkeys according to 
time of reactivation: early reactivation (reactivated TB in <17 weeks post SIV infection) and 
later reactivation (reactivated >26 weeks post SIV). 
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Table 1. Clinical evidence for reactivated TB in co-infected monkeys 
 
 
6.4.3 Relationship between peripheral T cell depletion and virus loads and time to 
reactivation 
SIV infection affects lymphocyte numbers, and changes in CD4 and CD8 T cell numbers were 
followed in the PBMC and axillary or inguinal lymph nodes (referred to here as peripheral 
lymph nodes) of co-infected monkeys over the course of SIV infection to better understand the 
dynamics between lymphocyte numbers and reactivation. All co-infected monkeys experienced 
declines in numbers of CD4 and CD8 T cells in the PBMC (Figure 10) and peripheral lymph 
nodes (Figure 11) between 2-4 weeks post SIV infection, a time corresponding with peak 
viremia (Figure 10A). After 8 weeks, T cells recovered to pre-SIV levels in all monkeys. No 
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differences in CD4 or CD8 frequencies were found among the SIV-only, early and late 
reactivators  (Figure 11). Peripheral T cell numbers in co-infected animals were averaged during 
acute SIV infection (weeks 1-8 post-SIV) and plotted against the week that either indicators of 
reactivated TB were noted or the week that necropsy occurred to address the relationship 
between T cells and reactivation.  
 
Figure 10. Acute CD4 T cell depletion correlates with reactivated TB. 
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 Necropsy time was based on the aggregate clinical signs in a monkey. There was a 
significant correlation between extent of depletion of CD4 T cell numbers 2-8 weeks post-SIV 
and time to reactivation (P = 0.011, R2 = 0.755) and necropsy time (P = 0.0007, R2 = 0.9172) 
(Figure 10B). The correlation between reactivation signs and early depletion of CD8 T cell was 
not significant (P = 0.112, R2 = 0.425) but extent of early depletion of CD8 T cells did correlate 
with time of necropsy (P = 0.0202, R2
 
 = 0.6923; Figure 10C). Although depletion in the 
periphery is an indicator of the overall effect of SIV infection, T cell depletion in the local 
granuloma environment is more likely to have an influence on reactivation. It was not possible to 
directly sample granulomas to measure T cell frequencies over the course of SIV infection 
(except at necropsy, see below), so we sampled the airways and analyzed BAL cells instead. The 
early-reactivating monkeys had lower frequencies of CD4 T cells (p=0.0571) in the airway at 10 
weeks post-SIV than monkeys that reactivated later (Figure 10D).  
Figure 11. Changes in T cell frequencies in the peripheral lymph nodes of co-infected and SIV-only 
infected macaques 
  87 
6.4.4 Peripheral IFNg responses increase in response to SIV infection 
Previous studies using IFNg ELISPOT indicate macaques with active or reactivating TB have 
more IFNg-producing PBMC than animals with latent TB [116, 354]. Given this, we performed 
IFNg ELISPOT to determine whether changes in the frequency of M. tuberculosis- or SIV-
specific T cells within PBMC could predict reactivation in co-infected animals (Figure 12). 
Unexpectedly, numbers of M. tuberculosis- and SIV-specific T cells increased sharply in all 
monkeys between 7-8 weeks post SIV infection. This increase in SIV- and M. tuberculosis-
specific T cells quickly declined in all late reactivators and one early reactivator. The number of 
SIV-specific T cells within the SIV-only group did not change considerably between 8 and 32 
weeks post SIV infection.  
 
Figure 12. Co-infected monkeys experience an increase in numbers of M. tuberculosis-specific T cells 
following early after SIV infection. 
 The increase in M. tuberculosis-specific T cells coincided with an increase in the 
expression of late (CD29) but not early (CD69) activation markers on both CD4 and CD8 T cells 
(Figure 13). We hypothesized that the initial burst of M. tuberculosis-specific IFNg responses 
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shortly after SIV infection may reflect a transient perturbation of the local control of infection at 
the level of the granuloma, resulting in an increase in antigen load due to bacterial replication.  
 
Figure 13. T cell activation markers increase following SIV infection. 
6.4.5  SIV causes an acute spike in plasma concentrations of IFN-g, TNF and IL-10 in the 
co-infected monkeys.  
After SIV inoculation we observed a trend in the increase of IFN-g, TNF and IL-10 in the co-
infected monkeys (Figure 14). This increase was not significant but occurs 3 weeks post SIV 
inoculation when compared to the day of inoculation. We did not observe any difference in 
cytokine concentrations between the early reactivators (red) and the late reactivators (blue) 
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within the co-infected group. Cytokine concentrations in SIV-only monkeys appear to be more 
sporadic than the co-infected monkeys (Figure 14).   
 
Figure 14. Changes in cytokine concentrations in plasma during acute SIV in co-infected and SIV-only 
infected animals. 
6.4.6 Co-infected monkeys had more pathology, higher bacterial numbers, and more 
dissemination than latent monkeys  
Each co-infected monkey displayed clinical indicators of TB following SIV infection that are not 
seen in monkeys with latent TB. Reactivated disease was confirmed at necropsy by pathology- 
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and microbiology-based measurements that characterize the extent of visible and microscopic 
disease. Gross pathology at necropsy was quantified by a metric referred to as the necropsy score 
[113] that reflects the grossly visible tuberculous disease including the number and size of visible 
granulomas in each lung lobe and thoracic lymph node and extent of dissemination beyond the 
thoracic cavity. The monkeys that reactivated early post-SIV infection (<17 weeks) had more 
TB-related pathology than monkeys that reactivated later post-SIV infection, and thus had a 
trend towards higher necropsy scores (P= 0.0571, Figure 15A). We also scored the total bacterial 
burden for each monkey, and the percent of tissues sampled at necropsy that were M. 
tuberculosis culture-positive. A bacterial number score [113] was used to reflect the total 
bacterial load and was obtained by summing the log-transformed number of colony forming 
units (CFU) from all sampled tissues. The percent positive score measured the proportion of 
sampled tissues that are M. tuberculosis culture positive, thereby indicating the extent of 
bacterial dissemination in visibly involved and uninvolved tissues. The co-infected monkeys had 
gross pathology, percent positive and bacterial number scores that were similar to SIV-negative 
monkeys with active TB and significantly higher than what is seen in latent monkeys (Figure 
15B). These metrics, therefore, support the pre-necropsy clinical data indicating that the co-
infected monkeys had disease consistent with reactivated TB. 
  91 
 
Figure 15. Pathology associated with reactivation of co-infected monkeys. 
6.4.7 Histology reveals a mixture of chronic and active granulomas in co-infected 
monkeys 
The granulomas seen in active and latent monkeys have been described previously and are 
extremely similar to those seen in human TB [113, 116, 356]. To summarize, monkeys classified 
as having latent infection typically have at least one granuloma in one lung lobe and associated 
draining thoracic lymph node(s). These granulomas are generally caseous with partial or total 
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mineralization, often combined with extensive peripheral fibrous connective tissue deposition 
[113]. Completely fibrotic (sclerotic) lesions are occasionally observed. In contrast, monkeys 
with active TB frequently have a range of lesion types, including caseous with or without 
peripheral fibrosis, non-necrotizing (primarily epithelioid macrophages with a lymphocytic 
component), and suppurative (with significant neutrophilic infiltrate) [113]. Mineralized or 
completely fibrotic lesions indicative of more chronic immunologic responses to subclinical 
(latent) infection are rarely observed in monkeys with active TB. 
Table 2. Granulomas observed in M. tuberculosis-only and co-infected monkeys 
 
In general, the co-infected monkeys had a mix of active and chronic lesions (Table 2). 
Monkey 1407, which reactivated early post-SIV infection, had extensive widespread active 
lesions with little evidence of chronic disease. Monkeys 2407 and 1207, which also reactivated 
early post SIV infection, had pathology consistent with disseminated active TB (Figure 16A), but 
additionally showed some chronic appearing lesions, including a few solid fibrotic lesions. 
Certain chronic caseous granulomas had signs of reactivation foci around the perimeter (Figure 
16B) as indicated by the presence of macrophage and lymphocyte-rich “satellite” granulomas 
associated with reactivation [113, 354]. Monkeys that reactivated later post-SIV infection 
experienced a range of involvement, with 3007 and 1907 having more active-type lesions than 
10405 and 1807, although these monkeys as a group had fewer active-appearing lesions than the 
animals that reactivated earlier following SIV-infection. Additionally, there were more 
mineralized granulomas reflecting the original latent infection. However, a striking finding was 
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the presence of substantially more completely fibrotic granulomas, especially in 3007, (Figure 
16C,D and Table 2) than is normally noted in active or latent monkeys. In our experience to date, 
these completely fibrotic granulomas are usually seen in monkeys that had active disease but 
were then treated with anti-tuberculous drugs for 1-2 months (Flynn and Lin unpublished data), 
strongly suggesting that this phenotype represents healing of active granulomas. These 
granulomas are occasionally seen in latent monkeys, but are present in a higher proportion of 
granulomas examined histologically from the co-infected monkeys (Table 2). Table 2 also 
demonstrates that many more granulomas were found in the co-infected monkeys than in M. 
tuberculosis-only latent monkeys, which reflects reactivation and likely the spread of infection. 
Taken in the context of the co-infection, a possible interpretation of the increased presence of 
completely fibrotic granulomas is that SIV infection perturbed the local control of the latent 
infection, leading to subclinical reactivation in some monkeys and spread of infection in the 
lungs, with subsequent healing of some granulomas as the host controlled virus load and 
regained control of the M. tuberculosis infection. 
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Figure 16. Histopathology associated with co-infected monkeys. 
6.4.8 M. tuberculosis-specific IFNg production in thoracic lymph nodes was reduced by 
SIV infection 
IFNg ELISPOTs were performed on tissue homogenates of lung lobes and thoracic 
lymph nodes at necropsy to determine whether SIV infection impaired anti-mycobacterial IFNg 
responses (Figure 17 and 18). Lung tissues were separated into tissue containing grossly visible 
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granulomas (involved) and those without (uninvolved) (Figure 17). Uninvolved lung tissue did 
not demonstrate a strong response to either M. tuberculosis or SIV peptides in any monkeys, 
except 1907 which had M. tuberculosis-culture positive tissues that did not contain visible 
granulomas, but likely had microscopic disease. Two monkeys had very high frequencies of M. 
tuberculosis and SIV-specific IFNg-producing cells in involved lung tissue; these monkeys also 
had the most disease and highest bacterial burdens. Previously, we demonstrated that IFNg 
producing T cells in the tissues of monkeys are higher in monkeys with more disease, likely 
reflecting the amount of antigen present in the tissues, due to higher numbers of bacilli [113]. 
IFNg responses from the thoracic lymph nodes in co-infected monkeys to M. tuberculosis 
antigens (ESAT-6 and CFP-10) was lower than monkeys with active TB without SIV (Figure 
18A). Co-infected monkeys had similar frequencies of SIV-specific IFNg-releasing cells 
compared to SIV-only monkeys in thoracic draining lymph nodes (Figure 18B).  
 
Figure 17. Antigen specific T cells in involved and uninvolved tissue of co-infected monkeys 
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Figure 18. SIV causes a significant decrease in IFN-g releasing M. tuberculosis-specific T cells in thoracic 
lymph nodes of co-infected monkeys compared to monkeys with active TB without SIV 
6.4.9 Correlation between mycobacterial CFU and viral titer  
It has been reported that TB-involved lung lobes have higher virus loads than uninvolved 
lobes in humans [274], suggesting that M. tuberculosis-related inflammation infection can 
increase viral replication. To address this, we directly sampled granulomas and other tissues at 
necropsy to measure bacteria and virus loads. While we found a broad range of M. tuberculosis 
and SIV loads, both between monkeys and within the same monkey, there was no correlation of 
viral titers with bacterial loads in either granulomas or thoracic lymph nodes (Table 3). 
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Table 3. Virus and bacterial burden in uninvolved and involved tissues 
 
6.4.10 Co-infected monkeys had fewer T cells in involved tissues than SIV- or M. 
tuberculosis-only animals  
To determine that SIVmac251 depleted CD4 T cells in mucosal (uninvolved) tissue, we 
compared CD4 and CD8 T cell frequencies in gut tissue in monkeys with infected with M. 
tuberculosis (no SIV), co-infected monkeys and an SIV-only monkey. There was substantial 
depletion of CD4 T cells in the colon (25.3% M. tuberculosis, 5.7% co-infected) and 
ileum/jejunum (14.0% M. tuberculosis, 1.6% co-infected, 8.6% SIV only). CD8 T cells were 
only slightly decreased in the co-infected monkey gut tissues compared to controls. These data 
indicate that SIVmac251 is capable of reducing T cells in the mucosal tissue, as has been 
previously reported for rhesus macaques [357] and for humans (with HIV) [358]. 
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We measured CD4 and CD8 T cell numbers in draining lymph nodes and TB-involved 
lung from co-infected monkeys to better understand how SIV infection affects cell numbers in 
tissues infected with TB. A trend of fewer CD4 T cell numbers in the thoracic lymph nodes of 
co-infected monkeys compared to SIV-only monkeys was observed (Figure 19). T cell numbers 
in lung tissue were also examined although we did not obtain sufficient numbers of T cells from 
lung tissue from SIV-only monkeys for comparison, probably because these monkeys did not 
have pulmonary infections with other pathogens. As previously reported, T cell numbers are 
higher in involved lung tissue from active monkeys compared to latent monkeys [113]. Here, the 
co-infected monkeys had T cell numbers similar to the number observed in latent monkeys 
(Figure 19) even though they had significant disease and increased bacterial numbers, similar to 
active TB monkeys. This observation suggests co-infected monkeys may have critical defects in 
their ability to mount or maintain T cell-mediated immune responses at the site of infection.  
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Figure 19. CD4 and CD8 T cell numbers in lung and thoracic lymph nodes. 
6.4.11 Co-infected monkeys did not have higher tissue viral loads than SIV-only macaques 
Viral titers in the thoracic lymph nodes, peripheral lymph nodes and spleen co-infected monkeys 
and SIV-only monkeys were not significantly different at time of necropsy (Figure 20). 
However, co-infected monkeys did have a trend of higher viral loads on average when compared 
to monkeys infected with SIV alone (Figure 20).  
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Figure 20. No significant differences in tissue viral loads between co-infected and SIV-only infected 
monkeys.  
6.5 DISCUSSION 
Reactivated TB is a major source of morbidity and mortality among HIV-infected individuals. 
While most opportunistic infections commonly occur when CD4 T cell numbers have 
significantly declined, TB occurs throughout the entire spectrum of HIV disease, including when 
CD4 T cells numbers are well preserved and stable [340-342]. Despite the severe risk of TB in 
HIV-infected persons, research into factors underlying early reactivation has been hampered by 
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lack of appropriate animal models combining latent TB and HIV infection. In this study, 
cynomolgus macaques with latent TB were infected with SIVmac251 to investigate the factors 
that could lead to reactivation of latent TB. All the monkeys with latent TB co-infected with SIV 
experienced clinical signs, pathology and bacterial load consistent with reactivated disease while 
the M. tuberculosis-negative SIV-infected monkeys did not develop simian AIDS or 
opportunistic infections within 11 months of infection. SIV-negative cynomolgus macaques with 
latent TB have a <5% chance of undergoing reactivation and can maintain latent TB without 
reactivation for more than three years (Flynn and Lin unpublished data). These observations 
suggest that while these monkeys can control either SIV or latent M. tuberculosis infection 
independently, SIV-induced immune dysfunction disrupted the immunologic pressure 
constraining mycobacterial growth, inducing reactivation. To our knowledge, this is the first 
animal model of latent TB where the immunologic and microbiologic responses to SIV co-
infection can be directly investigated.  
Although individuals are at a high risk of developing TB within the first year of HIV-
seroconversion [242], clinical studies of HIV-M. tuberculosis co-infection indicate that depletion 
of peripheral CD4 T cell numbers is not predictive of when individuals are most likely to 
experience TB [342]. However HIV+ individuals with low peripheral CD4 T cells have been 
shown to be at greater risk of developing active TB [270]. All the monkeys experienced T cell 
depletion during acute SIV infection, with reactivated TB occurring during the period when the 
animals had regained normal and stable peripheral T cell numbers. Our data suggests that rather 
than the T cell numbers during chronic SIV infection being a major factor in reactivation, the 
extent of initial depletion and post-acute recovery may affect ultimate control of latent M. 
tuberculosis infection.  Monkeys 1407 and 2407, which reactivated early post-SIV, had fewer 
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peripheral T cells than other monkeys and didn’t recover from the initial depletion as well as 
monkeys that reactivated later. Similarly, 1807 and 1907, which also had fewer peripheral T cells 
following SIV infection, displayed signs of active disease earlier than the other late reactivators, 
supporting the hypothesis that early perturbations of the immune response may ultimately affect 
disease progression. Prior to the development of the SIVmac251/M. tuberculosis animal model 
experiments, we infected two latent cynomolgus macaques with SHIV89.6 (Santosh and Flynn 
unpublished data). These monkeys had significant sustained CD4 T cell depletion in the 
periphery as has been reported for cynomolgus macaques infected with SHIV89.6 [331], yet did 
not experience reactivation by seven months post-SHIV infection (Santosh and Flynn 
unpublished data). Although SHIV89.6 induces a dramatic loss of peripheral CD4 T cells it did 
not cause significant decreases of mucosal CD4 T cells (Santosh and Flynn unpublished data). 
Taken together, these data support the conventional paradigm that peripheral CD4 T cell 
populations are imperfect indicators of an individual’s susceptibility to TB, and instead indicate 
that early T cell depletion by SIV (or perhaps HIV) that depletes both peripheral and mucosal 
CD4 T cells may predict risk of reactivation.  
Although the link between peripheral cells and maintenance of latency is not clear, 
depletion in the periphery shortly after SIV infection may reflect significant depletion of T cells 
in the granuloma. Monkeys 1407 and 2407, which didn’t recover well from acute SIV infection 
and reactivated early, displayed more disease than later reactivators, possibly indicating that 
significant disruption occurred within granulomas and the subsequent inability to replace T cells 
lead to reactivated TB. This link between events in the periphery and the local granuloma 
environment is supported by the decreases observed in the frequency of CD4 T cells in the 
airways from the early-reactivating macaques. The acute phase of SIV infection was 
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accompanied by increased numbers of M. tuberculosis-specific IFNg-producing T cells in the 
periphery. This may be caused by SIV-induced impairment of granuloma function leading to 
increased mycobacterial growth and dissemination, which results in increased amounts of 
bacterial antigen released. Taken together, these data suggest that systemic T cell depletion 
permits resumption of bacterial growth and perhaps reactivation. Indeed, HIV-induced depletion 
of M. tuberculosis-specific CD4 T cells in the granuloma, and subsequent disruption of cellular 
architecture critical [27] for bacterial containment, have been hypothesized as factors 
contributing to increased reactivation rates in co-infected humans [249, 359].  
The extensive histological examination of granuloma-containing tissue from animals with 
widely different amounts of disease expanded our basic understanding of how HIV may change 
the pathology of tuberculosis. Granulomas from the earliest-reactivating animals were most 
similar to animals with active disease [113] whereas macaques that reactivated later had more 
mineralized granulomas, which are most often associated with latent disease, with evidence for 
some localized dissemination and reactivation. The lungs of latent monkeys normally contain 
few granulomas, and they are usually either completely calcified lesions or caseous ones with 
significant mineralization, with an occasional completely fibrotic granuloma in some monkeys. 
The most striking finding in the co-infected monkeys was the presence of numerous completely 
fibrotic granulomas in the lungs, which are rarely seen in latent infection [113]. We have 
observed this granuloma type in the setting of short-term drug treatment in the macaque model 
(Flynn and Lin unpublished data), and thus associate this fibrosis with a healing response. Our 
interpretation of this unusual pathology is that the initial events surrounding SIV infection 
caused a depression in the local immune response (the granulomas) in latent animals, allowing 
increased bacterial growth, spread to other areas of the lung, and formation of additional 
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granulomas. After this initial event, some animals may regain partial control of the infection, and 
these new granulomas begin to heal and become fibrotic. Thus, the interaction of SIV with the 
latent TB granuloma is a dynamic, and can lead to various outcomes. The cytokine milieu in the 
SIV-infected lungs may also promote more fibrotic-type healing, leading to the abundance of this 
type of lesion; this hypothesis requires further study. 
There was a trend of fewer total CD4 T cells and significantly fewer IFN-g releasing T 
cells in the thoracic lymph nodes of co-infected monkeys compared to SIV-only monkeys, 
indicating that the presence of mycobacteria, and perhaps the increased T cell activity in the 
lymph nodes, leads to more depletion of these cells in the lymphoid tissue, and may contribute to 
enhanced disease. Co-infected monkeys had fewer CD4 and CD8 T cells within TB-involved 
lung tissues when compared to SIV-negative monkeys with active TB. This contradicts what 
normally happens in animals with active TB, which have more T cells in involved tissues than 
latent monkeys. Significant reductions in T cell numbers within the lung tissue of the co-infected 
monkeys suggest that SIV is interfering with migration of T cells to the site of infection as has 
been seen with HIV [360]. Alternatively, SIV may be inducing T cell death within the granuloma 
like that observed in HIV-M. tuberculosis co-infected humans [251]. Exposure to M. 
tuberculosis antigens is linked to apoptosis in HIV-infected cells [282], which could 
mechanistically explain why tissues in co-infected animals were depleted when compared with 
animals only infected with M. tuberculosis. To our knowledge, this study provides the first 
evidence demonstrating quantitative T cell depletion within granulomatous tissue, supporting 
hypotheses for mechanisms by which HIV disrupts the maintenance of latent M. tuberculosis 
infection [249, 343].  
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Several groups have investigated the effects of HIV-M. tuberculosis co-infection on the 
replication of both pathogens [254, 256, 257, 288] and the relationship between virus load and 
disease progression [273, 275, 281]. We found similar peripheral and tissue virus loads in co-
infected and SIV-only monkeys, suggesting that virus loads were not influenced by M. 
tuberculosis infection. Granulomatous tissue might be an ideal environment for HIV replication 
as abundant T cells, increased cell-cell interaction, and high TNF expression promote cell-cell 
transmission and virus replication [249, 256, 257]. We were unable to confirm this, however, and 
could not correlate virus loads with M. tuberculosis burden in individual granulomas (Table 3). 
Differences in viral titer did not appear to be the cause of reactivation either, as viral titers (peak 
and during the chronic phase) were similar between the early and late reactivators. Similar 
findings have come from the HIV-TB clinical literature [361, 362], highlighting the clinical 
relevance of the cynomolgus macaque co-infection model. Our viral titers were relatively low 
following the acute infection, however, and it is possible that higher viral titers in a different 
macaque species or with a different virus strain could lead to different results. Even with the low 
virus loads observed in these cynomolgus macaques they all experienced reactivation of latent 
TB. 
We have developed a tractable animal model of reactivated TB in HIV-co-infected 
humans. Although numerous clinical studies have been undertaken to investigate HIV-M. 
tuberculosis co-infection, most examine patients with active TB and many are either 
retrospective or limited by the number and types of tissues and time points that could be 
sampled. This novel model will be a useful tool for investigating interactions between M. 
tuberculosis and HIV, and the immunologic events that lead to reactivation of latent TB or 
exacerbation of primary infection. 
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7.0  SIV REDUCES TNF RELEASE BY M. TUBERCULOSIS-SPECIFIC T CELLS 
THROUGH A MONOCYTE-DERIVED IL-5 DEPENDENT MECHANISM  
An adapted version of this chapter is in preparation:  
Collin R Diedrich, Joshua T Mattila, Kyle H Rhode, Dawn M O’Dee, David G Russell, JoAnne 
L Flynn. SIV reduces TNF release by M. tuberculosis-specific T cells through a monocyte-
derived IL-5 dependent mechanism. In preparation. 
7.1 INTRODUCTION  
 The mechanisms responsible for the increased susceptibility of HIV-infected persons to M. 
tuberculosis are not currently known, but multiple hypotheses have been proposed [238, 249, 
271, 363], including loss of CD4 T cells, as described in Chapter 4. HIV-induced manipulation 
of M. tuberculosis-specific effector T cell function and inhibition of the ability of macrophages 
to kill M. tuberculosis are two possible contributors to this increased susceptibility to TB [238, 
363]. 
Co-infected individuals have significantly fewer peripheral M. tuberculosis-specific T 
cells that can release IFN-g, TNF, and IL-2 or proliferate compared to individuals with active TB 
alone [261, 282, 283, 302, 303]. HIV decreases IFN-g mRNA production and proliferation of M. 
tuberculosis-specific T cells within the airways of AIDS patients with TB compared to 
individuals with active TB without AIDS [304, 305]. HIV also reduces the function of other 
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mycobacterial-specific T cell responses by reducing IFN-g–TNF–IL-2 polyfunctional BCG-
specific CD4 T cells within the airways of BCG-vaccinated individuals without signs of TB 
compared to HIV-uninfected controls [286]. The cause of M. tuberculosis-specific T cell 
dysfunction in HIV-co-infected individuals is not known, but may result from the ability of HIV 
to exhaust T cells [177]. HIV may be able to directly manipulate M. tuberculosis-specific T cells 
due to its close proximity to these cells within granulomas since SIV replication occurs within 
granulomas of macaques [271] and HIV is present at sites of active TB in humans [274, 276, 
364]. Taken together, the close proximity of HIV and M. tuberculosis within the granuloma 
provides an ideal environment for HIV to directly manipulate the function of M. tuberculosis-
specific T cells and M. tuberculosis-infected macrophages.  
In Chapter 6, I described the development of an animal model of HIV/M. tuberculosis co-
infection, where we demonstrated that SIVmac251 induces reactivation of latent TB in 
cynomolgus macaques [77, 271]. We correlated changes in peripheral T cell counts during the 
acute phase of SIV to the reactivation of latent TB [271] and hypothesized that the outcome of 
latent infection (i.e. reactivation or control of the latent infection) in a co-infected individual is 
strongly influenced by the host response to the acute phase of HIV infection. Our hypothesis is 
that during the acute phase of infection HIV almost immediately disrupts M. tuberculosis-
specific T cell function within the granulomas. Multiple studies demonstrate that HIV 
manipulates T cell effector function [261, 282, 283, 302, 303] but they do not address how long 
it takes HIV to inhibit M. tuberculosis-specific T cell responses or how and where the inhibition 
takes place. The cause of the reduction in T cell function is not known, but it may be a result of 
direct T cell manipulation or changes in antigen presenting cell function.  
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We developed in vitro and ex vivo models to investigate the mechanisms HIV-induced M. 
tuberculosis-specific T cell dysfunction to overcome the difficulties of studying this 
phenomenon in vivo. Using T cells and monocytes from SIV-uninfected monkeys with active or 
latent TB, we demonstrate here that exogenously added SIV causes a significant decrease in the 
frequency of TNF and IFN-g releasing M. tuberculosis-specific T cells. This was due to SIV 
manipulating monocytes and not the T cells directly. M. tuberculosis/SIV-co-infected monocytes 
produced significantly more IL-5 than monocytes infected with M. tuberculosis-alone. By 
manipulating levels of IL-5 in our in vitro system, we determined that the reduction in M. 
tuberculosis-specific TNF-releasing CD4 T cells was due, at least in part to the SIV-induced 
production of IL-5 by monocytes. This study provides evidence for a novel role for IL-5 and its 
ability to reduce M. tuberculosis-specific T cell functions in co-infected individuals.  
7.2 METHODS 
7.2.1 M. tuberculosis infection 
Cynomolgus macaques were infected with ~25 or ~200 CFU Erdman strain M. tuberculosis via 
intrabronchial instillation as previously described [113] for other ongoing studies. Ninety percent 
of monkeys infected with 200 CFU developed active TB, while 50% of the monkeys infected 
with 25 CFU developed active TB. Blood samples from monkeys with active or latent infection 
were used for the in vitro studies described here.  
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7.2.2 PBMC and tissue isolations 
Blood was drawn from M. tuberculosis-infected monkeys (without SIV) enrolled in other 
studies. PBMCs were isolated via Percoll gradient centrifugation as previously described [72, 
112, 113]. Animals were humanely euthanized and necropsies performed as previously described 
[72, 112, 113]. Thoracic lymph nodes from M. tuberculosis-infected monkeys were 
homogenized into single-cell suspensions with Medimachines (BD Bio- sciences, San Jose, CA) 
as described previously [72, 112, 113].  
7.2.3 Magnetic separation 
Magnetic beads were used to separate CD3+ T cells (Miltenyi Biotec, 130-092-012) and CD14+ 
monocytes (Miltenyi Biotech, 130-091-097) from PBMC of SIV-uninfected and M. tuberculosis-
infected cynomolgus macaques. Manufacturers instructions were followed for magnetic 
separations.  Isolated monocytes were plated (5x105 to 1.2x106 cells/ml) in RPMI media 
supplemented with 10% human AB serum (Gemini Bio-Products, West Sacramento, CA), 1% L-
glutamine (Sigma-Aldrich, St. Louis, MO), and 1% HEPES (Sigma) in a 5ml polypropylene 
round-bottom tube (Becton Dickinson), 24 well flat bottom plate or 96 well round bottom-plate 
(Becton Dickson), depending on the assay run. Isolated CD3 T cells were resuspended in 
supplemented RPMI +10% hAB serum at a density of 5x106 cells/ml in 24-well flat bottom 
plate. Cells were incubated overnight at 37C with 5% CO2 before adding back to the CD3-
depleted PBMC or monocytes (see below).  
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7.2.4 Infections and Stimulations 
7.2.4.1 PBMC Stimulations 
Freshly isolated PBMCs were resuspended in supplemented RPMI media at a density of 5x105 to 
1x106 cells/ml and transferred to FACS tubes for stimulation with M. tuberculosis culture filtrate 
protein- (CFP overlapping peptide pools ȝg/ml) or phytohemagglutinin (P+A ȝg/ml) 
for 5-6 hours at 37C at 5% CO2
7.2.4.2 M. tuberculosis -infection of CD3-depleted PBMC 
. After the first 1 hour of stimulation, brefeldin A was added to 
the cells and incubated for an additional 4-5 hours. After stimulation cells were washed and 
stained. 
For M. tuberculosis-infected cells, CD3 T cell-depleted PBMC were incubated for 24 hrs with 
M. tuberculosis (MOI 0.5) in 500ml of supplemented RPMI+10% hAB serum, then washed and 
resuspended in 500ml of fresh media. One aliquot of M. tuberculosis-infected cells was incubated 
with SIVmac251 (MOI 0.1) for 12 to 16 hrs. Analysis by trypan blue exclusion showed that SIV 
did not increase cell death during this incubation, compared to SIV-uninfected cells. One aliquot 
of cells was not infected with SIV or M. tuberculosis. The CD3 T cells were added back to the 
CD3-depleted PBMC and resuspended in a total of 250ml of supplemented RPMI +10% hAB 
with brefeldin A (GolgiPlug; BD Bioscience) for 5 hours. After stimulation cells were washed 
and stained (see flow cytometry methods, 7.2.5, below). 
7.2.4.3 M. tuberculosis-infection of monocytes 
Isolated CD14+ monocytes isolated from PBMC and incubated overnight in RPMI + 10% hAB 
in 5ml round bottom tubes overnight. Monocytes were aliquoted into 4 groups: Media, SIV, M. 
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tuberculosis and M. tuberculosis/SIV. T cells were also isolated from PBMC and incubated in 
RPMI +10% hAB for later use. Two groups of monocytes were infected with M. tuberculosis 
(MOI 0.5) in 500ml for 4 hours, then 1 ml of media was added to each tube and the cells were 
incubated overnight. After the overnight incubation cells were washed with warm RPMI and 
incubated in 500ml RPMI. Appropriate cells were incubated with SIVmac251 (MOI 1.0) 
overnight (12 to 16hrs). The next morning the cells were washed with RPMI and autologus T 
cells were added to the monocytes at a ~3:1 T cell to monocyte ratio in 250ml of media with 
brefeldin A. T cells and monocytes were incubated for 6 hrs.  After stimulation cells were 
washed and stained.  
7.2.4.4 Using inactivated SIVmac251 in M. tuberculosis-infected monocytes  
Experiments were performed the same as described above except that an inactivated virus was 
added to determine whether live SIVmac251 was needed to disrupted M. tuberculosis-specific T 
cell responses. Instead of adding SIVmac251, approximately 0.1pg p28 equivalents of 
inactivated SIVmac251 Aldrithiol-2 per 1x106
7.2.4.5  Lymphocyte proliferation assay  
 monocytes (Courtesy Dr. Jeff Lifson, AIDS & 
Cancer Virus Program, Frederick MD) were added to the M. tuberculosis-infected monocytes. T 
cells were then added and experiments resumed as previously described. 
PBMC from M. tuberculosis-infected monkeys were isolated and suspended in AIM V media 
(Invitrogen, Grand Island, NY) at 200,000 cells/well in 200ml. Cells were stimulated with PHA 
(5mg/ml), CFP10 peptides, or media in triplicate wells for 60 hours at 37°C, 5% CO2 with or 
without SIV; for the final 18 hours, [3H]-thymidine (1mCi/well, Amersham) was added. Cells 
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were harvested onto filters and radioactive incorporation measured. Data were reported as a 
stimulation index (SI): fold increase in cpm over unstimulated control. 
 
7.2.4.6 Neutralization of IL-5 and IL-13 
Isolated monocytes were placed in a 96 well plate (~2x105 monocytes per well). Monocytes were 
infected with M. tuberculosis (MOI 0.5) for 4 hours then washed with warm RPMI. Monocytes 
were washed and the media was replaced with 200ml of RPMI + 10% hAB and incubated 
overnight. Monocytes were incubated with SIVmac251 (MOI 1.0) the following day in 500ml of 
RPMI + 10% hAB. Neutralization antibodies to IL-5 (40pg/ml ebioscience 16-7059-81) or IL-13 
(64pg/ml Miltenyi biotec 130-093-053) were added to half of the SIV-exposed monocytes at the 
same time as the addition of SIV. Isotype antibodies were added to a group of co-infected 
monocytes as the baseline control. Monocytes were incubated overnight (12 to 16hrs) at 37C in 
5% CO2
7.2.4.7 Addition of recombinant IL-5 and IL-13 
. The following morning cells were washed with warm RPMI.  Autologous T cells were 
added to the monocytes in ~ 3:1 T cell to monocyte ratio in 100ml RPMI + 10% hAB with 
brefeldin A. T cells and monocytes were incubated for 6hrs.  
Isolated monocytes were infected with M. tuberculosis (MOI 0.5) for 4 hours then washed with 
warm RPMI in a 96 well plate (~2x105 monocytes per well). Media was replaced with 200ml of 
RPMI + 10% hAB and incubated overnight at 37C in 5% CO2. The following day monocytes 
were washed with warm RPMI and resuspended in 150ml of RPMI + 10% hAB. Either 
recombinant human IL-5 (PeproTech, Rocky Hill, NJ; 40pg/ml/1x106 cells) or human IL-13 
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(Miltenyi Biotec; 60pg/ml/1x106 cells) were added to the appropriate wells in 50ml of RPMI + 
10% hAB. The amount of recombinant protein added to the wells was equivalent to the highest 
amount of IL-5 or IL-13 produced by co-infected monocytes. Monocytes were incubated 
overnight at 37C in 5% CO2
7.2.5 Flow Cytometry 
. Autologous T cells were added to the monocytes at a ~3:1 T cell to 
monocyte ratio in 100ml RPMI + 10% hAB with brefeldan A. T cells and monocytes were 
incubated for 6hrs.   
All antibodies used for flow cytometry were direct conjugates against human proteins and 
obtained from BD Biosciences (San Jose, CA) unless otherwise noted. Approximately 1x106
7.2.6 Luminex 
 
PBMC or tissue cells were stained using combinations of the following antibodies: CD3 (clone 
SP34-2), CD4 (clone L200), CD8 (clone DK25 [Dako; Carpinteria, CA], clone SK-1, clone 
OKT8 [eBioscience; San Diego, CA]), IFN-g (clone B27; BD Bioscience), IL-2 (clone MQ1- 
17H12; eBioscience), and TNF (clone mab11; eBioscience).  Cell phenotypes were read with a 
LSR II flow cytometer (BD Biosciences) and positively stained populations gated using 
fluorochrome-matched isotype antibodies as negative controls using the FlowJo software 
package (Tree Star Inc., Ashland, OR). 
Isolated monocytes (3x106 to 1x106 cells) were divided into 4 groups (Media, SIV, M. 
tuberculosis, M. tuberculosis + SIV) incubated in 24 well plates in 1 ml of RPMI +10% hAB 
overnight. The following day the M. tuberculosis-infected monocytes were infected with M. 
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tuberculosis (MOI 0.5) for 4 hours incubation, then media was replaced with 1 ml of RPMI + 
10% hAB. The appropriate monocytes were then incubated with SIVmac251 (MOI 1.0) 
overnight. The media was removed, filtered (Millipore, 0.45um) and frozen for Luminex 
analysis. A 23-plex non-human primate Luminex assay (Millipore; Billerica, MA) was 
performed on the filtered supernatants following manufacturer’s instructions. Proteins analyzed 
were CD40 Ligand, G-CSF, GM-CSF, IFN-Ȗ I/-10, IL-12/23 (p40), IL-13, IL-15, IL-17, IL-18, 
IL-1ra, IL-ȕ I/-2, IL-4, IL-5, IL-6, IL-8, MCP-1, MIP-Į MIP-ȕ T*F-Į T1F-Į 9E*F 
Samples were read on a Luminex 100 IS Bio-Plex System machine (Luminex Corporation, 
Austin, TX). 
7.2.7 RNA isolation and IL-5 detection in monocytes 
Isolated monocytes (~4x106 cells) were divided into 4 groups (Media, SIV, M. tuberculosis, M. 
tuberculosis + SIV) incubated in 24 well plates in 1 ml of RPMI +10% hAB overnight. The 
following day the M. tuberculosis-infected monocytes were infected with M. tuberculosis (MOI 
0.5), for 4 hours, then media was replaced with 1 ml of RPMI + 10% hAB. The appropriate 
monocytes were then incubated with SIVmac251 (MOI 1.0) overnight, then the supernatant was 
removed and the RNA was isolated following Trizol Reagents (15596-026, Invitrogen, NY) 
manufacturing protocols. Isolated RNA was amplified using custom made IL-5 primers 
(Forward: GAGACCTTGGCACTGCTTTC and Reverse: ACTCTCCGCCTTTCTTCTCC) with 
AMV RT (M510F, Promega, WI) and PCR master mix (M750B, Promega) in the following 
program: 42C [30min], 94C [5min] (94C [30s], 55C [30s], 72C [30s])x30, 72C [5min]. 
Amplified products were run on a 2% agarose gel with 5x loading buffer (BioRad, CA) along 
with a 100bp molecular ruler (BioRad). Gel was then stained with ethidium bromide and imaged.  
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Primers were generated from the rhesus macaque mRNA sequence and the product identity was 
sequenced for confirmation (98% sequence homology). 
7.2.8 Statistics 
Wilcoxon ranked paired test was used to compare cells from each animal with different in vitro 
treatments, with P < 0.05 considered to be significant. Mann-Whitney analysis was used to 
compare two different groups with significance set at P < 0.05. Kruskal Wallis multiple 
comparison test with Dunn’s post-test were used to compare differences among three unpaired 
groups. Freidman test was used with Dunn’s multiple comparison test to determine significance 
among 3 or more paired groups with significance set at P < 0.05. 
7.3 RESULTS 
7.3.1 SIV specifically decreases TNF release in CFP10 stimulated PBMC from monkeys 
infected with M. tuberculosis.  
To determine whether SIV can cause an immediate disruption in M. tuberculosis-specific T cells, 
we incubated freshly isolated PBMC (from animals infected with M. tuberculosis, but not SIV) 
with SIVmac251 (MOI 0.1) or without the virus overnight. We split the cells into four groups 
and stimulated the PBMC with PHA, the M. tuberculosis antigen CFP10 (peptide pools), 
Pneumocystis jirovecii kexin (peptide pools) or media alone. After the 5-6 hour stimulation we 
measured TNF and IFN-g production by intracellular cytokine staining and flow cytometry.  
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SIVmac251 caused a significant decrease in the release of TNF by CFP10-stimulated 
CD4 T cells (Figure 21A) while no significant decrease occurred in CD8 T cells (Figure 21D). 
The decrease in TNF production by CD4 T cells did not occur in 2 out of the 16 monkeys 
(Figure 20A), which demonstrates the wide range of responses. No change in T cell IFN-g 
release was observed (Figure 22A, D). SIV did not cause a significant change in cytokine release 
by PBMC stimulated with PHA (Figure 21B,E and Figure 22B,E). Interestingly, SIV caused a 
significant increase in CD4 T cell TNF release (Figure 21C) and no significant change in IFN-g 
(Figure 22 C,F) in PBMC that were stimulated with Pneumocystis kexin peptide pools in kexin-
antibody responsive (i.e. Pneumocystis-exposed) monkeys. This supports that SIV explicitly 
inhibits the ability of M. tuberculosis-specific T cells to produce cytokines without decreasing 
the ability of all T cells to respond to a nonspecific T cell activator (PHA) or another pathogen 
(pneumocystis). To determine if the change in TNF production by CD4 T cells was the result of 
T cell death induced by SIV we determined changes apoptosis in these assays (Figure 23A,B). 
PBMC incubated with SIV did not result in an increase in activated caspase 3 in CD4 and CD8 T 
cells (Figure 23A,B).  
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Figure 21. SIV reduces TNF-production in CFP10-specific CD4 T cells. 
 
 
Figure 22. SIV does not cause a reduction in IFN-g-producing T cells 
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Figure 23. SIV does not cause an increase in cell death. 
7.3.2 SIV reduces CFP10-specific TNF release in CD4 and CD8 T cells from thoracic 
lymph nodes of M. tuberculosis infected monkeys  
To determine whether the results from peripheral T cells are recapitulated in tissue from M. 
tuberculosis-infected animals, SIV (MOI 0.1) was added to lung draining lymph node cells 
(thoracic lymph nodes) from monkeys with active TB (Figure 24). SIV was incubated with the 
lymph node cells overnight prior to the addition of CFP10. SIV caused a significant decrease in 
TNF release from both CFP10-specific CD4 and CD8 T cells (Figure 24A,B) without affecting 
IFN-g release (Figure 24C-D) from lung draining lymph node homogenates.  
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Figure 24. SIV reduces TNF production in CFP10-specific T cells within thoracic lymph nodes. 
7.3.3 SIV induces changes in antigen presenting cells that decrease the ability of T cells to 
respond to CFP10 
We next wanted to determine whether the decrease in TNF release from CD4 T cells was a result 
of SIV directly manipulating T cells or indirectly manipulating T cells through effects on  
antigen-presenting cells. We separated peripheral CD3+ T cells from PBMC of M. tuberculosis 
infected monkeys. We exposed either the CD3+ T cells or CD3-depleted PBMC (containing 
monocytes among other cells) to SIVmac251 (MOI 0.1) or media alone. After an overnight 
incubation, we combined the cells together as follows: SIV-exposed CD3 T cells with CD3- 
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PBMC; CD3 T cells with SIV-exposed CD3- PBMC; or CD3 T cells with CD3- PBMC (with no 
exposure to SIV). Each group of cells was stimulated with CFP10 peptides for 5-6 hrs. We 
compared the SIV-exposed cell responses to the responses of SIV unexposed cells to quantify the 
percent decrease in TNF production. A significant decrease in TNF production was observed in 
both CD4 and CD8 T cells when T cells were added to SIV-exposed CD3- PBMC compared to 
cells stimulated with CFP10 without SIV (Figure 25). SIV-exposed CD3 T cells did not 
demonstrate a reduction of TNF production (Figure 25). These data support that SIV is not 
directly manipulating the CD3+ T cell population, but is affecting another cell type in PBMC, 
that then results in a reduction in cytokine production from the M. tuberculosis-specific T cells.  
 
Figure 25. The reduction in TNF-producing peripheral T cells is caused by SIV manipulating CD3- PBMC. 
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7.3.4 SIV causes a reduction in responsiveness of CD4 T cells to M. tuberculosis-infected 
cells 
The previous experiments used CFP10 peptide pools to demonstrate the SIV-induced reduction 
of TNF production by CD4 T cells. The addition of these peptides allows the antigen presenting 
cells to signal T cells without processing M. tuberculosis. We next asked whether SIV could 
decrease the ability of T cells to respond to M. tuberculosis-infected cells, rather than just cells 
presenting CFP10 peptides. CD3+ T cells and the CD3-PBMC were incubated overnight 
followed by infection of the CD3- PBMC with M. tuberculosis (MOI 0.5) for 24hrs. Half of the 
M. tuberculosis-infected cells were then exposed to SIVmac251 (MOI 0.1) overnight. 
Autologous T cells were then added to each group of cells. SIV incubation with M. tuberculosis-
infected CD3-depleted PBMC reduced the ability of CD4 T cells to produce TNF in response to 
M. tuberculosis (Figure 26), similar to our results with CFP10 peptides. We determined that the 
change in CD4 T cell TNF production did not result from SIV-induced cell death (Figure 23C), 
which could potentially manipulate cytokine production.  
 
Figure 26. SIV reduces the ability of CD4 T cells to respond to M. tuberculosis-infected CD3- PBMC. 
  123 
7.3.5 T cell dysfunction results from SIV disrupting M. tuberculosis infected monocytes 
We previously demonstrated that SIV was manipulating CD3- PBMC, which contain multiple 
cell types, including antigen-presenting cells (APC) that could potentially reduce T cell cytokine 
production. To determine whether the APC affected by SIV were monocytes, we magnetically 
separated CD14+ cells and CD3+ T cells from PBMC of monkeys infected with M. tuberculosis. 
After allowing the cells to rest overnight, we infected the adherent CD14+ monocytes with M. 
tuberculosis (MOI 0.5) for 24 hrs. Cells were then washed with RPMI and half of the M. 
tuberculosis-infected cells were inoculated with SIVmac251 (MOI 1.0) overnight. After the 
overnight incubation CD3+ T cells were added to the monocytes (~3:1 ratio) and incubated 
together for 5-6 hrs with brefeldin A. The MOI used in the monocyte experiments is 10 fold 
higher than the MOI used in the CD3- PBMC experiment. We determined that an MOI of 1 in 
the monocyte-T cell experiment approximately recapitulates an MOI of 0.1 in CD3- PBMC 
because monocytes make up approximately 10% of CD3- PBMC.  
 
Figure 27. SIV reduces TNF and IFN-g production in CD4 T cells through the manipulation of M. 
tuberculosis-infected monocytes. 
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CD4 T cells incubated with monocytes that had been infected with M. tuberculosis and 
cultured with SIVmac251 were inhibited for TNF and IFN-g production compared to CD4 T 
cells incubated with monocytes infected with M. tuberculosis alone (Figure 27A, B). No change 
in IL-2 release occurred in CD4 T cells (Figure 27C). SIV did not lead to a significant change in 
CD8 T cell function (Figure 27D-F), however a trend in the decrease of TNF (Figure 27D; P = 
0.0781) and IL-2 (Figure 27F; P = 0.0547) was observed. No significant decrease in CD107a 
cytolytic marker was observed on CD8 T cells (Figure 27G). Co-infected monocytes had no 
change in cell count compared to M. tuberculosis-only infected monocytes (Figure 23D). We 
also observed similar SIV-induced changes in cytokine responses within the same monkey in 
serial repeat experiments, which indicates that in this assay SIV-induced dysfunction in vitro is 
fairly consistent over time (Figure 28). The SIV-induced decrease in TNF-production by CD4 T 
cells was relatively consistent despite variability in TNF production over time (Figure 28). 
  
Figure 28. SIV causes similar reductions in TNF production by M. tuberculosis-specific CD4 T cells over 
time in the same monkey. 
Monocytes differentiate into macrophages in tissues, including granulomas. A pilot 
experiment was performed with monocyte-derived macrophages (MDM) instead of monocytes to 
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confirm the effects of SIV on macrophages as antigen presenting cells. Only 4 animals were used 
for this experiment. SIV caused a modest reduction in TNF (Figure 29A, N = 4, 84%±24.5) and 
IFN-g (Figure 29B, N = 4, 87%±9.3) production by M. tuberculosis-specific CD4 T cells. 
However, SIV did cause a moderate increase in CD8 T cells producing TNF (Figure 29C, N = 4, 
109%±12.9) and IFN-g (Figure 29D, N = 4, 150%±39).  
 
Figure 29. TNF and IFN-g production by CD4 T cells is reduced when treating M. tuberculosis-infected 
monocytes derived macrophages with SIV. 
7.3.6 Non-infectious virus does not cause a significant reduction in CD4 TNF and IFNg 
release. 
We repeated the same monocyte-T cell experiment from above with inactivated SIVmac251 to 
determine if SIV requires the infection of monocytes to cause a significant decrease in cytokine 
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responses. Incubation with inactivated SIV did not result in significant changes in TNF or IFN-g 
production by M. tuberculosis-specific T cells (Figure 30). The results with the inactivated virus 
were quite variable with some moneys demonstrating a dramatic decrease in TNF production, 
while the majority showed no change or an increase in cytokine production. We determined that 
infectious virus was needed to cause a consistent and significant reduction in CD4 TNF and IFN-
g release (Figure 30).  
 
Figure 30. Inactivated virus does not reduce cytokine production in M. tuberculosis-specific CD4 T cells. 
7.3.7 SIV does not change lymphocyte proliferation or monocyte expression of co-
stimulatory molecules or MHCs.  
Changes in cytokine production by M. tuberculosis-specific T cells may result from a change in 
the presence of co-stimulatory and MHC molecules on monocytes. In order to determine how 
SIV causes a decrease in TNF and IFN-g production in M. tuberculosis-specific CD4 T cells we 
examined monocyte expression of co-stimulatory molecules CD40, CD40L and CD80, and the 
antigen presentation molecules MHC-I (HLA-A,B,C) or MHC-II (HLA-DR,DQ,DP) (Figure 31). 
  127 
SIV did not cause a change in co-stimulatory or MHC expression on M. tuberculosis-infected 
monocytes. There was also no difference in the expression levels of these proteins [as assessed 
by mean fluorescent intensity (MFI)] between co-infected and M. tuberculosis-only infected 
monocytes.  
 
Figure 31. SIV does not change co-stimulatory 
molecules or MHC expression on monocytes. 
 Lymphocyte proliferation assay (LPA) 
was performed to determine whether the 
decrease in cytokine expression resulted from 
a decrease in proliferation of CD4 T cells 
(Figure 32). SIV did not cause a change in 
proliferation in PBMC incubated with media, 
PHA or CFP10.  
 
Figure 32. SIV treatment of monocytes does not cause a change in lymphocyte proliferation. 
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7.3.8 SIV-induces a significant increase in monocyte-derived IL-5 production by 
monocytes incubated with media or M. tuberculosis.  
The data presented thus far supports that SIV affects the monocyte population, and indirectly 
inhibits cytokine production from M. tuberculosis-specific T cells. One possibility is that SIV 
modulates cytokine production in the M. tuberculosis-infected monocytes, and that the monocyte 
derived cytokines influence changes in the T cell responses. I took a broad approach to 
identifying changes cytokine production by monocytes in response to SIV. Monocytes were 
prepared from 10 monkeys and incubated with media, SIV, M. tuberculosis, or SIV+M. 
tuberculosis for 24 hours. A 23-plex Luminex assay was performed on the supernatants of 
monocytes (Figure 33 and 34). M. tuberculosis caused an increase in production of TNF (656% 
± 769.1, mean ± S.D; P = 0.0195) and IL-1b (686% ± 573.4; P = 0.002) compared to the media-
only groups (Figure 33A,B), which is consistent with published results from human studies [212, 
289, 365]. SIV reduced TNF (76% ± 19.2; P= 0.002) and IL-1b (76% ± 14.7; P = 0.0059) release 
by co-infected monocytes compared to monocytes infected with M. tuberculosis alone (Figure 
33C-D).  
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Figure 33. SIV/M. tuberculosis treated monocytes produce more IL-5 and IL-13 than monocytes incubated 
with M. tuberculosis. 
SIV caused a significant increase in the production of IL-5 by monocytes (SIV-only compared to 
uninfected monocytes, 3054% ± 4606.7; P = 0.0039 and M. tuberculosis/SIV treated cells 
compared to M. tuberculosis-only infected cells, 2496% ± 3777.9; P = 0.0039; Figure 33E). SIV 
also induced IL-13 production in the absence (1187% ± 1582.8; P = 0.0078 compared to 
uninfected monocytes) or presence of M. tuberculosis coinfection (774% ± 1122, P = 0.0117; 
SIV/M. tuberculosis compared to M. tuberculosis-only infected monocytes; Figure 33F). SIV 
also caused a slight reduction in GMCSF (89% ± 21; P = 0.0371; SIV/M. tuberculosis compared 
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to M. tuberculosis-only treated monocytes) and IL-4 (63% ± 36; P = 0.0781; SIV/M. tuberculosis 
compared to M. tuberculosis-only treated monocytes) production (Figure 33).  SIV did not cause 
a change in monocyte production of IFN-g, IL-2, G-CSF, IL-1a, IL-6, IL-8, IL-10, IL-12/23 p40, 
IL-15, IL-17, MCP-1, MIP-1b, MIP-1a, sCD40L, VEGF or IL-18 (Figure 34).  
 
Figure 34. Changes in SIV-induced cytokine production by monocytes 
 To confirm monocytes were producing IL-5 we examined IL-5 mRNA production in SIV 
infected monocytes from two different monkeys after a 12 hour incubation period (Figure 35). 
All of our SIV infected monocytes contained IL-5 mRNA. To our surprise, we detected IL-5 
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RNA in the monocytes from monkey 22910, irrespective of SIV infection. From monkey 22410, 
the media only cells did not express IL-5, but the SIV, M. tuberculosis, and co-infected cells did 
have a detectable IL-5 message. We confirmed the IL-5 bands were 98% homologous to Homo 
sapien IL-5 mRNA through genomic sequencing followed by a blast search (Figure 36).  
 
Figure 35. Monocytes express IL-5 mRNA. 
 
Figure 36. Sequence homology of IL-5 bands is 98% homologous to Homo Sapien IL-5 
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7.3.9 Neutralizing IL-5 in monocytes rescues TNF release within CD4 T cells  
Since both IL-5 and IL-13 were induced by SIV, neutralizing antibodies to IL-5 or IL-13 were 
added to monocytes incubated with SIV and M. tuberculosis to determine whether either 
cytokine was responsible for the decrease in T cell cytokine production. Neutralizing antibodies 
were added to the M. tuberculosis-infected monocytes at the same time as the SIV inoculation. 
After an overnight incubation the cells were washed and autologous T cells were added to the co-
infected monocytes.   Anti-IL-5 antibody caused an increase in the percentage of CD4 T cells 
releasing TNF from most monkeys, reversing the SIV-induced reduction in TNF (Figure 37A) 
and no change in IFN-g (Figure 37B), (p < 0.05, comparing CD4 T cell TNF production 
incubated with co-infected monocytes treated with anti-IL-5 antibody or an IgG isotype control). 
Neutralization of IL-13 did not rescue TNF or IFN-g production by T cells (Figure 37C,D).  
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Figure 37. Neutralization of SIV-induced monocyte production of IL-5 and not IL-13 rescues CD4 T cell 
TNF production without affecting IFN-g production. 
7.3.10 IL-5 recapitulates the effect of SIV on M. tuberculosis-infected monocytes  
To confirm that IL-5 is responsible for the inhibition of TNF release by T cells, recombinant IL-
5 was added to monocytes infected with M. tuberculosis overnight for 24hrs. Exogenous IL-5 
was removed by washing the cells prior to the addition of T cells. A significant decrease in TNF 
release within CD4 T cells was observed (Figure 38), similar to that seen with SIV-treated 
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monocytes. There was a similar trend in CD4 TNF release when we added 4pg of rIL-5 to the M. 
tuberculosis-infected monocytes, although it was not significant (Figure 38). 
 
Figure 38. Adding recombinant IL-5 to M. tuberculosis-infected monocytes recapitulates the affect SIV has 
on TNF-releasing M. tuberculosis-specific CD4 T cells. 
7.4 DISCUSSION  
A reduction in M. tuberculosis-specific T cell responses in HIV-co-infected individuals has been 
described in several studies [261, 282, 283, 286, 310], although the mechanisms responsible are 
not fully understood. In this chapter, we demonstrate that SIV causes a significant decrease in 
TNF-production by M. tuberculosis-specific T cells in PBMC and thoracic lymph nodes. The 
data support that this effect is due to the interaction of SIV with monocytes. The similar, albeit 
not identical decrease in T cell responses in both blood and thoracic lymph nodes help validate 
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the approach of using PBMC to identify mechanisms by which changes might be occurring in M. 
tuberculosis-involved tissue, which is needed to better understand the co-infection [238]. In this 
study we demonstrated that SIV can manipulate both peripheral and thoracic lymph node T cell 
responses within the first 24hrs of incubation, which is important because the outcome of disease 
status in co-infected individuals is likely to be at least partially dictated during the acute phase of 
HIV infection [77, 271].  
 The decrease in M. tuberculosis-responsive T cells appears to be specific to M. 
tuberculosis. HIV preferentially infects and kills peripheral M. tuberculosis-specific CD4 T cells 
without affecting CMV-specific T cells [261]. Similarly, we demonstrated that SIV did not cause 
a significant decrease in pneumocystis-specific (PCP, kexin stimulated) or non-specifically 
activated T cells (PHA stimulated). However, SIV did increase TNF release in PCP-specific 
CD4 T cells. One reason may be that the Pneumocystis-specific T cells in the monkeys are likely 
true memory cells, as these monkeys were serologically positive for Pneumocystis but had no 
signs of active infection, although it remains possible that they were colonized. In contrast, the 
persistence and replication of M. tuberculosis bacilli, even in latently infected animals, may 
result in a higher percentage of effector T cells, rather than true memory T cells, and these may 
be differently affected by SIV interactions with the monocytes.  
Monkeys co-infected with SIV and M. tuberculosis had significantly fewer IFN-g 
releasing cells in their thoracic lymph nodes compared to monkeys with active TB without SIV. 
Thoracic lymph nodes drain the lungs and often contain granulomas, and therefore are useful for 
investigating how HIV manipulates granulomas. The decrease in T cell responses occurred 
without a significant loss in total T cell numbers; there was however a trend towards fewer T 
cells in the lymph nodes of in co-infected monkeys compared to M. tuberculosis-infected 
  136 
monkeys [271]. This study provides the first quantifiable in vivo evidence that HIV may inhibit 
the function of M. tuberculosis-specific T cells within granulomatous tissue.  
 To our surprise the data from our in vitro model system, using PBMC, indicated that SIV 
was not directly manipulating T cells. SIV causes a significant decrease in T cell functionality 
through the manipulation of monocytes, the antigen presenting cells. M. tuberculosis-specific 
CD4 T cells released less IFN-g and TNF when stimulated by SIV/M. tuberculosis-infected 
monocytes, compared to stimulation with monocytes infected with M. tuberculosis alone. These 
data were recapitulated using CFP-10 peptides to stimulate the M. tuberculosis specific T cells, 
rather than M. tuberculosis-infected monocytes. These results suggest that the reduction in M. 
tuberculosis-specific T cell responses that occurs in co-infected individuals may be due to a 
combination of factors, including manipulation of antigen presenting cells and infection or direct 
manipulation of CD4 T cells. The manipulation of antigen presenting cells occurs within a 24hr 
incubation period, which demonstrates that this defect occurs during acute viral infection. This 
suggests that viral surface proteins, and not viral replication, are manipulating the monocytes in 
such a way that decreases their ability to signal M. tuberculosis-specific CD4 T cells. 
HIV [257, 264, 276] and SIV [271] are present in M. tuberculosis-infected tissues, which 
provide an opportunity for HIV to directly manipulate macrophage function within granulomas. 
HIV has been reported to inhibit the killing of intracellular M. tuberculosis by interfering with 
macrophage production of TNF [289, 293], M. tuberculosis-induced macrophage apoptosis [212, 
289], and the acidification of vacuoles [290, 297]. As an additional mechanism for immune 
suppression, we propose that HIV inhibits the ability of macrophages to signal M. tuberculosis-
specific T cells. HIV can decrease MHC expression [366], co-stimulatory molecule expression 
[367] and antigen processing [368] within macrophages. Although we did not observe a 
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significant decrease in MHC or co-stimulatory molecules, the sensitivity of our assay was 
limiting, since we could not specifically analyze the co-infected cells for expression of these 
molecules, and instead analyzed the total population of monocytes. Thus, it remains a possibility 
that SIV is modulating expression of co-stimulatory and antigen presenting molecules on co-
infected macrophages.  
A limitation of our in vitro model was that we were using monocytes for our antigen 
presenting cells. Monocytes differentiate into macrophages when they migrate to tissues, and 
therefore are likely present only at low levels in granulomas. We confirmed our monocyte 
findings using monocyte-derived macrophages from a small subset of monkeys. SIV modulated 
the ability of macrophages to stimulate cytokine production from M. tuberculosis-specific T 
cells. The M. tuberculosis-infected monocytes produce more TNF and IL-1b than uninfected or 
SIV-only infected monocytes, which is similar to how macrophages respond to M. tuberculosis 
infection. Co-infected monocytes produced less TNF than monocytes infected with M. 
tuberculosis-alone, as was previously reported for HIV [212, 289]. TNF is required for control of 
M. tuberculosis infection [72] and the combination of reduced monocyte TNF production 
together with the decrease in TNF production of CD4 T cells could result in a substantial 
reduction in overall TNF in the granulomas of co-infected persons, which may lead to 
reactivation. We previously demonstrated that neutralization of TNF in monkeys with latent M. 
tuberculosis infection leads to reactivation within 5-8 weeks [72].    
A surprise finding from this work was that the SIV-induced IL-5 production by 
monocytes was key to the ability of these cells to inhibit TNF production by M. tuberculosis-
specific CD4 T cells. Increased IL-5 production was observed in SIV-exposed monocytes, 
regardless of whether the cells were infected with M. tuberculosis. Neutralization of IL-5 in co-
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infected monocytes reversed the effects of SIV on stimulation of T cells, while addition of 
recombinant IL-5 to M. tuberculosis-infected monocytes replicated the inhibition of TNF 
production observed with M. tuberculosis/SIV-exposed monocytes. This study presents a novel 
role for IL-5, suggesting that the cytokine may be one of the factors responsible for the reduction 
of M. tuberculosis-specific T cells within co-infected individuals. Interestingly, we observed IL-
5 (and SIV) inhibits TNF release but not always IFN-g. One possible reason for this discrepancy 
is that T cell kinetics suggests that TNF production occurs before IFN-g upon mycobacterial 
stimulation in CD4 and CD8 T cells [369], so IL-5 or SIV may need more time to modulate IFN-
g production. If this is the case, varying stimulation times can address this hypothesis. 
IL-5 is considered a Th2 cytokine that is primarily involved in eosinophil maturation and 
function, along with B cell growth and antibody production [370, 371]. IL-5 has also been shown 
to be involved in the development of cytolytic T cells in mice [372]. IL-5 is primarily produced 
by CD4 T cells [373, 374], however macrophages and monocytes have been reported as sources 
of IL-5 as well [375-378]. Similar to our study, low levels of IL-5 have been detected from 
macrophage-like cells stimulated with IFN-g and Mycobacterium avium [375], murine 
macrophages infected with M. tuberculosis [377], macrophages/monocytes from HIV-infected 
individuals [376] and intestinal macrophages from individuals with Crohn’s disease [378].   
IL-5 is also detected in CFP and PPD stimulated PBMC [379-381] and plasma [382] of 
HIV/M. tuberculosis co-infected individuals. However, the function of IL-5 in the co-infection of 
HIV and M. tuberculosis is not understood. High incidence of TB within co-infected individuals 
that received BCG vaccine correlated with increased IL-5 production in response to stimulation 
of PBMC with mycobacterial protein mixtures [PPD and culture filtrate protein (CFP)][379, 
381]. A sustained increase in IL-5 production by CFP-stimulated PBMC also occurred in 
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tuberculin skin test (TST) positive co-infected individuals [381]. Conversely, plasma IL-5 levels 
significantly increased over 1-3 months of anti-retroviral treatment in HIV/M. tuberculosis co-
infected individuals, which did not correlate to IFN-g production [382]. These studies 
demonstrate that mycobacteria are capable of stimulating PBMCs in co-infected individuals to 
release IL-5 with no correlation to IFN-Ȗ production  
It is not obvious how SIV-induced IL-5 is modulating the ability of monocytes to 
stimulate cytokine production from T cells. IL-5 may interact with macrophages directly by 
decreasing their responsiveness to intracellular pathogens. IL-5 stimulated J774 A.1 cells (a 
murine macrophage-like cell line) induced 57% of the mRNA species observed in IL-10 
stimulated cells, which supports that macrophages can respond to IL-5 [383] but does not 
demonstrate how IL-5 affects macrophage functionality. One study of individuals with chronic 
rhinosinusitis with nasal polyps (CRSwNP) demonstrated a correlation with presence of IL-5 and 
alternatively activated (M2) macrophages in nasal tissue, and a decreased ability to phagocytose 
Staphlyococcus aureus [384]. CRSwNP with high levels of IL-5 had less IFN-Ȗ I/-ȕ and T*F-
ȕ in nasal tissue homogenates compared to CRSwNP with low levels of IL-5. It was also 
determined that the addition of recombinant IL-5 to CD206+ macrophages increased the survival 
of S. aureus in vitro. This study demonstrates that IL-5 may decrease the ability of macrophages 
to kill intracellular pathogens and signal T cells by changing their activation status, because 
classically activated (M1) macrophages reduce M. tuberculosis growth more readily than 
alternatively activated (M2) macrophages [80].  
 IL-5, as a Th2 cytokine is generally categorized as anti-inflammatory [377, 380-382]. It 
is possible that an increase in IL-5 production may disrupt the Th1/Th2 balance needed to 
maintain proper functionality of M. tuberculosis-infected macrophages and M. tuberculosis-
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specific T cells. More pathogenic strains of M. tuberculosis preferentially induce Th2 cytokine 
production (IL-4, IL-5, IL-10 and IL-13) while less virulent strains induce more Th1 cytokines 
(IFN-g, TNF) by infected macrophages or monocytes [377, 385, 386]. For example, significantly 
more IL-5 mRNA was produced in mouse macrophages infected with virulent M. tuberculosis 
strain H37Rv compared to the avirulent strain H37Ra [377]. This upregulation of IL-5, along 
with IL-10 and IL-13, may play a role in the increased virulence of H37Rv compared to H37Ra. 
We showed that monkeys with latent TB that were co-infected with SIVmac251 had increased 
Th2 cytokine producing peripheral T cells in vivo during acute SIV infection [77], with the level 
correlating with time of reactivation. HIV can also lead to the production of Th2 cytokines ([387, 
388] reviewed in [199]).  Taken together, these studies demonstrate that a shift from Th1 to Th2 
cytokines may cause a loss of immunologic control of TB. Whether IL-5 from monocytes, rather 
than T cells, can contribute to this shift remains unknown. 
 The ability of IL-5 to manipulate M. tuberculosis-specific T cells warrants more 
investigation and needs to be confirmed in human macrophages and T cells.  If these results 
occur within human cells the next step should be to examine IL-5 neutralization in vivo because 
it may augment co-infection treatment. Humanized neutralizing antibodies to IL-5 are already in 
use to treat eosinophilia (reviewed in [389]), so the implementation of these antibodies is 
possible. This has the potential to be extremely beneficial because it would represent a 
completely novel treatment that could be used in parallel with chemotherapy. 
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8.0  SUMMARY OF THESIS 
8.1 THE CO-INFECTION: DISEASE OF THE POOR 
 
Figure 39. The cost of TB control as a percentage of total health expenditures by public sector in 2009. 
Tuberculosis and HIV/AIDS are two major independent health concerns [11, 22]. Together, they 
cause much more mortality and morbidity than either pathogen alone [16, 244, 249, 285]. A 
major obstacle in controlling tuberculosis has been the emergence of HIV. HIV-infection is the 
single greatest risk factor for tuberculosis [11]. The highest rates of HIV and tuberculosis are in 
sub-Saharan Africa [11, 22], which is made up of resource-poor nations [390]. In some of these 
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nations, TB control accounts for more than 7% of total health expenditures, which is far more 
than the United States and other developed world countries (Figure 39) [11]. The high cost of 
tuberculosis control has not correlated with a significant reduction of tuberculosis in countries 
with the most disease [391]. Prevention, treatment and early tuberculosis detection have led to a 
gradual decline in incidence, prevalence and mortality of tuberculosis globally over the last 
decade (Figure 40). Unfortunately, this decline has been less prevalent in Africa (Figure 41), the 
area where tuberculosis and HIV are most detrimental.  
 
Figure 40. Global trends in estimated rates of TB incidence, prevalence and mortality. 
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Figure 41. Estimated TB incidence rates by WHO region, 1990 to 2010. 
 A more aggressive strategy is needed for identifying and treating the co-infection to make 
the largest impact in countries with the highest disease burden [391]. To help reduce tuberculosis 
and HIV burden we need to identify infected individuals earlier so they can get appropriate 
treatments, along with researching more effective chemotherapies and vaccines. Development of 
new cures and prevention strategies is dependent on a major increase in our understanding of 
how HIV and M. tuberculosis interact within the host. The main goal of this thesis is to expand 
our basic understanding of how HIV manipulates M. tuberculosis-specific immunologic 
responses to increase TB susceptibility.   
  145 
8.2 OVERALL IMPACT OF THESIS 
As mentioned in Chapter 4 there are intelligent hypotheses suggesting possible causes for the 
increased susceptibly of tuberculosis in HIV-infected individuals, based on peripheral sample 
evidence in humans, that need to be confirmed in tissue-based experiments (Table 4, [238]). 
Although these hypotheses are probably correct, the development of an HIV/TB animal model 
(Chapter 6), based on cynomolgus macaques with latent TB that are then co-infected with 
SIVmac251, helped address these hypotheses in a way that is not ethically possible in human 
studies. This model provided a platform for examining immunological and microbiological 
changes over the entire course of disease that included both tissue- and peripherally-based 
experiments over time and at necropsy. We also developed in vitro and ex vivo systems to 
address how HIV reduces M. tuberculosis-specific effector T cell responses by manipulating 
antigen-presenting cells (Chapter 7).  The overall goal of my thesis work, to provide insight into 
the mechanisms by which SIV increases the risk of tuberculosis, has been achieved through the 
integration of data from the in vivo and in vitro systems, along with comparisons to available 
data from human studies.  
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Table 4. How does HIV increase TB risk? 
Adapted from Diedrich C R , Flynn J L Infect. Immun. 2011 (238); with permission. 
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8.2.1 A Novel HIV/M. tuberculosis co-infection animal model 
The need to better understand how HIV induces the reactivation of latent TB led us to designing 
an HIV/M. tuberculosis co-infection animal model [77, 271].  This model is critical because it 
allows researchers to use known and characterized strains and doses of SIV and M. tuberculosis, 
and provides easy and repeated access to PBMC, peripheral lymph nodes, and bronchial alveolar 
lavage (BAL) cells over the entire course of disease. Of great importance, an animal model of 
co-infection allows one to measure immunologic responses along with viral loads and bacterial 
growth within granulomatous and non-granulomatous tissue at necropsy. Human studies 
generally take a metaphorical snapshot of peripheral immunological responses between co-
infected and singly infected individuals [16, 252, 261, 270, 283, 286, 392-395]. Although these 
studies are extremely useful in increasing our basic understanding of HIV and TB immunology, 
they may not demonstrate the whole picture, because immunologic responses in TB wax and 
wane over time [72, 77, 113, 271, 396], and the peripheral responses do not adequately reflect 
the tissue based responses [77].  
8.2.1.1 In vivo firsts: Acute phase of SIV infection dictates tuberculosis reactivation time 
We demonstrated, for the first time, that the acute depletion of peripheral CD4 and CD8 T cells 
during the first 8 weeks of infection significantly correlated to reactivation time [271]. We also 
observed a transient spike in IFN-g releasing M. tuberculosis- and SIV-specific peripheral T cells 
along with an increase in activated (CD29+) T cells between 6 and 10 weeks post SIV 
inoculation. A spike in plasma IFN-g, TNF and IL-10 concentrations between 2 and 4 weeks post 
SIV inoculation preceded the increase in the number of effector T cells. We believe these 
transient increases in cytokine levels and effector T cells are a result of SIV disrupting the 
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homeostatic balance within granulomas, causing a rapid increase in bacterial growth and viral 
replication, resulting in more available antigen that activates effector T cells and primes naïve T 
cells. We generally observe higher peripheral effector T cell responses in monkeys with active 
TB than monkeys with latent disease (both without SIV) [113]. These data led us to our current 
hypothesis that the acute phase of HIV directly dictates the longer-term effects on control of 
latent tuberculosis (Table 4). This idea was supported by not only the increased depletion of CD4 
and CD8 T cells within co-infected monkeys compared to monkeys with TB alone but the 
increased number of fibrotic granulomas in late reactivating co-infected monkeys, which suggest 
a healing response (Flynn and Lin unpublished data, [271]). Taken together, these data suggest 
that the acute peripheral T cell depletion may also be occurring within granulomas. Animals that 
cannot contain disease reactivate early after SIV inoculation (<17 weeks) with late reactivators 
(>26 weeks) temporarily regaining or maintaining control of the M. tuberculosis infection. 
If the early events after HIV infection influence the risk of reactivation in humans, it 
demonstrates the need to start retroviral therapy for co-infected individuals as soon as possible. 
Starting antiretroviral therapy early on has been proposed to prevent CD4 T cell depletion in co-
infected individuals to lessen their risk of TB by maintaining a higher level of peripheral CD4 T 
cells [270]. However, the acute depletion of CD4 T cells did not correlate to peripheral T cell 
counts at time of necropsy or reactivation; in fact some of the monkeys in our study regained and 
maintained “normal” peripheral CD4 T cell levels, even when they reactivated.  This suggests 
that peripheral T cell counts are not the only factor that influences the risk of TB in co-infected 
individuals. 
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8.2.1.2 In vivo firsts: SIV decreases T cell counts within M. tuberculosis granulomas 
One hypothesis is that HIV increases TB susceptibility by causing a reduction of CD4 T cells 
within the granuloma (reviewed in [238, 249, 363]), although there are no human data to support 
this. The non-human primate study detailed in this thesis was the first time a retrovirus has been 
shown to cause a decrease in T cells in pulmonary granulomas. One previous study demonstrated 
that patients with tuberculosis adenitis with AIDS had reduced levels of CD4 T cells within their 
affected lymph nodes [252], which is not surprising because AIDS patients have a significant 
reduction in CD4 T cells in blood and tissues. Since most co-infected patients do not have AIDS 
it is important to understand the pathology of HIV-infected individuals before they are in a 
‘worst case scenario.’ Our study demonstrated that a ‘normal’ level of T cells within PBMC, 
axillary and inguinal lymph nodes did not correlate to T cell composition within lung granulomas 
at time of necropsy. This means that peripheral T cell levels may not be representative of 
granulomatous T cells after the acute phase of infection. This further demonstrates that 
peripheral responses probably do not accurately reflect T cell responses at sites of disease. Our 
study provides the first evidence that retroviruses actually reduce T cell levels in granulomas! 
8.2.1.3 In vivo firsts: HIV infects M. tuberculosis lung granulomas 
 Granulomas have also been proposed as ideal sites for HIV replication (reviewed in [238, 249, 
363]). Surprisingly, no published studies have demonstrated that HIV infects granulomas. This 
aforementioned hypothesis is based on co-infection macrophage data demonstrating more HIV 
replication than macrophages infected with HIV alone [257, 288], a study that demonstrated 
BAL cells extracted from areas of lungs with M. tuberculosis-infiltrate determined by x-ray 
contained higher viral replication and p24 levels than normal lung [274] and pleural fluid in co-
infected individuals with pleural TB have a higher viral load than their plasma [264, 276]. It is 
  150 
important to remember that TB is not an airway disease and these samples may not represent 
what is occurring within lung granulomas. 
We provide the first evidence that a retrovirus infects lung and thoracic lymph node M. 
tuberculosis granulomas in a highly variable manner at necropsy [271]. Reactivation and 
pathology did not correlate to viral load, which suggests that viral load within granulomas does 
not directly correlate to TB susceptibility. We believe that there is a low threshold amount of 
HIV (or SIV) that is needed to disrupt granuloma function. This study demonstrated, for the first 
time that TB granulomas contain SIV, although they are not necessarily ideal for viral 
replication!  
8.2.1.4 In vivo firsts: SIV decreases granulomatous M. tuberculosis-specific T cell responses  
Another hypothesis is that SIV manipulates M. tuberculosis-specific T cell responses within 
granulomas to increase susceptibility to active TB (reviewed in [238, 249, 363]). This hypothesis 
is based on an extensive amount of work examining changes in M. tuberculosis-specific T cell 
responses in PBMC [16, 261, 282, 283, 302] and BAL cells [286] in co-infected individuals. 
Comparing T cell responses in PBMC, BAL cells, lung and lymph node granulomas at the same 
time demonstrate a dramatic difference in responses [77, 112, 113], which may mean that the 
studies demonstrating that HIV decreases peripheral T cell responses may not correlate to 
changes in the granuloma. Although our study demonstrated no significant difference in the 
number of IFN-g releasing T cells within lung granulomas [271] we did demonstrate a significant 
decrease in IFN-g releasing T cells within thoracic draining lymph nodes between co-infected 
monkeys and monkeys with active TB (Diedrich, paper in preparation). This adds the first 
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evidence that granulomatous M. tuberculosis-specific T cells within thoracic lymph nodes may 
be affected by a retrovirus!  
8.2.1.5 No experiment is perfect: Issues with our model. 
I believe our model can make a lasting impact on understanding HIV/M. tuberculosis co-
infection immunology, however there are some issues that should be addressed prior to using this 
model again to examine different parameters. One issue with our co-infection model is that we 
inoculated the macaques with 106 to 107 271TCID50 units of SIVmac251 [ ]. This amount of 
virus is higher than an individual would contract during intravenous drug use or sexual contact. 
Despite this high level of inoculum, the animal’s peripheral viral loads did peak within a normal 
level (plasma: 107 /ml and PBMC: 106
397
/ml) and viral loads were generally lower after the acute 
phase of infection than in the plasma and PBMC than what is normally observed in humans 
[ ]. This demonstrates that viral load may not be as important to TB reactivation during the 
chronic phase of HIV as previously thought. However, cynomolgus macaques are not as 
susceptible to SIV as rhesus macaques. We could not use rhesus macaques for these studies, 
because they rarely develop latent M. tuberculosis infection. So the lower viral load set points 
are likely due in part to the choice of macaque species. This may be remedied by studying co-
infection in cynomolgus macaques from the island of Mauritius, as some of these animals have 
been shown to maintain higher viral burdens, similar to rhesus macaques.  
 We also may want to use different strains of SIV in future experiments. SIVmac251 was 
chosen because it would infect tissues readily and it does not cause a significant and sustained 
depletion of peripheral CD4 T cells. However, our in vitro data suggests that SIVmac251 infects 
macrophages and monocytes more readily than it infects T cells  (Mattila, unpublished data). 
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Since HIV generally infects both T cells and macrophages to different degrees over the course of 
disease [118], using a different M- and T-tropic strain may prove useful.  
One issue that cannot ethically or cost-effectively be dealt with in any nonhuman primate 
model is the low number of animals used in each study. We used 7 co-infected and 4 SIV-only 
infected animals, which is a reasonable number of nonhuman primates in any study. One issue 
that may come up is that we included historical TB-only controls to compare our findings too. 
Although, the TB-only controls underwent the same immunological procedures, individual 
reviewers have presented reservations to comparing data to these controls.  
All of the animals with latent TB in our study that were co-infected with SIV and M. 
tuberculosis reactivated their latent TB [271]. There is a 10% annualized risk of reactivating 
latent TB in co-infected humans [11, 16, 285]. This rate is less than the 100% reactivation that 
we observed after 48 weeks post SIV inoculation, which may present an issue in correlating the 
model to humans. However, the objective of our study was to examine SIV-induced reactivation 
of latent TB so it is desirable that they all reactivate. We also monitor the monkeys far more 
intensely that humans with latent M. tuberculosis infection are monitored, so we catch very early 
signs of reactivation. Adjusting viral strains and inoculum dosage may address the issue of early 
reactivation in future studies that primarily want to examine specific immunological responses. 
8.2.1.6 Future directions for the HIV/TB animal model 
The animal model developed in this thesis work will provide an opportunity to examine basic 
immunological and microbiological questions along with the effectiveness of new drugs or 
vaccines on co-infected animals. Effective vaccines or drugs against tuberculosis need to work in 
HIV-infected individuals because of their increased susceptibility and the high prevalence of co-
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infection. Determining the effectiveness of a vaccine in a co-infected nonhuman primate model 
would be an ideal step before moving on to humans.   
Addressing whether there truly is a correlation between TB reactivation and acute 
granulomatous T cell depletion and dysfunction is an important continuation of this work. Our 
hypothesis could be tested by necropsying a group of co-infected monkeys with latent TB within 
the first 8 weeks post SIV inoculation and determining T cell counts, viral and bacterial loads 
and M. tuberculosis-specific T cell activity within granulomatous tissues. Although these 
experiments would not correlate to reactivation, they could determine specific SIV-induced 
changes that occur during the acute phase of infection that cannot ethically be examined in 
humans.  Using serial PET-CT scanning, researchers could also determine whether the acute 
phase of SIV infection leads to reactivation by examining changes in the size, dissemination and 
metabolic activity of the granulomas in real time. PET-CT will provide a chance to determine 
how long it takes SIV to induce these changes and whether these changes are predictive of TB 
reactivation.  PET-CT may also be used to determine anti-retroviral effectiveness at preventing 
M. tuberculosis dissemination. We could also determine anti-retroviral concentrations within 
granulomas to establish which type of drug penetrates granulomas most efficiently. Correlating 
anti-retroviral concentrations to viral loads and T cell counts within granulomas may help 
augment treatment. 
Humans with HIV are more susceptible to primary tuberculosis, not just reactivation of 
latent infection. Inoculating SIV-infected monkeys with M. tuberculosis to determine how HIV 
changes initial tuberculosis susceptibility can be a simple and informative change to the animal 
model. These experiments may be used to predict TB susceptibility by correlating viral load and 
T cell counts prior to M. tuberculosis inoculation. This could also be used to determine the 
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effectiveness of a tuberculosis vaccine on an HIV-infected individual by vaccinating SIV-
infected macaques prior to M. tuberculosis inoculation.  
The co-infection animal model provides a chance for researchers to ask, “How HIV is 
manipulating host responses to M. tuberculosis during the entire course of disease?” Results 
obtained in this model could be translated into human studies. It is my hope that it will continue 
to increase our basic understanding of both of these pathogens. 
8.2.2 In vitro examination of how SIV manipulates M. tuberculosis-specific T cell 
functions 
It is well established that HIV manipulates M. tuberculosis-specific effector T cell function [16, 
77, 238, 261, 282, 283, 286, 302]. It is not known how long it takes HIV to manipulate these 
cells or how HIV is causing this dysfunction. It has been hypothesized that HIV is exhausting 
and/or killing M. tuberculosis-specific T cells ([261], reviewed in [238, 249, 363]). Although M. 
tuberculosis-specific CD4 T cells may be preferentially infected by HIV, the majority of these 
cells are not infected [261] so another cause of this effector dysfunction needs to be determined. 
In order to determine a potential mechanism for this dysfunction we developed an in vitro T cell-
monocyte model. These in vitro models were designed in part because they are more cost 
effective and more amenable to manipulation than co-infection animal studies.  
8.2.2.1 In vitro firsts: SIV immediately disrupts M. tuberculosis-specific T cell effector 
functions 
Since we hypothesize that the progression to TB reactivation is dictated during the acute phase of 
HIV we set out to determine whether SIV immediately causes a reduction in M. tuberculosis-
  155 
specific T cell effector function. In chapter 7 we demonstrate that exogenously added SIV 
overnight can decrease both CFP10-specific peripheral CD4 TNF-producing T cells and CFP10-
specific TNF producing CD4 and CD8 T cells in thoracic lymph nodes from monkeys with TB 
(without SIV). The similar responses in both the involved tissues and PBMC demonstrate that 
SIV may manipulate these cells similarly, at least during the first day of in vitro infection. This 
effect also occurred in M. tuberculosis-specific peripheral T cells.  Taken together, these data 
demonstrate that SIV decreases TNF production almost immediately. If this occurs in humans, 
when HIV enters a granuloma it may immediately cause a disruption in the homeostatic balance 
between immune function and bacterial growth (Figure 42). The literature and our study 
demonstrate that HIV/M. tuberculosis-infected macrophages release less TNF than M. 
tuberculosis-only infected macrophages [212, 289]. This is important because TNF is essential in 
granuloma function [72] and if HIV causes a decrease in TNF production by both CD4 T cells 
and macrophages granuloma integrity and function will probably be disturbed. This immediate 
disruption in TNF production supports the idea that co-infected individuals need to be treated 
with anti-retrovirals immediately.  
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Figure 42. Proposed mechanism of HIV-induced reactivation of latent TB. 
 We determined that incubating SIV with M. tuberculosis-infected monocytes indirectly 
caused a significant decrease in TNF and IFN-g production in M. tuberculosis-specific T cells 
after a 24hr incubation period compared to T cells incubated with M. tuberculosis-only infected 
monocytes. The decrease in cytokine production by M. tuberculosis-specific T cells occurred 
when SIVmac251 was incubated with antigen-presenting cells and not when it was incubated 
with T cells overnight. This suggests that macrophages, the major component of granulomas, 
may be responsible for decreases in M. tuberculosis-specific T cell functions we observed in the 
thoracic lymph nodes of co-infected monkeys compared to active monkeys. 
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8.2.2.2 In vitro firsts: SIV induced monocyte production of IL-5 causes a decrease in TNF 
production in CD4 T cells 
The observed decrease in TNF and IFN-g production by M. tuberculosis-specific CD4 T cells 
results from a manipulation of the antigen-presenting cells. This manipulation was caused by 
SIV-induced production of IL-5 by monocytes. Neutralizing IL-5 during the incubation of SIV in 
M. tuberculosis-infected monocytes rescued autologous TNF production in CD4 T cells. The 
addition of recombinant IL-5 to M. tuberculosis-infected monocytes prior to the addition of 
autologous T cells caused a reduction in TNF.  Neutralizing antibodies to IL-5 and recombinant 
IL-5 were only added to the infected monocytes so it appears that IL-5 is acting on the 
monocytes exclusively. Since IL-5 is considered a Th2 cytokine [374], it is possible that it is 
changing the activation status of infected monocytes from M1 to M2 [383-385], which have been 
shown to be less effective at killing M. tuberculosis [80]. However, since M2 macrophages may 
be needed to prevent too much inflammation within granulomas (reviewed in [28]), a treatment 
that prevents M2 activation would probably be detrimental. If these results are recapitulated in 
humans, neutralizing IL-5 in co-infected individuals may augment drug treatment.  
8.2.2.3 No experiment is perfect: Issues with our in vitro model. 
As with any in vitro experiment it is impossible to model exactly what is occurring in vivo. The 
monocyte-T cell model is less complex than the granuloma. However, this model does have its 
place because it allows us to examine changes in specific cells that could not be observed in vivo. 
This means that the in vitro results need to be recapitulated in vivo. Another issue is that 
monocytes are different from granulomatous macrophages. We used monocytes because of the 
relative ease of obtaining them and their availability; in addition, the experimental set-up then 
did not require two sequential blood draws from each monkey (one for monocytes to 
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differentiate into macrophages and another one for T cells). For a subset of monkeys, we 
repeated these experiments using monocyte-derived macrophages, and the TNF and IL-1b 
induction by M. tuberculosis was similar in our monocytes as compared to that in the literature 
for macrophages [212, 289, 365]. However, macrophages in the granuloma may be very different 
than monocyte or monocyte-derived macrophages, and these studies should be repeated using 
macrophages isolated from granulomas.  
8.2.2.4 Future directions for the HIV/TB in vitro model 
This model can be used to determine potential causes for M. tuberculosis-specific T cell 
dysfunction caused by antigen presenting cells. IL-5 production is probably not the only cause of 
CD4 T cell dysfunction so attempting to determine other factors that result in cytokine T cell 
dysfunction can be performed. This is especially important because IFN-g production was not 
affected by monocyte production of IL-5. SIV (and HIV) may be disrupting MHC expression, 
co-stimulatory molecules, antigen presentation or processing within the antigen-presenting cell 
in a specific manner that affects the activation of M. tuberculosis-specific T cells.  
 These experiments also should be performed in human T cells and macrophages to 
validate the model. If HIV causes similar changes in TNF production by CD4 T cells then the 
possibility of using neutralizing antibodies to IL-5 in the SIV/M. tuberculosis co-infection model 
may be used to determine if it reduces TB reaction or susceptibility.  
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8.3 OVERALL CONCLUSION 
This thesis developed both an HIV/M. tuberculosis co-infection animal model and an in vitro 
assay to examine how HIV increases TB susceptibility. These experiments provided the first 
tissue-based evidence that support current hypotheses of how HIV increases susceptibility (Table 
4). Combining data from this thesis with HIV/tuberculosis literature, we developed a schematic 
of how HIV induces TB reactivation within a granuloma (Figure 42). These experiments also 
suggest novel hypotheses of how HIV manipulates M. tuberculosis-specific immunological 
functions. These experiments can and should be repeated with varying parameters to continue to 
build our basic understanding of the immunological ramifications of the co-infection.  For 
example, both our animal model and in vitro data suggest that anti-retrovirals should be 
administered as soon as possible, regardless of CD4 T cell count in co-infected individuals. In 
addition, if the in vitro experiments hold true in human cells, neutralizing antibodies to IL-5 can 
also be used in conjunction with the SIV/TB animal model to determine if IL-5 is exacerbating 
TB in co-infected individuals. The more basic science we understand about the co-infection the 
better we can augment treatment and design vaccines.  
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